Tender Ref. No.: BPPI/DRUG/RC-116/2019 **Dated: 04/10/2019**

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA

(Set up under the Department of Pharmaceuticals, Govt. of India)

8th Floor, Videocon Tower, Block E1
Jhandewalan Extension, New Delhi-110055
Telephone: 011- 011-49431800/49431811/49431829/49431830/49431854;

Website: janaushadhi.gov.in

e- TENDER FOR SUPPLY OF DRUGS

TO

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI) FOR TWO YEARS

RATE CONTRACT

LAST DATE FOR ONLINE SUBMISSION OF TENDER: 25/10/2019

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

(SET UP UNDER THE DEPARTMENT OF PHARMACEUTICALS, GOVERNMENT OF INDIA)

Regd. Office: Core No. 6, First Floor, SCOPE Complex, Lodi Road, New Delhi-110003

Working Office: 8th Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055

Telephone: 011- 49431800/49431811/49431829/49431830/49431854;

Website: **janaushadhi.gov.in**

e-TENDER FOR TWO YEARS RATE CONTRACT

FOR SUPPLY OF DRUGS TO BUREAU OF PHARMA PSU OF INDIA

Tender Reference		**BPPI/DRUG/RC-116/2019 Dt. 04/10/2019**
Tender Website		**https://eprocure.gov.in**
Date of availability of tender documents on website		**04/10/2019 (Friday)**
Doubts and queries regarding Tender document should be sent by e-mail to e-mail id "proc6@janaushadhi.gov.in proc9@janausadhi.gov.in, procure13@janausadhi.gov.in" by the likely bidders latest by		**10/10/2019 (Thursday)**
Time and date and place pre-bid meeting		**11:00 AM on 11/10/2019 (Friday)** Bureau of Pharma **PSUs** of India, 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
Last date and time for submission of Online Bid i.e. Bid Submission End Date and time		**25/10/2019 up to 17.00 Hours.**
Last Date and time for submission of *EMD and Original Required Documents as per ANNEXURE III, in physical Form* in office of Bureau of Pharma PSUs of India, 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055		**30/10/2019**
Time and date of opening of Technical Bid		**11:30 AM on 01/11/2019 (Friday)**

Place of opening of tender		**Bureau of Pharma PSUs of India,** 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
Opening of Tender		Online on https://eprocure.gov.in
Address for Communication		**Bureau of Pharma PSUs of India,** 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
Cost of the Tender Document		**Free of cost**
Contact Person for clarification if any		1. Sh. P. K. Thakur Sr. Executive (Procurement) Phone: - 011-49431829 Email: - proc6@janaushadhi.gov.in
		2. Sh. Manik Bera, Dy. Manager (Procurement) Phone: - 011-49431854 Email: - proc7@janaushadhi.gov.in
		3. Sh. Pritam Singh Manager (Procurement) Phone: - 011-49431812 Email: - proc8@janaushadhi.gov.in

The tender document can be downloaded free of cost from the CPPP e-Procurement Portal https://eprocure.gov.in and from *the website of BPPI:* ***janaushadhi.gov.in.***

Note: ***The bidders shall be solely responsible for checking these websites at least 3 days prior to closing date of submission of tender for any addendum/amendment issued subsequently to the bid document and take into consideration the same while preparing and submitting the bids. Bids will be opened online.***

TABLE OF CONTENTS

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

e-TENDER FOR RATE CONTRACT FOR THE SUPPLY OF DRUGS TO

BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA (BPPI)

PRADHAN MANTRI BHARTIYA JANAUSHADHI PARIYOJANA (PMBJP) is the initiative of Department of Pharmaceuticals, Ministry of Chemical and Fertilizer, Government of India launching with the noble objective of making quality generic medicines available at affordable prices for all, particularly the poor and disadvantaged, through specialized outlets called PRADHAN MANTRI BHARTRIYA JANAUSHADHI KENDRA (PMBJK). BPPI was established in December 2008 under the Department of Pharmaceuticals, Government of India, with the support of all the CPSUs, and identified as the executing agency for PMBJP.

The Bureau has been registered as an independent society under the Societies Registration Act, 1860, in April 2010.

At present, more than 5000 stores are functional. It is proposed to channelize efforts to popularize PMBJP and ensure availability of the complete basket of medicines at affordable prices.

Tender Inviting Authority – C.E.O, Bureau of Pharma Public Sector Undertakings of India, 8th Floor, Videocon Tower, Block E1, Jhandewalan Extension, New Delhi-110055 (hereinafter referred as **Tender Inviting Authority** unless the context otherwise requires).

Tender Accepting Authority – CEO, Bureau of Pharma Public Sector Undertakings of India (hereinafter referred as **BPPI** unless the context otherwise requires).

Tender Inviting Authority Invites **Tender for the supply of Drugs to BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA for Two Years.**

1.TENDERING SYSTEM:

The Bids are to be submitted in two Parts i.e.

i. Technical Bid **(Cover "A")**
ii. Financial Bid / Price Bid **(Cover "B")**

i. The **TECHNICAL BID** shall contain the complete technical details of the firm and the documents to provide the eligibility and competency of the bidder and shall be submitted online only in the manner prescribed in Bid document.

The documents like Tender Document and EMD shall be submitted before the specified schedule at the office of BPPI super scribed, **"Tender Documents & Earnest Money Deposit for Tender Reference No.-BPPI/DRUG/RC-116/2019 dated 04/10/2019 for the procurement of Drugs for the year 2019-2021".** However complete hard copy of uploaded tender shall be provided by the bidder firm along-with the mandatory required documents as per clause 3 of Bid and EMD for evaluation purpose only. This hard copy shall under no case substitute/modify the provisions of e-tender system.

ii. The **Financial Bid/Price Bid** shall be valid for a period of 150 days from the date of opening of Technical Bid. Prior to the expiry of the bid validity, the Tender Inviting Authority may request the Tenderers to extend the bid validity for further period as deemed fit on their original quoted prices and all terms & conditions. However, BPPI reserves the right to place purchase orders at the quoted rate till such period.

a) The Tenderer shall fill in the rate per unit size, % age rate of GST in respective column of BOQ for the items quoted**.**

b) In determining the lowest evaluated price, the rate quoted per unit size exclusive of GST as indicated in column No. 7 of the **BOQ** shall be taken into consideration.

c) Tender has been called for in the **Generic name of drugs**. The Tenderers should quote the rates for the generic products only. The composition, strength and packing of each product should be as per specifications given in **ANNEXURE-XII** and Shape, Colour, Packing Type etc. of drugs should be as per **ANNEXURE XIV** (attached). Any variation, if found, will result in rejection of the tender.

d) Rates (inclusive of customs duty, packing & forwarding charges, transportation, insurance and any incidental charges, but exclusive **GST** should be quoted for each of the required drugs, medicines etc., on door delivery basis according to the unit ordered. Tender for the supply of drugs, medicines, etc. with cross conditions like "AT CURRENT MARKET RATES" shall not be accepted. Handling, clearing, transport charges etc., will not be paid separately. The delivery should be made as stipulated in the purchase order placed with Tenderers.

e) The price quoted by the tenderers shall not, in any case exceed the DPCO controlled price, if any, fixed by the Central/State Government, the Maximum Retail Price (MRP) and the selling price of the tenderer.

In case any tenderer quotes higher than the DPCO controlled price, competent authority shall be informed for appropriate action.

2. LAST DATE AND TIME FOR SUBMISSION OF ONLINE TENDER:

i. Online Bids [in two separate Cover {Technical bid (Cover "A") and price bid (Cover "B")}] shall be submitted till 17.00 Hours Up to 25/10/2019 (Friday) on CPP portal i.e. https://eprocure.gov.in.
Hard copy of complete required documents as Per Clause 3. Eligibility Criteria of Bid and EMD shall be submitted as before the specified schedule at the below mentioned address of BPPI with super scribed, **"Tender Document & Earnest Money Deposit for Tender Reference No.- BPPI/DRUG/RC-116/2019 dated 04/10/2019 for the procurement of Drugs for the year 2019-2021"**

"Bureau of Pharma PSUs of India, (BPPI)
8th Floor, Videocon Tower, Block-E1,
Jhandewalan Extension, New Delhi-110055"

ii. **Late Tender: -**There is NO PROVISION of uploading late tender beyond stipulated date & time in the e-tendering system.

3. ELIGIBILITY CRITERIA (TECHNICAL BID -COVER "A"):

Minimum Eligibility criteria along with list of documents to be submitted in Cover 'A'. Bidders should meet the following criteria to be eligible for bidding and relevant papers/documents must be submitted by them in their technical bid (Cover- 'A') in support of their eligibility for the tender.

A) **EMD (Earnest Money Deposit)**: EMD of **Rs.10,00,000/-** (Rupees Ten Lakh only as specified in Clause 6 of the Tender document in the form of **Bank Guarantee or National Electronic Fund Transfer (NEFT) or Bankers Cheque or Demand Draft from Nationalized/Scheduled Bank** favoring "Bureau of Pharma Public Sector Undertakings of India "payable at Delhi **which is to be submitted in original to BPPI, New Delhi on or before the date and time stipulated in tender document**. Name & full address of the bidder may be written at the back of the Demand Draft/Pay Order. Signed and scanned soft copy of the EMD instrument must be uploaded **(ANNEXURE III)** to the e-Procurement portal.
EMD in any other form like ***Cheque/cash/postal order*** etc. **will not be accepted. The Bid (in case not exempted for EMD as mentioned in tender document) without EMD shall be summarily rejected.**

Account Details for National Electronic Fund Transfer (NEFT):
Bank Name: Bank of Baroda, Account No. 05860200001696, IFSC Code: BARB0PARLIA

Note: Tenderer may be exempted from the payment of EMD, if valid registration certificate from NSIC/MSME is uploaded and submitted self-attested copy with Technical Bid for the product for which bidder has submitted quotation.

B) Documentary evidence of the constitution of the company/firm/Proprietorship such as Memorandum and Articles of Association, Partnership Deed etc. should be submitted with details of the Name, Address, Telephone Number, Fax Number, e-mail address of the firm and of the Managing Director / Partners / Proprietor should be submitted.
C) Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidding firm to sign the documents should be submitted.
D) Bidders must have: -

a) Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate.
b) Approved product list as per the license issued for quoted drugs for minimum three years.
c) Manufacturing License along with approved product list must be valid till the last date of the submission of tender.
d) In Case of those drugs which are notified first time in IP 2018 then Manufacturing and Marketing license should be in any official compendium (USP/BP/IP) along with current valid License in IP in continuation.
e) Market standing certificate & Manufacturing certificate issued by the Licensing Authority as a Manufacturer for each drug quoted for the last 3 years (Certificate should be enclosed with list of items) except for the drugs falling under the category of **'New Drug'** as defined by CDSCO (Central Drugs Standard Control Organisation). If permission in Form 46 from DCGI has been obtained, then the 3 years Manufacturing & Market standing clause will be relaxed. The provisions of Rule 122 E of Drugs and Cosmetics Act rule 1945 shall be applicable.
f) FFS (Flow Fill & Seal Process) Technology will be accepted wherever applicable.

Note: If Manufacturing License for the quoted product is issued under "for export only" category will not be accepted.

Bidders shall submit dully attested copies of required manufacturing license and approved product list in support of above-mentioned condition and they are required to specify the quoted product in their approved product list by highlighting it.

E) Bidder must have Market Standing Certificate (in India) of minimum two batches of quoted product in last three years issued by the concerned Licensing Authority from Drugs Control Department for the quoted product. Self-attested copies are to be submitted.

F) Non-Conviction Certificate (NCC) issued by the concerned Licensing of the state certifying that the firm/company has not been convicted in last three years should be submitted. It should be not more than 12 months old. Self-attested copies are to be submitted.

G) **WHO-GMP** (WHO-Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department. The WHO-GMP certificate must not be older than one year from the last date of submission of tender. Self-attested copies are to be submitted.
Explanation- Generally the WHO-GMP Certificate issued for one-year validity. Hence the provision that it should not be older than one year from the last date of submission of tender implies mutatis mutandis that the GMP certificate should remain valid till the last date of submission of tender.

H) Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority Form Drugs Control Department highlighting the quoted product section. Self-attested copies are to be submitted.

I) Copies of the Audited Balance Sheet, Profit and Loss statement showing details of their annual average turnover for last three consecutive financial years not less than **25 Crores (Twenty-Five crore).** In case of loan licensee average annual turnover of manufacturing unit/ Host Company for the last three consecutive financial years not less than **25 Crores (Twenty-Five crore).** Details shall be provided in per Annexure IV. Self-attested copies are to be submitted.

J) Declaration for eligibility in participating the tender for quoted drugs in prescribed format as per **Annexure-II.**

K) Tenderer shall furnish Company's bank details as per Annexure V (Mandate Form).

L) Tenderers are required to submit **Annexure-VI** indicating details of manufacturing License and three years Market Standing Certificate (MSC) as mentioned there in.

M) Tenderer are required to submit declaration duly signed to supply the drugs as per the design in enclosure 1 and enclosure 2 in Annexure VII as well as other instructions given in this regard.

N) Duly attested Checklist as per (**ANNEXURE- I**) shall be submitted.

O) Copy of PAN Card of the bidder company should be submitted (self-attested).

P) Copy of certificate of valid GST registration of the bidder company should be submitted (self-attested).

Q) Copy of Income Tax Return for any three of last four Consecutive Assessment years should be submitted (self-attested).

R) Duly attested Copy of valid GS-1 registration certificate from GS1 India.

S) The copies of relevant pages approved by drug authorities of concerned country for any quoted Drug/product offering CoPP certificate (if any) and quoted drugs/ products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa (if any) should be uploaded with technical bid.

Note: -

(i) The certificates/ reports / annexure submitted with the bid document should be self-attested by the authorized signatory of the firm with official seal, wherever required.

ii) Technical evaluation of the Bid will be done on the basis of the above mentioned criteria and documents mentioned in Clause no. 3 (TECHNICAL BID- COVER 'A') Mandatory Documents shall be submitted online only at CPPP portal: https://eprocure.gov.in Failing which the bid will not be considered for technical evaluation.

iii) Hard copy of required documents uploaded shall be submitted along with EMD and other required documents on or before the last day of submission of tender for purely evaluation purposes. However, the submission of hard copy of uploaded tender document submitted shall not substitute/modify the provisions of e-tendering system.

iv) The technical evaluation shall be done only on the basis of documents/papers submitted by the bidder on https://eprocure.gov.in

v) Clear copy of valid drug license highlighting the drug code should be uploaded. In case scanned copy of license uploaded is not visible or tempered, BPPI shall not considered the license for such drug.

4. GENERAL CONDITIONS:

A) Tender bid is invited directly from Manufacturers in India. Loan licensee is also eligible. Distributors/agents/contract manufacturers/Importers are not eligible to participate in the tender.

B) Manufacturer has Production & financial capacity to manufacture and deliver the drugs quoted by the firm in the tender as per quantity mentioned in tender during contract period.

C) Bidders are advised to quote only for such drugs which meets the drug specification as mentioned in Annexure XII. Do not quote if it differs with regard to any parameter.

D) The quantities specified in the tender is for the tender purpose only and it represents the basis of unit for ease of pricing. The actual quantity may vary from zero to the maximum required quantity during the contract. The quantity will be drawn from successful tenderers as and when required from time to time during the contract period.

E) STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance.

F) The bidder shall submit the complete stability data (long term stability studies and accelerated stability studies) for all awarded drugs whenever required by the BPPI. For New drugs,

complete stability data of 6 months' period shall be acceptable. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor should be submitted along with licensing agreement.)

G) The manufacturer shall declare the active API polymorphic form used in formulation for all quoted drugs and declare that it is internationally accepted active polymorph when ask by BPPI.

H) The Tenderer should have not been blacklisted/debarred/de-registered/banned due to quality failure for the quoted product /firm by any State Government / Central Government/ BPPI/Central or State Government's Drug procurement agencies **at the time of submission of bid**. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/BPPI during last two years. If any tenderer has been blacklisted/debarred/de-registered/banned due to quality failure, such tenderer or their Partner/Director/Owner shall not be permitted to participate in the tender.

I) During the validity of the tender if the firm / Company is blacklisted/debarred/de-registered/banned by any State Government/ Central Government/ BPPI/ Central or State Government's Drug procurement agencies / convicted by any Court of law in India, it shall be intimated to BPPI along with relevant authentic document by the tenderer firm/ company within one month.

J) During tender or Rate Contract period, if L1 bidder is debarred/deregistered /blacklisted/ banned by any Central Government or State Government or its procurement agencies due to quality failure, BPPI may purchase the drugs from other bidders at L1 rate or may go for fresh tender as per discretion of BPPI.

K) The BPPI reserves the right to purchase any drugs from PSUs as per discretion of BPPI. In case of emergencies, BPPI may go to PSUs and price will be as per negotiation and at the discretion of BPPI.

L) The Tenderer should confirm that they have read tender document including Amendment(s) to Tender document (if any) along with terms and condition and these terms and condition of tender document including Amendment(s) to Tender document (if any) are acceptable unconditionally to them.

M) Validity of Rate Contract: -The rate contract will be applicable for 2(two) year from the date of acceptance of LOA. The validity of contract may be extended with mutual consent for some specified period to the maximum of 1(one) year by BPPI, if necessary.

N) During the contract period at any stage, if certificate submitted with their bid is found fabricated/forged/not complying CoPP and products manufactured by manufacturing units having approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa as declared in tender, penal action shall be taken as per the tender terms and condition and in addition to penal action recovery shall be made (if any).

O) If a company/firm has two or more separate manufacturing units at different sites / States, which are not separate entities then the company will be allowed to submit only one tender for all units but necessary document regarding separate manufacturing units will uploaded as a separate set with the same tender. However, one bidder will be allowed to submit only one offer for one product.

P) Only authorized employee of the Company/Tenderer will be allowed to transact the business with the Tender Inviting Authority.

5. PRICE BID – "COVER-B" (Financial Bid/BOQ)

A) Cover "B" (Financial Bid/BOQ) contains the Price Bid of the Tenderer. The Tenderer shall fill in the rate per unit size, % age rate of GST in respective column of BOQ for the items quoted**.**

B) **Determination of L1 Bidder:**

a) In determining the lowest evaluated price, the rate quoted per unit size for the given specification, exclusive of GST as indicated in column No. 7 of the **BOQ** shall be taken into consideration. **The rates quoted should be in rupees and paisa up to 2 digits.** The Tenderer is not permitted to change/alter specification or unit size given in the **ANNEXURE-XII.**

b) **GST (Goods and Services Tax)-The Tenderers must indicate the rate of GST applicable and payable by them. In case no information is given, it shall be presumed that rate is inclusive of GST and no GST shall be charged by them under any circumstances.**

c) **The bidder is required to indicate rate of GST (%) as digit only in column 9 of BOQ without suffixing the % sign and not to indicate amount of GST in Rs. at particular cell of excel sheet of BOQ.**

d) Purchase preference shall be given over acceptable L1 bidder to bidder **offering CoPP products/ Products manufactured by manufacturing units approved by US FDA, TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa subject to matching of** acceptable L1 rate.

e) (i) If the participating Micro and Small Enterprises (MSE) meets all the other eligibility criteria and their quoting price is within price band of L1+15 (fifteen) per cent shall also be allowed to supply a portion of requirement by bringing down their price to L1 price in a situation where L1 price is from someone other than a MSE and such MSE shall be allowed to supply up to 20 (twenty) per cent of total tendered value. The 20 (twenty) per cent quantity is to be distributed proportionately among these bidders, in case there are more than one MSMEs within such price band.

(ii) Within this 20% (Twenty Percent) quantity, a purchase preference of four per cent (that is, 20 (twenty) per cent out of 20 (twenty) per cent) will be reserved for MSEs owned by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs (if they participate in the tender process and match the L1 price). Provided that, in event of failure of such SC/ST MSE to participate in tender process or meet tender requirements and L1 price, four per cent sub-target shall be met from other MSE. MSEs would be treated as owned by SC/ ST entrepreneurs: a) In case of proprietary MSE, proprietor(s) shall be SC /ST b) In case of partnership MSE, the SC/ST partners shall be holding at least 51% (fifty-one percent) shares in the unit c) In case of Private Limited Companies, at least 51% (fifty-one percent) share shall be held by SC/ST promoters.

6. EARNEST MONEY DEPOSIT:

A) The Earnest Money Deposit referred to under Clause 3.A, shall be **Rs. 10 lakhs. The Earnest Money Deposit shall be paid in the form of Bank Guarantee or National Electronic Fund Transfer (NEFT) or Bankers Cheque/ Demand Draft in favour of BUREAU OF PHARMA PUBLIC SECTOR UNDERTAKINGS OF INDIA, payable at Delhi. EMD in form of Bank Guarantee, Irrevocable Bank Guarantee** in favour of Bureau of Pharma Public Sector Undertakings of India from any Nationalized/scheduled Bank should be valid for a period of 12 months **from the date of tender opening**. The format of Bank Guarantee is at **ANNEXURE-X.** BPPI will not pay interest on any deposit held in the form of **Bankers Cheque or Demand Draft or Electronic Fund Transfer.**

Account Details for National Electronic Fund Transfer (NEFT):

Bank Name: Bank of Baroda, Account No. 05860200001696, IFSC Code: BARB0PARLIA

B) Tenderer may be exempted from the payment of EMD, if valid **registration** certificate from NSIC/MSME is uploaded **for the product for which bidder has submitted quotation.**

C) PSUs are exempted from the payment of EMD.
D) The tender submitted without sufficient EMD will be summarily rejected.
E) Non-payment of EMD (except in cases where payment of EMD is specifically exempted) will result in rejection of the bid.
F) The Earnest Money Deposit will be refunded to the successful bidders after successful completion of first supply.
G) **The Earnest Money Deposit of the Tender will be forfeited without further notice if:**

a) If the tenderer withdraws his bid any time after opening of price bid.
b) On refusal to supply medicine after the award of contract/Letter of Acceptance (LOA).
c) In case of the lowest bidder (L1 bidder), fails to execute the contract or fails to complete the first supply successfully within the stipulated time.
d) If the undertaking as Annexure II is not found correct at any stage during the contract period.

7. GUIDELINES FOR THE PREPARATION OF TENDER:

A) The bidder shall bear all costs associated with the preparation and submission of its bid and Tender Inviting Authority will in no case be responsible or liable for these costs, regardless of the conduct or outcome of the bidding process.
B) **Language of Bid: -** The Bid prepared by the bidder and all correspondence and documents relating to the bid exchanged by the bidder and the Tender Inviting Authority, shall be in English language, Supporting documents furnished by the bidder may be in other languages provided they are accompanied by an authenticated (by the authority concerned) accurate translation of the relevant passages in the English language in which case, for purposes of interpretation of the Bid, the English translation shall alone govern. Failure to submit authentic translation of documents would result in rejection of bids. No bid can be partly in one language and partly in another language.
C) Power of Attorney or Resolution of the Board by which the authorized signatory has been authorized by the bidder firm should sign the documents in cases where person other than the Managing Director/Managing Partner or sole Proprietor signs the document.

8. PERIOD OF VALIDITY OF TENDER:

a) The tender must remain valid for minimum 150 days from the date of opening of Technical Bid. (As mentioned in Clause 1.ii)
b) Prior to the expiration of the bid validity the Tender Inviting Authority may extend the bid validity for further period with mutual consent of the bidder.
c) The bidder who has extended the bid validity is not required or permitted to modify its bid.
d) The bidder cannot withdraw the bid within validity of Tender.

9. AMENDMENT OF TENDER DOCUMENTS:

At any time prior to the last date of submission of online bid, Tender Inviting Authority may, for any reason, whether on own initiative or in response to a clarification requested by a prospective Tenderer, may modify the condition in Tender documents by uploading an amendment on BPPI website: ***www.janaushadhi.gov.in;*** and on CPP portal i.e. ***https://eprocure.gov.in*** will be binding on them. In order to provide reasonable time to take the amendment into account in preparing their bid, Tender Inviting Authority may at discretion, extend the date and time for submission of online bid.

A) Bidders are advised to check the *website of BPPI:* ***www.janaushadhi.gov.in;*** and CPP Portal i.e., ***https://eprocure.gov.in****; regularly* at least 3 days prior to closing date of submission of tender for any corrigendum or amendment to the tender document.

B) BPPI will not issue separate communication for any corrigendum or amendment.

10. METHOD OF SUBMISSION OF TENDER:

A) The tender document shall be downloaded from the websites janaushadhi.gov.in; and CPP portal i.e. https://eprocure.gov.in. Tender Document is free of cost. No tender cost is to be deposited

B) Bids shall be submitted online only at CPP Portal i.e., ***https://eprocure.gov.in.*** Manual bids shall not be accepted except for the original documents/instruments as mentioned in Clause 3 of tender document.

C) Bidders are advised to follow the 'Special Instructions to the Contractors/Bidders for the e-submission of the bids online' available through the link 'Help for Contractors' at the e-Procurement Portal https://eprocure.gov.in.

D) If a particular document/Certificate to be uploaded as specified in bid, is not applicable for a bidder, the bidder shall attach a scanned copy of declaration in the letter head stating that the specific document is not applicable/exempted for the bidder in connection to this tender.

E) Bidder shall not modify the downloaded tender form including downloaded price Bid template in any manner. In case any tender form/Price bid template is found to be tampered with/modified in any manner, such bid will be summarily rejected, Bid Security would be forfeited, and bidder is liable to be banned from doing business with BPPI.

F) Interested eligible Tenderer may obtain further information in this regard from the office of the Tender Inviting Authority on all working days between 10:00 AM and 5:00 PM.

G) Once the bid have been uploaded in the CPP Portal https://eprocure.gov.in the bidder has to make sure that he has uploaded the files in the correct format and the bidder has to download the uploaded files from their own end and has to check whether the files uploaded is in proper format or not, no corrupted files have to be uploaded.

11. MODIFICATION AND WITHDRAWAL OF BIDS:

A) The bidder may modify or withdraw its bid after the bid submission before last time and date of submission of online Technical Bid.

B) No bid will be allowed to be withdrawn after the last date & time of submission of online Technical Bids.

12. OPENING OF TENDER:

A) The opening of the Technical Bid and the Price Bid will be done online as specified. The date of technical bid opening is published in advance. The date of opening of price bid will be announced only after the opening and evaluation of Technical bid. The bidder who are found eligible and on satisfying the criteria for technical evaluation/based on undertakings & Declaration, will only be informed the time and date of opening of Price Bid - Cover "B" of the tender.

B) Only authorized employee of tenderer is entitled to be present at the time of opening of Technical Bid - Cover "A" of the tender submitted by them.

C) In case, the date for opening of technical bid is declared holiday, the technical bid shall be opened on next working day at 11.30 A.M.

D) The original/attested hard copies (as mentioned in Clause no. 3, eligibility criteria) must reach the BPPI Head office on or before stipulated time, failing which the bid shall be summarily rejected.

13. EVALUATION OF TENDER:

A) Technical evaluation of the Bid will be done on the basis of criteria and documents mentioned in S.N. 3 (TECHNICAL BID-COVER A) which are present in the CPP Portal i.e. https://eprocure.gov.in.

B) Bids of firms who have furnished all the required documents for each of the product quoted will be considered.

C) If at any stage, it is found that the contract has been successfully obtained by the bidder by submitting forged/fabricated certificates/documents/licenses and/or by concealing the fact about blacklisting/debarring/de-registration of the firm by Govt. of India/Suspension/Cancellation/non-renewal of the manufacturing license of the bidder firm, the tender bid/rate contract may be rejected/terminated and suitable punitive action may be taken against the firm.

D) **In event of financial bid opening, due to provisions/compulsion of e-tendering system if complete quoted product list of financial bids of a bidder is opened then only those financial bids of quoted product shall be considered of whose technical bid has been found eligible by the Technical Evaluation Committee**.

E) **After evaluation of technical bid of tenderer/bidder, BPPI may ask the objection/clarification from tenderer/ bidder**.

14. INSPECTION OF MANUFACTURING FACILITIES:

A) BPPI or its authorized representative(s) has/have the right to inspect the manufacturing premises of Tenderers, before accepting the rate quoted by them or before releasing any purchase order(s) or at any point of time during the continuance of tender and also has the right to reject the tender or terminate/cancel the purchase orders issued and/or not to place further order, based on adverse reports brought out during such inspections. Copy of one full set of the documents submitted for the bid should be made available at the time of inspection.

B) Originals of all the documents uploaded/submitted in the Technical Bids should be produced for verification during Site inspection and Physical Verification.

15. ACCEPTANCE /REJECTION OF BIDS:

A) BPPI reserves the right to accept or reject the tender for the supply of all or any one or more items of the drugs tendered for in a tender without assigning any reason.

B) Evaluation of the tender and determination of the L1 rate (Lowest rate) will be done based on rate per unit size exclusive of GST as mentioned in column 7 of **BOQ.** BPPI shall have the right to call other eligible bidders those are willing to match L1 rates. If such firms are found, then the order quantity may be dispersed in ratio of: -

"Minimum 30% quantity to L1 bidder and remaining among the bidder's subject to the matching of L1 price for quoted drugs at the discretion of BPPI".
Purchase preference shall be given to the bidders having CoPP product / manufacturing units approved by foreign accredation i.e., US FDA. TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa.

C) However, in case the price quoted by the lowest responsive tenderer (L1) is not reasonable and un-acceptable, the price may be negotiated with L1 only as per CVC guidelines and, if it reduces the price to the desirable level, rate contract may be concluded with L1. To meet the demand, BPPI shall conclude parallel rate contract by counter offering the L1 rate to higher eligible bidders as per above provision.

D) Negotiation if required will be done strictly as per Central Vigilance Commission guidelines.

E) Letter of acceptance of tenders for Rate Contract will be communicated to the Tenderers in writing as per **ANNEXURE XI.**

16. AWARD OF CONTRACT:

A) The contract will be awarded to the lowest evaluated responsive bidder qualifying to the final round after Technical and Price Bid evaluation as per the clause 5. B) Determination of L1 bidder and clause 16. B. Acceptance /Rejection of BID, subject to the reservations and preferences to BPPI.

"Minimum 30% quantity to L1 bidder and remaining among the bidder's subject to the matching of L1 price for quoted drugs at the discretion of BPPI".
Purchase preference shall be given to the bidders having CoPP product / manufacturing units approved by foreign accredation i.e., US FDA. TG Australia, Health Canada, EU approval, MCC South Africa approval, Brazil Anvisa.

B) Letter of Acceptance:

The Tender Inviting Authority shall issue Letter of Acceptance (LOA) as per Annexure-XI to the lowest responsive bidder in respect of the drugs selected. Communication by e-mail / fax / letter will be deemed as valid communication.

C) The successful bidder, upon receipt of the Letter of Acceptance (LOA), shall communicate the acceptance of the same to the BPPI and shall furnish the documents, asked if any.

D) The bidder shall not, at any time, assign, sub-let or make over the contract or the benefit thereof or any part thereof to any person or persons whatsoever. Such practices will be deemed as fraudulent practices and also as breach of terms of contract and shall invite punitive action.

17. PERFORMANCE SECURITY DEPOSIT:

A) On being informed about the acceptance of the tender for Rate Contract, the Performance Security Deposit @5% will be deducted from each running bills and accumulated security deposit will be refunded without any interest by BPPI to the tenderer within 60 days following the date of completion of tenderers performance obligations under the contract including the shelf life obligation.

B) The Security deposit of supplier will be returned by BPPI only after the supplier has given undertaking to replace such medicines and indemnify BPPI against any losses on account of quality parameters duly notarized.

18. METHODOLOGY FOR PLACING ORDERS:

For the above purpose the following procedures will be adopted

A) After the conclusion of Price Bid opening (Cover B), the rates offered by tenderers for each product are evaluated and lowest acceptable rate (L1 Rate) arrived at is declared and that tenderer is informed**.**

B) **BPPI reserves right to issue purchase order for any drug on any one rate contract holder or more than one rate contract holder for same drugs**.

C) If two or more than two Tenderer's are declared as lowest suppliers for the same item(s), such Tenderers are eligible for Rate Contract and the placement of Purchase Orders for such item(s) for which they are declared as lowest.

D) The supplier shall start supply of the Drugs/Medicines to any or all the Warehouse (Address/Location) **as mentioned in clause 19.(A)** or any other place decided by BPPI and supply shall confirm to the conditions mentioned in the provision of tender documents, viz, logo, nomenclature, specification etc. within the stipulated period.

E) Once The supplier shall supply the Drugs/Medicines at any of the BPPI Warehouse **as mentioned in purchase order** (or any other place decided by BPPI) along with copy of Purchase order, copy of test reports and 3 original copies of Invoice. No payment will be processed without test reports.

F) A purchase order is placed on supplier for supply of definite quantity in terms of Rate Contract during validity period of Rate Contract that purchase order is valid and binding contract.

G) No Minimum drawl is in the Rate Contract. The actual quantity may vary from nil to maximum required quantity during validity of Rate Contract.

H) The Drugs/Medicines supplied in excess of the ordered quantity shall not be accepted and the supplier shall take back the excess at their cost. BPPI will not be responsible for the loss to the supplier and will not entertain any demand/claim.

I) The purchaser reserves the right to conclude one or more than one rate contract for the same item.

J) The purchaser has the option to renegotiate the price with the rate contract holders. In case of emergency, the purchaser may purchase the same item through Ad hoc contract with a new supplier.

K) Purchase orders, incorporating definite quantity of drugs/products to be supplied along with all other required conditions following the rate contract terms, shall be issued for obtaining supplies through the rate contract.

L) The purchaser is entitled to place purchase orders up to the last day of the validity of the rate contract and, though supplies against such purchase orders will be affected beyond the validity period of the rate contract, all such supplies will be guided by the terms & conditions of the rate contract.

M) The details of the required drugs, medicines, etc. are shown in **ANNEXURE -XII**. ***The tender quantity mentioned herein is not a fixed procurement quantity and it is only a tentative requirement and may be increased or decreased*** by the BPPI, at its discretion, depending on it is actual need. Though the tentative quantity is indicated in the Rate Contract, the BPPI, will confirm the actual requirement through purchase order/orders from time to time. The tenderers shall supply the drugs only on the basis of the purchase order issued time to time within validity of Rate contract period by the BPPI. Any supply without a valid purchase order will not be acceptable by BPPI and the BPPI shall not be responsible for any loss on this account.

N) However, once the purchase order/orders is/are issued by the BPPI, the tenderer shall not renege from the commitment of supplying the quantity mentioned in the acceptance of tender for Rate Contract.

O) The rates quoted shall not be varied with the Purchase order quantity during the full contract period.

P) The rates quoted and accepted will be binding on the Tenderer for the full contract period of two years and any increase in the price will not be entertained till the completion of this contract period. Accordingly, this clause will be applicable for all orders placed during the contract period. **However, Rate Contract validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.**

Q) No Tenderer shall be allowed at any time and on any ground, whatsoever it may be, to claim revision or modification in the rates quoted by them. Representation to make correction in the tender documents on the ground of Clerical error, typographical error, etc., committed by the Tenderers in the Bids shall not be entertained after submission of the tenders. Cross Conditions such as "SUBJECT TO AVAILABILITY", "SUPPLIES WILL BE MADE AS AND WHEN SUPPLIES ARE RECEIVED" etc., will not be entertained under any circumstances and the tenders of those who have mentioned such conditions shall be treated as incomplete and accordingly the Tender will be summarily rejected.

R) Supplies should be made directly by the tenderer and not through any other Agency / Dealer / Distributors.

S) The supplier shall take utmost care in supplying the quality Drugs/Medicines and ensure that the batch number mentioned in the packages of the Drugs/Medicines tally with the batch number mentioned in the Invoice produced to BPPI for payment. Also, the supplier shall ensure the quantity

relevant to the Batch Number of the Drugs/Medicines is mentioned in the invoice. Drugs to be supplied of any batch shall not be accepted with different MRP.

T) "MRP inclusive of all taxes" is to be printed on each unit/label. MRP will be intimated to successful bidders at the time of placing purchase orders.

U) **The Rate Contract (RC) awarded under the present tender enquiry will be in the nature of standing offer. Purchase Order (PO) may be placed from time to time against Rate Contract (RC).**

NOTE: BPPI don't give any guarantee of minimum purchase under this Rate Contract.

19. SUPPLY CONDITIONS:

A) Purchase orders will be issued to the Tenderer(s) at the discretion of the BPPI as per actual requirements. All the supplies shall be received at any or all of the following warehouse of BPPI or any other place decided by BPPI:

i) **Central Warehouse Gurugram (Bureau of Pharma Public Sector Undertaking of India (BPPI)**
Sugal Logistic Park, Warehouse No.1, Opp. GITM College, Bilaspur-Tauru Road
Village Bilaspur and Khasra No. 60//14/2, 17,24,6,15, 16, 25, 7/1, 14/1, 61//9, 10, 11,62//3/2, 4,10//17, 24, 19//3, 8/2, 9/1/1, 12/2/2/2 min 13/1/1 min.
Pin Code – 122413
Phone No. – 011-49431800

ii) **Regional Warehouse Guwahati (Bureau of Pharma Public Sector Undertaking of India (BPPI)**
DAG No. 884 of K P PATTA No. 04, Mughuapara, Pamohi Village, Dist. Kamrup(M) Guwahati, Assam India 781035.
Phone No. – 011-49431800

iii) **Regional Warehouse Chennai (Bureau of Pharma Public Sector Undertaking of India (BPPI)**
79, KIZHMUTHALAMPEDU, PANAPAKKAM,
City Tiruvallur, State Tamil Nadu
Pin Code – 601201
Phone No. – 011-49431800

B) Within 3 days from the receipt of purchase orders the Tenderer should inform BPPI through mail the confirmation for the receipt of the purchase order.

C) The Tenderer should also fax / mail the details of supply/delivery schedule to BPPI within 7 days from the receipt of the purchase order. In case, the supply shall not be made by the date as conveyed by the supplier, supply order shall be cancelled at their risk and cost. If no response is received within 7 days from the supplier / tenderer about supply of drugs as per purchase order, it shall be presumed that the supplier/tenderer is not interested to supply the drugs ordered as per purchase order and BPPI shall purchase the drugs from alternative sources.

D) The supplier must supply the ordered quantity as follow delivery schedule:

Sl. No.	Nature of Product	Delivery Schedule (Days)
1	Delivery Schedule against first P.O. for injectable/Infusion/Vials (Products required sterility testing)	60 days
2	Delivery Schedule against subsequent P.O. for Injectable/Infusion/Vials (Products required sterility testing)	45 days
3	Delivery Schedule against first P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)	45 days
4	Delivery Schedule against subsequent P.O. for all drugs except Injectable/Infusion/Vials (Products do not required sterility testing)	30 days
5	For biological products	60 days
6	Vaccines and Blood products	120 Days

E) If the delivery date happened to be a holiday for BPPI, the supply should be completed by 5.00 PM on the next working day.

F) In case of Non- execution of the order, BPPI reserves the right to place purchase orders (partially/fully) on alternate source at the risk and cost of the default tenderer(s) without any notice/Information.

G) If a supplier fails to execute supply as per Purchase Order, the 5% of value of unexecuted quantity of Purchase Order shall be recovered from pending bill or EMD/Bank Guarantee/Performance security deposit and their bad performance shall be kept in record of BPPI for future dealing as considered appropriate by BPPI.

H) If the Tenderer fails to execute the supply within the stipulated time, the BPPI is at liberty to make alternative arrangement for purchase of the items for which the Purchase orders have been placed, from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the defaulted supplier and in such cases the BPPI has every right to recover the cost and impose Liquidated Damages as mentioned in Clause 25.

I) The liquidated damages as specified in clause 25. (B) of the tender conditions will be levied on the quantity supplied after the schedule as mentions in "Clause 19.(D) from the date of issue of purchase order. However, no supplies will be accepted after 30 days of the expiry of delivery date i.e., completion of specified liquidated damages period as per clause 25 (B), the purchase order shall be cancelled at the risk and cost of the supplier. **However, the supplier must take prior approval from BPPI for supply of drugs beyond stipulated delivery period in Purchase order.**

J) Supplier shall complete the earliest pending purchase order before commencing the supply of subsequent purchase orders. **Further, supplies against a purchase order are to be made in minimum numbers of batches as far as possible and same batch should not be supplied in repeated consignment.**

K) Bidder must comply to the shelf life of each quoted drugs as mentioned in the Annexure XIII of the tender document and hey must fill the required shelf-life detail in Para VI of Annexure II.

L) The Tenderer must submit an Analysis report for every batch of drug along with invoice. In case of failure on part of the supplier to furnish such report, the batch of drugs will be returned to the suppliers and he is bound to replenish the same with Govt. approved lab test report. The Drugs supplied by the successful Tenderer shall be of the best quality and shall comply with IP/BP/USP and the specifications, stipulations and conditions specified in the tender.

M) Tenderer should supply the product as follow:

(i) Within 2 months excluding month of manufacture of products having shelf life up to 2 years,
(ii) Within 3 months excluding month of manufacture of products having shelf life more than 2 years & up to 3 years and
(iii) Within 4 months excluding month of manufacture of products having shelf life more than 3 years
(iv) Within 3.5 months excluding month of manufacture of products for drug code 574 HUMAN RABIES VACCINE INJECTION 2.5 IU.

Products supplied beyond the above-mentioned period from the date of manufacturing shall levied a LD as Per Clause 25. (E) of tender documents. For example, product having manufacturing of November 2019 must be supplied by 31st January 2020 in case shelf life up to 2 Years.

N) If at any time the Tenderer has, in the opinion of the BPPI delayed the supply of drugs due to one or more reasons related to **Force Majeure events** such as riots, mutinies, wars, fire, storm, tempest or other exceptional events at the manufacturing premises, the time for supplying the drugs may be extended by the BPPI at discretion for such period as may be considered reasonable. However, such extension shall be considered only if a specific written request is made by the Tenderer within 10 days from the date of occurrence of such event with necessary documentary evidence. The supplier shall not be liable to pay LD and forfeiture of Security deposit for the delay in executing the contract on account of the extension of supply period on the ground of force majeure events.

O) The exceptional events do not include the Scarcity of raw material, Increase in the cost of raw material, Electricity failure, Labour disputes/Strikes, Insolvency, and Closure of the Factory/Manufacturing unit on any grounds etc.

P) Suppliers are required to supply the drugs within the delivery period mentioned in the purchase order. In this regard it is informed to the bidders that their performance shall be considered unsatisfactory in case of delayed supply (beyond delivery period) or non-supply of products. BPPI may reject their bid in future tenders considering their unsatisfactory performance of supplies.

Q) Leaked, soiled, broken containers with damaged labels shall not be accepted.

R) If BPPI observes some physical defects (like empty blisters, improper labelling) of the supplies during sampling, the batch shall be rejected. If supplier wants to take back the batch for rectification, they can take back at their cost, rectify and send back to BPPI within 15 days otherwise same batch shall not be accepted. Due to rectification, if its shelf life condition as per tender provision does not meet, it shall be discretion of BPPI depending upon requirement to accept the goods with penalty.

S) Tenderers shall not supply the drugs declared banned by Government of India, even if Purchase Order is placed.

20. LOGOGRAM:

Logogram means, wherever the context occurs, the design as specified in **Enclosure 1 & 2 of ANNEXURE-VII. The name of the drug shall be mentioned in English and Hindi** as per pharmacopoeia and its strength.

A) Tenders should supply for Drugs etc., as per the specifications such as name, strength, minimum size and packed with appropriate size of the strips/blisters/bottles/tubes etc as per the design enclosed as per **Enclosure 1 to ANNEXURE –VII** and **Enclosure 2 to ANNEXURE –VII.**

B) All dosage form has to be supplied in packing as specified in product list (**ANNEXURE XII**) and shall also conform to Schedule P1 of the Drugs & Cosmetics Act & Rules 1945, wherever it applies. Affixing of stickers and rubber stamps shall not be accepted and supplies will be returned back at supplier's cost.

C) Vials, Ampoules (more or equal than 5 ml) and Bottles containing the items tendered for should also carry the printed PMBJP logogram of proportionate size.

D) Failure to supply Drugs etc., with the printed logogram of proportionate size will be treated as breach of the terms of Rate Contract / violation of tender conditions. The purchase order shall be cancelled at the risk and cost of the supplier. However, if such failure continuous despite notice, will be viewed as a serious lapse and initiate blacklisting of the supplier and levied a LD as per clause 25 (D) of tender documents.

E) Drugs without GS-1 Standard Barcoding on Primary, Secondary and Tertiary Packaging will not be accepted.

21. PACKING:

A) The drugs shall be supplied in the package specified in **ANNEXURE -VIII** and **ANNEXURE - XII** and the package shall carry the logograms of proportionate size specified in 1 to **ANNEXURE –VII & 2 to ANNEXURE –VII** and shall also conform to Schedule P1 of the Drug & Cosmetic Act & Rules 1945, whether it applicable.

Non-affixing of logograms will be treated as violation of tender conditions and fine will be deducted from the amount payable as per condition in Clause 25 (D) of tender documents.

B) The drugs in any dosage form to be supplied by the supplier should not be embossed indicating any code no./logo or name of the company. Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 25. (D)

C) The packing in each carton shall be strictly as per the specification mentioned in **Annexure-VIII**. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**)**. The material to be used for carton should be from virgin chemical pulp.** Failure to comply with this shall lead to non-acceptance of the goods besides imposition of penalties as per clause 25 (D). Storage conditions must be indicated on outer label.

D) The cap of bottle preparations should not carry the name/logo/other details of the supplier. However, cap may contain BPPI logogram.

E) The labels in the case of Injectable preparations should clearly indicate whether the preparations are meant for Intravenous (IV), Intramuscular (IM), Intra Dermal (ID), Subcutaneous (SC) administration etc.

F) It should be ensured that only virgin packaging material of uniform size, including bottle and vial, is used for packing.

G) All primary packing containers should be strictly conforming to the specification included in the relevant pharmacopoeia.

H) Packing should be able to prevent damage or deterioration during transit.

I) The packings/labels of two different products of a same supplier should be clearly distinct from each other

J) In the event of items of drug supplied found to be **not as per specifications in respect of their packing and logogram**, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier. In such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 25 & 26.

K) Designs of packaging with the logograms shall be subject to approval by BPPI within 3 days of receipt of purchase order or within 30 days of release of letter of acceptance. Text matter of all type of label must be checked and responsibility shall be of manufacturer.

In case of failure of BPPI to do so, the supplier may go ahead with the design as per the specification in Enclosure-1 to ANNEXURE VII and Enclosure-2 to ANNEXURE VII.
STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance.

L) The colour of the strength must be different from the colour of the generic name of the drug on primary and secondary packaging and the approval for the same should be taken from the quality/regulatory department while taking artwork approval. The printing ink used should be of good quality (clarity, brightness, contrast) which is easily readable.

M) WHO-GMP certified, Therapeutic code & NABL lab tested shall be indicated on the primary and secondary packaging and shall be incorporated as per the approval from the quality/regulatory department while taking artwork approval.

N) Barcodes as per GS-1 standards are required to be printed on products at various packaging levels (Primary, Secondary and Tertiary) as per Annexure-IX.

22. QUALITY TESTING & QUALITY CONTROL:

A. All the batches of the drugs supplied shall be supported by test/ analysis reports furnished by independent NABL Accredited Drugs Testing Laboratory/Central Drug Testing Laboratory/In House Quality Control Laboratory. The Tender Inviting Authority has the right to get the drugs tested at the laboratories of his choice for further verifications, from BPPI empanelled laboratories.

B. Random samples of each supplied batch will be chosen at the point of supply or distribution/storage points for testing. The samples will be sent to different BPPI empanelled laboratories including Government Drugs Testing Laboratory/NIPER/PSU labs for testing. Handling and testing charges will be deducted by BPPI for the above purpose, as specified in Clause 24.

C. **STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit within 15 days from the date of Letter of Acceptance by mail to Quality and Regulatory officer of BPPI with artwork approval for design of packaging with the logogram as per Clause 21.K.**

D. The Drugs shall have the active ingredients at the prescribed level as indicated in official compendiums throughout the shelf life period of the drug. The samples will be drawn periodically throughout the shelf life period and if found "Not of Standard Quality", the cost of entire batch paid will be recovered whether consumed fully/partially. Also, action will be initiated for blacklisting as per clause 26 irrespective of the period of supply.The supplies will be deemed to be completed only upon receipt of the quality certificates from the laboratories. Samples which do not meet quality requirement shall render the relevant batches liable to be rejected. If the sample is declared to be "Not of Standard Quality" or spurious or adulterated or misbranded, such batch/batches will be deemed to be rejected goods.

E. In the event of the samples of Drugs supplied fails in quality tests or found to be not as per specifications, the BPPI is at liberty to make alternative purchase of the items of drugs for which the Purchase orders have been placed from any other sources or in the open market or from any other Tenderer who might have quoted higher rates, at the risk and the cost of the supplier and in such cases the BPPI has every right to recover the cost and impose penalty as mentioned in Clause 26(I).

F. If the product / sample fails in quality test, every failed batch shall be taken back by the supplier at their own cost and BPPI shall not be responsible for any damage during this period.

G. The supplier shall furnish evidence of the basis for shelf life and other stability data concerning the commercial final package on request by the BPPI. In case of any complaint in the field, the B.M.R/B.P.R for the particular batch of the product(s) supplied shall be produced when demanded. **For New drugs, complete stability data of 6 months' period shall be acceptable.**

H. **The** products should conform to the standards of IP/BP/USP/EP/JP as the case may be.**However, the drugs notified in the IP (amended up to date) shall be accepted only if supplied conforming to the standards outlined in the IP.** In case the product is not included in the any of the said compendiums, the supplier, upon award of the contract, must provide the reference standards and testing protocols for quality control testing.

I. The case of admixture of drugs will be treated as a violation of tender conditions and fine will be levied as per clause 26. If such lapses happen more than twice in a tender period such cases will be treated as "Misbranded Drugs".

23. PAYMENT PROVISION:

A) No advance payments towards costs of drugs will be made to the supplier.

B) Payments towards the supply of drugs will be made within 90 days from the date of receipt of goods, strictly as per the tender terms and condition. The payment will be made either by means of a/c payee Cheque or through RTGS (Real Time Gross Settlement System)/Core Banking/NEFT. The Tenderer shall furnish the relevant details in original **(ANNEXURE -V)** to make the payment through RTGS/Core Banking/NEFT.

C) All bills/Invoices should be raised in triplicate and the bills should be drawn as per GST Rules in the name of Bureau of Pharma Public Sector Undertakings of India. 8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055 or in the name of any other authority as may be designated.

D) (i) Payments for supply will be considered only after supply of minimum 50% of Drugs ordered in the individual Purchase Order PROVIDED reports of Standard Quality on samples testing are received from Government Analyst or Approved Laboratories of BPPI.

(ii) However, in case of cancellation of a particular purchase order due to failure in delivery, payment for part supplies less than 50% of the purchase order quantity on the date of cancellation of the purchase order may be considered for release of payment subject to the following:

a) If the Tenderer have supplied at least 50% of the quantity ordered in the subsequent purchase order within delivery period stipulated in purchase order from the issue of such purchase order.
b) If further purchase order is not placed with the supplier due to any reason, not attributable to the supplier, the amount eligible will be paid within 90 days from the date of last supply.
c) The payment for part supply as mentioned above will subject to the deduction of liquidated damages, penalty towards unexecuted quantity, risk and cost etc., as per the tender conditions.

E) If at any time during the period of contract, the price of tendered items is reduced or brought down by any law or Act of the Central or State Government or by the Tenderer himself, the Tenderer shall be bound to inform the BPPI immediately about such reduction in the contracted prices. Tender Inviting Authority is empowered to unilaterally effect such reduction as is necessary in rates in case the Tenderer fails to notify or fails to agree for such reduction of rates.

F) In case of any increase of decrease in the Taxes/GST after the date of submission of tenders and during the tender period, such variation in the taxes/GST will be to the account of the BPPI. For claiming the additional cost on account of the increase in taxes/GST, the Tenderer should produce the proof of having paid additional amount on this account on the goods supplied to BPPI from the concerned authorities and also must claim the same in the invoice separately. However, the basic price structure and the price of the Drugs approved under the tender shall not be altered. Similarly, if there is any reduction in the taxes/GST and statutory levies as notified by the Govt., after the date of submission of tender, the Tenderer will be paid based on the unit rate worked out on the

basis of the reduced taxes/GST/statutory levies without any change in the basic price or the price structure of the drugs approved under the tender. Any increase or decrease in taxes/GST and statutory levies will be considered based on the notification issued by the Government.

G) However, if the firm supplies after originally stipulated Delivery period, increase in taxes/GST due to statutory variation in taxes/GST shall be borne by the supplier. In case of decrease in taxes/GST due to statutory variation in taxes/GST, the same shall be passed on by the supplier to the BPPI.

24. HANDLING & TESTING CHARGES:

In all supplies, 1.5% of the supply value shall be deducted towards handling & testing charges.

25. LIQIDATED DAMAGES & OTHER PENALTIES:

A) All supply should be made within the stipulated time as per the clause 19.D of the Delivery Schedule and quantity as mentioned in the Purchase Order.

B) If the supply reaches the Drug Warehouses beyond the stipulated time as mentioned in PO/Bid document, liquidated damages will be levied at the rates 2% per week or part thereof, subject to maximum of 10% irrespective of the fact that whether the BPPI has suffered any damage/loss or not, on account of delay in effecting supply

C) If the supply is received in damaged condition it shall not be accepted. The supplier shall have to replace the goods with damage and the penalty equal to the penalty for unexecuted supplies will be levied for the damaged goods and payments will be withheld till proper replacement.

D) All the Tenderers are required to supply the product(s) with printed MRP as per purchase order and logogram of appropriate size on the strips, blisters, vials, ampoules& bottles and with prescribed packing specification. If there are any deviation in these Tender conditions, action will be taken to blacklist the product, and/or a separate damage will be levied @ 5% of value of the defaulted quantity irrespective of the Tender Inviting Authority having actually suffered any damage/loss or not, without prejudice the rights of alternative purchase specified in Clause No.19F,19 H and 21.J.

E) If supplier supplied the drug time beyond the manufacturing date as mentioned in clause 19. (M) of supply conditions, a liquidation damage will be levied @ 5% per month subject to maximum 30% (Up to 6 months).

F) In all the above conditions, the decision of the Tender Inviting Authority shall be final and binding.

26. DEDUCTION & OTHER PENALTIES ON ACCOUNT OF QUALITY FAILURE:

A) If the samples do not conform to statutory standards, the Tenderer will be liable for relevant action under the existing laws and the entire stock in such batch has to be taken back by the Tenderer within a period of 30 days of the issue of the letter from the BPPI. Such stock shall be taken back at the expense of the Tenderer. Further, actual handling and testing charges shall be paid to BPPI by the supplier otherwise these charges shall be recovered from their pending bill/EMD/Performance Security Deposit.

B) The BPPI has the right to destroy such "NOT OF STANDARD QUALITY DRUGS" if the Tenderer does not take back the goods within the stipulated time. The BPPI will arrange to destroy the "NOT OF STANDARD QUALITY DRUGS" after the expiry of 30 days mentioned above without further notice and shall also collect handling charges (in case the product is sent back to supplier on freight to pay basis)/ demurrage charges calculated at the rate of 2% per week

on the value of the drugs rejected till such time stipulated. Further, the cost of disposal shall be recovered from the supplier.

C) If any items of Drugs/Medicines supplied by the Tenderer have been partially or wholly used or consumed after supply and are subsequently found to be in bad odour, unsound, inferior in quality or description(Adulterated/Spurious/Misbranded) or otherwise faulty or unfit for consumption, then the contract price or prices of total such batches supplied will be recovered from the Tenderer, if payment had already been made to him. In other words, the Tenderer will not be entitled to any payment whatsoever for Items of drugs found to be of "NOT OF STANDARD QUALITY" whether consumed or not consumed and the Tender Inviting Authority is entitled to deduct the cost of such batch of drugs from any amount payable to the Tenderer. On the basis of the nature of failure, action will be initiated to blacklist the product/supplier.

D) For the supply of Adulterated/Spurious/Misbranded, as defined in the Drugs and Cosmetics Act, 1940, to BPPI. BPPI reserves the right to blacklist the supplier. No further supplies shall be accepted from the firm/company.

If the tenderer is blacklisted, the tenderer shall also not be eligible to participate in tenders of Tender Inviting Authority of BPPI for supply of Drugs for a period of 5 years from the date of blacklisting.

In case of supply of NOT OF STANDARD QUALITY drug(s) to BPPI, the product shall be blacklisted by BPPI and no further supplies shall be accepted for the particular drug(s). The Tenderer shall also not be eligible to participate in tenders of BPPI for supply of such Drugs for a period of 2 years from the date of blacklisting.

In addition, the Director of Drugs Control of concerned State will be informed for initiating necessary action on the Tenderer in their state. Performance Security Deposit will also be forfeited without any intimation.

E) The Tenderer shall furnish the source of procurement of raw material utilized in the formulations, if required by the BPPI. The BPPI reserves the right to cancel the purchase orders, if the source of supply is not furnished.

F) The decision of the BPPI or any officer authorized by him, as to the quality of the supplied drugs, medicines etc., shall be final and binding. In such cases, the BPPI will be at liberty to terminate, the contract either wholly or in part on 30 days' notice. The Tenderer will not be entitled for any compensation whatsoever in respect of such termination besides forfeiture of Performance Security Deposit.

G) For contravention of the stipulations of the contract or for other justifiable reasons, the contract may be terminated by the BPPI, and the Tenderer shall be liable to pay for all losses sustained by the BPPI in consequence of the termination which may be recovered from the Tenderer, as per rules besides forfeiture of Performance Security Deposit.

H) Non-performance of any of the contract conditions and provisions will disqualify a firm from participating in the tender for the next 2 years/ Blacklisting the tenderer.

I) In the event of making Alternative Purchase, as specified in Clause 19.H, Clause 21.J and in Clause 22.F penalty will be imposed on the supplier. The excess expenditure over and above contracted prices incurred by the BPPI in making such purchases from any other sources or in the open market or from any other Tenderer who has quoted higher rates and other losses sustained in the process, shall be recovered from the Performance Security Deposit or from any other money due and become due to the supplier and in the event of such amount being insufficient, the balance will be recovered personally from the supplier as per rules.

J) In all the above conditions, the decision of the BPPI shall be final and binding.

27. BLACKLISTING IN THE EVENT OF WITHDRAWAL FROM THE TENDER, AND NON-ADHERENCE TO THE QUALITY STANDARDS AND SUPPLY SCHEDULE:

A) BLACKLISTING OF PRODUCT/TENDERER ON WITHDRAWAL OF TENDER

If the Tenderer fails to perform the obligations under the tender conditions / commits default in the performance of the contract/LOA, such Tenderers will be blacklisted for a period of **2 years** by BPPI from the date of intimation besides forfeiture of EMD/ Performance Guarantee.

The Tenderers who have withdrawn after participating in the tender after the last date and time of submission of online bid, either fully or partially, **the entire firm/company** will be blacklisted for a period of **2 years** from the date of intimation by BPPI apart from forfeiture of the Security Deposit/EMD.

B) BLACKLISTING FOR QUALITY FAILURE/QUALITY TEST BY THE EMPANELLED LABORATORIES OF BPPI.

a) Each and every batch of drugs/medicines supplied by the supplier shall be subjected to quality test by the Empaneled laboratories as per the procedure adopted by BPPI.
BPPI shall also draw the samples of products supplied in the marketplace and get the same tested, to make sure the products are conforming to quality requirements till Self life.

b) If the sample of any batch fails in quality test and report is received stating "Not of standard quality "in any test the report along with the chromatograms etc. such batch of drugs shall be rejected & no further procurement of that drug from the supplier will be taken for two years from the date of sample being declared not of standard quality.

(i) If the supplier challenges and request for retesting, the sample shall be tested at government testing laboratory or reputed govt. institute like NIPER. The test report of govt. lab or NIPER will be final and will be binding to the supplier.

(ii) The cost of such Re-testing shall be recovered from the supplier.

(iii) If **2** batches of item/drug supplied by the same supplier is reported to NOT OF STANDARD QUALITY in specification, then the firm shall be blacklisted for 2 years after observing procedure laid down in Para 27.B.(d) besides forfeiture of Performance Security Deposit.

(iv) If a single batch of any product(s) supplied by the company/firm declared as Adulterated/spurious/ Misbranded by the Government Authorities during the shelf life of the product supplied irrespective of tender period, the company/firm shall be blacklisted for a period of **2 years from the date of intimation & forfeiture of security deposit.**

C) Quality Test by Statutory Authorities:

(i) If any drug is declared "NOT OF STANDARD QUALITY", by any government agencies or drug licensing authority, the issue of available stock of the particular item will be stopped. Further, the available stock of the product in hospitals/JAS will be retrieved.

(ii) If any batch of any product(s) supplied by the company/firm declared, NOT OF STANDARD QUALITY in specification as defined in the Drugs and Cosmetics Act, 1940, by the Government Authorities during the relevant tender period or during quality check within shelf life period, the company/firm shall be blacklisted for a period of 2 **years from the date of blacklisting** after observing procedure laid down in Para 27.B(d)

D) Procedure for Blacklisting:

(i) On receipt of complaint from Distributer/retailers/customers or report from Govt. Analyst/Drug Testing Laboratory indicating that a particular Item/Drug is "**NOT OF STANDARD QUALITY/ ADULTERATED/ SPURIOUS/MISBRANDED" (**As the case may be), a show cause notice shall be issued to the supplier calling for explanation within 7 days from the date of notice. On receipt of explanation from the supplier, the CEO, BPPI may take appropriate action on merits of the case and impose penalty including the blacklisting of the item of the product/company or firm as deemed fit besides forfeiture of Performance Security Deposit.

(ii) If a particular item of the drug has been blacklisted according to the procedure stated above, the supplier is not eligible to participate in any of the tenders for such item floated by the BPPI until the period of blacklisting is over.

(iii) If a supplier company/firm is blacklisted according to the procedure stated above, such supplier is not eligible to participate in any of the tenders floated by the BPPI until the period of blacklisting is over.

E) BLACKLISTING FOR NON-SUPPLY:

Due to non-supply of item against any purchase order, 5 % value of purchase order shall be recovered from the supplier in addition of other penal like risk purchase.

In case of repeated circumstances of non-supply of items i.e. 2 times, the supplier may be blacklisted for 2 years in addition of forfeiture of Performance Security Deposit/ EMD and other penal action.

28. SAVING CLAUSE:

No suit, prosecution or any legal proceedings shall lie against the Tender Inviting Authority or any person for anything that is done in good faith or intended to be done in pursuance of the tender.

29. RESOLUTION OF DISPUTES

The BPPI and the supplier shall make every effort to resolve, amicably by direct informal negotiation any disagreement or dispute arising between them under or in connection with the contract.

A) ARBITRATION AND JURISDICTION;

Normally, there should not be any scope of dispute between the BPPI and the supplier after entering into a mutually agreed valid contract/ Rate Contract.

However, due to various unforeseen reasons, problems may arise during the progress of the contract/ Rate Contract leading to disagreement BPPI and the supplier shall first try to resolve the same amicably by mutual Consultation. If the parties fail to resolve the dispute by such mutual consultation within twenty-one days, then, depending on the position of the case, either the BPPI or the supplier shall give notice to other party of its intension to commence Arbitration procedure as per Indian Arbitration and Conciliation Act, 1996. Such disputes/differences shall be referred to Sole Arbitrator to be appointed by the CEO of BPPI. The venue of Arbitration Shall be at New Delhi. The award published by the Arbitrator shall be final and binding on the parties.

B) **APPEAL:**

a) Any Tenderer aggrieved by the order passed by the Tender Accepting Authority under section 10 of the said Act, may appeal to the Chairman, BPPI within ten days from the date of receipt of order and the Chairman, BPPI shall dispose the appeal within fifteen days from the date of receipt of such appeal.

b) No Appeal shall be preferred while the tender is in process and until tender is finalized and Notification of award is issued by the BPPI.

30. CONTACTING THE BPPI BY THE BIDDER:

A) No bidder shall contact the BPPI on any matter relating to its bid, from the time of bid opening to the time the contract is awarded.

B) Any effort by a bidder to influence the BPPI in the Purchaser's bid evaluation, bid comparison or contract award decisions may result in rejection of the bidder's bid.

C) The bidder shall not make any attempt to establish unsolicited and unauthorized contact with the Tender Accepting Authority, Tender Inviting Authority or Tender Scrutiny Committee after opening of the bids and prior to the notification of award and any attempt by any bidder to bring to bear extraneous pressures on the Tender Accepting Authority, Inviting Authority or Tender Scrutiny Committee, shall be sufficient reason to disqualify the bidder.

D) Notwithstanding anything contained in clause (C) above the Tender Inviting Authority or the Tender Accepting Authority, may seek bonafide clarifications from bidders relating to the bids submitted by them during the evaluation of bids.

31. FRAUDULENT AND CORRUPT PRACTICES:

A) For Bidders:

It is purchaser's policy to ensure that suppliers and their authorized representatives/agents observe the highest standard of ethics during the procurement and execution of such contracts. (In this context, any action taken by a bidder, supplier, contractor, or by their authorized representatives/agent, to influence the procurement process or contract execution for undue advantage is improper) In pursuance of this policy, the purchaser;

a) Defines, for the purposes of this provision, the terms set forth below as follows:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party ("another party" refers to a public official acting in relation to the procurement process or contract execution]. In this context, "public official" includes staff and employees of other organizations taking or reviewing procurement decisions.

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation (a "party" refers to a public official; the terms "benefit" and "obligation" relate to the procurement process or contract execution; and the "act or omission" is intended to influence the procurement process or contract execution).

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party ["parties" refers to participants in the procurement process (including public officials) attempting to establish bid prices at artificial, non-competitive level].

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party (a "party" refers to a participant in the procurement process or contract execution).

(v) "obstructive practice" is (a) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from

disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for under sub-clause (e) below.

b) Will reject a proposal for award if it determines that the bidder considered for award has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for the contract in question;

c) will cancel the contract if the purchaser determines at any time that the bidder, supplier and contractors and their sub-contractors engaged in corrupt, fraudulent, collusive, or coercive practices

d) will sanction a firm or individual, including declaring in eligible, either indefinitely or for a stated period of time, to be awarded a contract if it at any time determines that the firm has, directly or through an agent, engaged in corrupt, fraudulent, collusive, coercive or obstructive practices in competing for, or in executing, a contract; and

e) will have the right to inspect the accounts and records of the bidders, supplier, and contractors and their subcontractors/authorized representatives and to have them audited by auditors appointed by the purchaser.

B) For Suppliers:

If the BPPI determines that a Supplier has engaged in corrupt, fraudulent, collusive, coercive or obstructive practices, in competing for or in executing the Contract, then the BPPI may, after giving 7 days' notice to the Supplier, terminate the Supplier's engagement under the Contract and cancel the contract, and the procurement will be made at the risk and cost of the supplier besides blacklisting the bidder for 5 years with forfeiture of Performance Security Deposit apart from other penal actions.

a) For the purposes of this Sub-Clause:

(i) "corrupt practice" is the offering, giving, receiving or soliciting, directly or indirectly, of anything of value to influence improperly the actions of another party;

(ii) "fraudulent practice" is any act or omission, including a misrepresentation, that knowingly or recklessly misleads, or attempts to mislead, a party to obtain a financial or other benefit or to avoid an obligation;

(iii) "collusive practice" is an arrangement between two or more parties designed to achieve an improper purpose, including to influence improperly the actions of another party;

(iv) "coercive practice" is impairing or harming, or threatening to impair or harm, directly or indirectly, any party or the property of the party to influence improperly the actions of a party;

(v) "obstructive practice" is (aa) deliberately destroying, falsifying, altering or concealing of evidence material to the investigation or making false statements to investigators in order to materially impede a purchaser investigation into allegations of a corrupt, fraudulent, coercive or collusive practice; and/or threatening, harassing or intimidating any party to prevent it from disclosing its knowledge of matters relevant to the investigation or from pursuing the investigation; or (bb)acts intended to materially impede the exercise of the purchaser's inspection and audit rights provided for.

32. JURISDICTION:

In the event of any dispute arising out of the tender such dispute would subject to the jurisdiction of the Civil Court within the city of Delhi only.

ANNEXURE – I

Ref. Clause 3 (N)

CHECK-LIST (Whether Uploaded the documents)

COVER – A

S. N.	Check List	YES/ No	Page No.	Remarks
1	Check list – ANNEXURE – I **as per clause 3. N.**			
2	EMD Rs. 10,00,000/- in the form of **Bank Guarantee or National Electronic Fund Transfer (NEFT) or Bankers Cheque or Demand Draft** as per **ANNEXURE-III (Clause 3. A & 6. A)**.			
3	NSIC or MSME certificate (If EMD is exempted as per Clause No. 3. A Note).			
4	Copies of documentary evidence for the constitutions of the company / Firm/ Proprietorship such as Memorandum and Article of Association, Partnership deed with complete address as per Clause 3. B.			
5	Power of attorney or Resolution of board by which the authorized signatory has been authorized by the Tenderer to sign the tender documents as per clause 3. C.			
6	Copies of **WHO-GMP** (WHO-Good Manufacturing Practice) as per revised Schedule- 'M'/COPP Certificate of the manufacturing unit issued by the Licensing Authority/ Drugs Control Department/FDA. The WHO-GMP certificate must not be older than one year from the last date of submission of tender as per Clause 3. G.			
7	Copy of Minimum three years old valid Manufacturing License of the product quoted with latest license renewal certificate as per Clause 3. D.			
8	Copy of Maximum Production Capacity Certificate (section wise) issued by concerned Licensing Authority Form Drugs Control Department/FDA highlighting the quoted product section as per Clause no. 3.H.			
9	Copy of valid GS-1 registration certificate for bar coding as per Clause 3. R.			
10	copy of Non-Conviction Certificate issued by the concerned Licensing Authority from Drug Controller Administration of the State, not older than 12 months as per Clause no. 3.F.			
11	copy of Market Standing Certificate issued by the Licensing Authority from Drug Controller Administration of the State for minimum 2 batches in last 3 Years as per Clause no. 3.E.			
12	Valid COPP certificate as per WHO format of their Principal Manufacturing company (If applicable)			
13	Copies of **approval of Manufacturing Unit of the any agency like** US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa, **if any.**			
14	Copy of Audited Annual Balance sheet and Profit and loss statement showing details of their Annual average turn over not less than 50 (Fifty) crores for three consecutive financial years as per Clause 3. I.			
15	Authorization letter nominating an employee of the tenderer to transact the business with the Tender Inviting Authority as per clause 4. P.			
16	ANNEXURE –II (Declaration for eligibility in participating the tender) **original Annexure II delivered to BPPI as per clause 3. J.**			

17	ANNEXURE IV {certificate from the C.A. (Chartered Accountant) or Company Secretary. **Original Annexure V delivered to BPPI as per clause 3. I.**			
18	ANNEXURE—V **(Mandate form) to furnish company bank details as per clause 24. B.**			
19	Annexure VI indicating manufacturing License, validity of license and market standing certificate details **as per clause 3. L.**			

NOTE: - EMD instrument, ANNEXURE II, ANNEXURE IV, ANNEXURE V and ANNEXURE VI are to be delivered in original to BPPI, rest of the document duly authorized should be submitted on or before stipulate date as mentioned in the tender document "technical cover A".

Name and signature of authorized signatory (with company seal) ……

ANNEXURE –II

(On nonjudicial Stamp Paper)

Ref. Clause No. 3.(J)

DECLARATION

I/We M/s. …… represented by its Proprietor/Managing Partner /Managing Director having its registered office at ……..…….....and its factory premises at ……

……do hereby declare as under: -

(I) that I/we have carefully read all the terms and conditions of tender in ref. no**. BPPI/DRUG/RC-116/2019 dated 04/10/2019** including Amendment(s) to Tender document (if any) issued by Bureau of pharma public sector undertakings of INDIA, New Delhi,110055 and accept unconditionally all terms and condition of tender document including Amendment(s) to Tender document (if any).

(II) **A**. that I/We are holding and have uploaded (a) valid drug license for quoted drugs,(b) valid WHO-GMP certificate , (c) 3 years market standing certificate for quoted products issued by licensing authority, (d) a certificate manufactured & marketed two batches within 3 years issued by C.A. for quoted drugs, (e) valid non conviction certificate not older than 12 months,(f) declaration of the active API polymorphic form used in formulation for quoted drugs and declare that it is internationally accepted active polymorph **(if any)** and (h) the copies of the specifications for all quoted drugs and STP (standard testing procedure) for Non- Pharmacopoeia quoted drugs and also enclosed all undertaking/declaration as per Annexure mentioned in the tender document.

(II) B. that I/We shall submit the complete stability data (long term stability studies and accelerated stability studies) for all awarded drugs within 15 days from the date of issue Letter of Acceptance. (If manufacturer has licensed a formula from another company and such licensed formula is used for the product, then the stability data of the licensor shall be submitted along with licensing agreement.)

(II) C. that I/we shall supply the drugs as per specification, composition, strength, design, logo and packing given in ANNEXURE-XIII and Shape, Colour, Packing Type, etc. of drugs shall be as given in ANNEXURE-XIV

On the basis of above undertaking/declaration, the price bid shall be opened subsequently after opening of technical bid. However, any document uploaded with technical bid is not complying as per undertaking, the contract/ Rate Contract shall be cancelled with forfeiture of EMD/Performance Security Deposit/Bank guarantee against tender no. BPPI/DRUG/RC-116/2019 dated **04/10/2019** along with other action**.**

(III) a.) I/We declare that we possess the valid drug manufacturing license for BPPI's tendered items as per details below:

Sr. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Drug Lic. No.	Date of Issue	Validity of Drug Lic.	Address of Manufacturing Unit

b.) I/We declare that we possess the valid WHO-GMP (World Health Organization-Good Manufacturing Practices) Certificate issued by competent authority and complies and continue to comply with the condition lied in schedule M of Drug & cosmetic act, 1940 the rules made there under.

I am / We are aware of the Tender inviting Authority's right to forfeit the Earnest Money Deposit and /or Performance Security Deposit and blacklist me/us for a period of 5 years if, any information furnished by us proved to be false at time the of inspection and not complying the condition as per schedule M of the said Act for a period of five years.

(IV)

(a) I do hereby declare that I have uploaded valid GS1 registration certificate for bar coding and will supply the drug with bar code as per ANNEXURE I and as per the design as per enclosures to ANNEXURE XII enclosed with tender document as well as other instruction given in this regard.

(b) We have valid COPP certificate as per WHO format and approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa, (if any) only for following quoted drugs and relevant certificate & approval indicating/highlighting drug code have been uploaded with technical bid: -

S. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Whether Valid COPP certificate (Yes/ No)	If Yes, then indicate the validity date of COPP Certificate	Whether approval of the any agency like US FDA, TG Australia, Health Canada, EU, MCC South Africa approval, Brazil Anvisa (yes/No)

(V) that in pursuant to the conditions in Clause No. 6.(A) of the tender, the Earnest Money Deposit can be forfeited by the Tender Inviting Authority in case of violation of any of the conditions and non-performance of the obligation under tender document.

(VI) that our company/applied items have not been blacklisted/debarred/de-registered/banned **due to quality failure for the quoted product /firm by any State Government / Central Government/ BPPI/ Central or State Government's Drug procurement agencies** for the following products quoted in the tender at the time of submission of bid. Further, quoted drugs have not been failed in house testing or testing by any State Government/Central Government / its Drug procurement agencies/BPPI during last two years. We are eligible to participate in the tender ref. No. **BPPI/DRUG/RC-116/2019 dated 04/10/2019** for the following quoted products with mentioned shelf life in Annexure XIII: -

S. No.	Drug Code	Description of Drug as per BPPI Tender	Unit Size	Shelf life in Annexure XIII

Signed.....
Name
Designation
(Company Seal)

Witness:-(1).....
(2).....

To be attested by the Notary

ANNEXURE-III

Ref. Clause No. 3(A), 6.(A)

DETAILS OF E.M.D SUBMITTED

UPLOAD THE SCANNED COPY OF DRAFT/ PAY ORDER/BANK GURANTEE/NEFT RECEIPT

ANNEXURE- IV

Ref. Clause No. 3. (I)

{Format for a certificate from the C.A. (Chartered Accountant) or Company Secretary}

(I) It is certified that M/s.....……is a Private Ltd./Ltd. /Proprietorship/Partnership company/firm and they have PAN no……..and GST registration no. ……..They have filed Income tax returned and GST returned up to date. The authorized signatory of the company/firm is Shri……and whose signature is attested as under: ----------

(II) The annual Turnover of M/s. .....for the last three years for manufacturing of drugs are given below and certified that the statement is true and correct.

Sl. No.	Financial Year	Turnover in Lakhs (Rs.)
1.	2015-16	
2.	2016-17	
3.	2017-18	
TOTAL		Rs..... Lakhs
Average Turnover per annual		Rs..... Lakhs

It is certified that M/S …….(Name of company and address)having factory at…… (address of factory) have required plant/plants, machinery/machineries, building/buildings & other infrastructure to manufacture the tendered drugs. It is also certified that the statement is true and correct.

(III) It is certified that M/s _____ has Production & financial
capacity to manufacture and deliver the drugs quoted by them in the tender as per quantity & delivery schedule mentioned in tender. This certificate is based on their Manufacturing capacity, inventory of raw Material and financial statement.

(IV) Further, It is certified that M/S ……is Micro and Small Enterprises (MSE) and registered with Director of Industries of concerned State/UT or appropriate authorities for quoted drugs against BPPI tender No. BPPI/Drug/RC-098/2019 and eligible for exemption of paying EMD. This MSMEs is owned by Scheduled Caste (SC)/Scheduled Tribe (ST) entrepreneurs.

(V) They have manufactured & marketed 2 or more commercial batches of each quoted drugs in last three years.

Date (Name, Signature & Stamp)
Registration no.

NOTE

(i) Strike which is not applicable in above certificate.

(ii) MSEs would be treated as owned by SC/ ST entrepreneurs: a) In case of proprietary MSE, proprietor(s) shall be SC /ST b) In case of partnership MSE, the SC/ST partners shall be holding at least 51% (fifty-one percent) shares in the unit c) In case of Private Limited Companies, at least 51% (fifty-one percent) share shall be held by SC/ST promoters.

ANNEXURE V

Ref. clause 23.(B)

MANDATE FORM

Sl. No.	Details Required	
1.	**Company Name**	
2.	Postal Address of the Company	
	GST No.	
	Telephone No.	
	Fax No.	
	E-mail ID	
3.	Name of the Managing Director / Director / Manager	
	Mobile No. / Phone No	
	E-mail ID	
4.	Name and Designation of the authorized company official	Name:
		Designation:
	Mobile No.	
	E-mail ID	
5.	**Bank Details**	
	a) Name of the Bank	
	b) Branch Name & address	
	c) Branch Code No.	
	d) Branch Manager Mobile No.	
	e) Branch Telephone no	
	f) Branch E-mail ID	
	g) 9-digit MICR code number of the bank and branch appearing on the MICR cheque issued by the bank	
	h) IFSC Code of the Branch	
	i) Type of Account (Current / Savings)	
	j) Account Number (as appear in cheque book)	

(In lieu of the bank certificate to be obtained, please **attach the original cancelled cheque** issued by your bank for verification of the above particulars).

I / We hereby declare that the particulars given above are correct and complete. If the transaction is delayed or not effected at all the reasons of incomplete or incorrect information, I would not hold Bureau of Pharma Public Sector Undertakings of India (BPPI) responsible. I have read the conditions of the tender / Rate contract entered and agree to discharge the responsibility expected of me / from the company as a tenderer / successful tenderer.

Date: Company Seal Signature
Place: (Name of the person signing & designation)

CERTIFIED THAT THE PARTICULARS FURNISHED ABOVE BY THE COMPANY ARE CORRECT AS PER OUR RECORDS.

Signature of the authorized official of the bank

Bank Seal with address:

Annexure VI
Additional Document

Tender No. BPPI/DRUG/RC-116/2019,
Ref Clause No. 3 (L)

Date:

S. N.	Drug Code (Only Quoted Drugs as mentioned in Annexure II)	Drug Specification (As per Tender Specification)	Unit Size	Drug Manufacturing License					Marketing standing Certificate (MSC)		
				Drug Manufacturing License No.	License Issue date	License Renewal Date	License Validity Date	Page no. of Document in uploaded Scan Copy	Market Standing Certificate Issue Date	Period of Marketing as per Marketing standing Certificate (MSC)	Page no. of Document in uploaded Scan Copy

Note: In case any details as desired above is missing/not submitted against quoted drugs, the bid for such drugs are liable to be rejected.

Signature:

Name:

Authorized Signatory:

Seal of the Company:

ANNEXURE -VII

Ref. Clause no 20 & 21

DECLARATION

I/We do hereby declare that I/we will supply the drug as per the design in Enclosure 1 to Annexure VII & Enclosure 1 to Annexure VII as well as other instruction given in this regard.

Signature of the Tenderer

Name

Designation

(Company Seal)

Enclosure–1 to ANNEXURE - VII

Ref. Clause No. 20

DESIGN FOR: Foil / blister of tablet and capsule

1. **Text Matter Printing on** Foil /Blister should be in minimum two colour i.e. Black & red. **However, colour and design of PMBJP (Pradhan Mantri Bhartiya Janaushadhi Pariyojana) logogram in standard colour format & BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply should be as given below.**

2. PMBJP Logogram should be placed along with the address as given below.
3. BPPI helpline number 1800 180 8080 should be printed.

4. Font type should in CALIBIRI format for any type of title name of generic medicines.

5. Title name of generic medicine should be **bold** in minimum 12 font size & the strength corresponding to it must be **bold** in minimum 14 font sizes and it may increase respectively according to size of label & the rest text matter should be in minimum 8 font size.
6. The stereo printing of batch no./manufacturing /expiry date & other details shouldn't overlap the text matter.

7. "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

1. Pradhan Mantri Bharitya Janaushadhi Priyojana should be printed in Hindi at side of strips.

Enclosure – 2 to ANNEXURE – VII
Ref. Clause No. 20

1. **Design for injection for primary packing**

a) Vial (5ml or more) should be supplied with the following PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as under:

b) BPPI helpline number 1800 180 8080 should be printed

c) Font type should in CALIBIRI format for any type of title name of generic medicines

d) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for:

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

b) Ampoules or Vials less than 5 ml for primary packing

(i) Injection in ampoule or vial (less than 5 ml) should be supplied with PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply**.

(ii) BPPI helpline number 1800 180 8080 should be printed.

(i) Font type should in CALIBIRI format for any type of title name of generic medicines.

(ii) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

(iii)"Bureau of Pharma PSUs of India" should be running text only and should not be prominent.

Manufactured for :

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE—XXXX

(ii) LIQUID:

a) Liquid preparation should be supply with pilfer proof ROPP cap.

b) Bottle cap should not bear the manufacturer's logogram

c) Bottle label should bear PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as below:

d) BPPI helpline number 1800 180 8080 should be printed

e) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent

f) Font type should in CALIBIRI format for any type of title name of generic medicines

g) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

Manufactured for :

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE--XXXX

OINTMENTS / CREAMS

a) Ointment / Cream /Gel /Glass Jar should bear PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as below:

Manufactured for :

Bureau of Pharma PSUs of India
8th Floor, Videocon Tower, Block-E1, Jhandewalan Extension, New Delhi-110055
BPPI helpline number 1800 180 8080 BPPI DRUG CODE—XXXX

b) BPPI helpline number 1800 180 8080 should be printed

c) Ointment / cream tube should be packed in mono carton (secondary packing) with PMBJP logogram **& BPPI Drug code-XXXX as given in PO as per approval at the time of ART WORK approval before supply** as given below.

d) "Bureau of Pharma PSUs of India" should be running text only and should not be prominent

e) Font type should in CALIBIRI format for any type of title name of generic medicines

f) Title name of generic medicine should be minimum 12 font sizes and it may increase respectively according to size of label.

ANNEXURE-VIII

Ref. Clause No. 21(A)

SCHEDULE FOR PACKAGING OF DRUGS

GENERAL SPECIFICATIONS

1. Strips of Aluminium foils should be 0.07 mm thickness and grammage of foil minimum 80 g/m^2, LDPE minimum 35 g/m^2 and total GSM not less than 110 g/m^2.
2. Aluminium foils back material for blisters should be minimum 0.025 mm thickness, grammage of foil minimum 75 g/m^2 and tensile strength minimum 400 Kg/cm^2.
3. The rigid PVC used in blister packing should be of not less than 250 microns (thickness) and grammage minimum 350 g/m^2.
4. ALU-ALU blisters, total grammage minimum 250 g/m^2, total minimum thickness 130 microns, and bursting strength minimum 15 Kg/cm^2.
5. Pin hole should be nil and toxicity should be comply as per USP in all foil and PVC.
6. All glass bottles should be new neutral glass, Type-1, free from visual defects.
7. Pet bottles used for syrups/solution should be clean, standard for market and so accepted as per drug laws stipulation.
8. Ointments should be packed in lacquer zed Aluminium Tubes or Lami tubes and properly sealed.
9. Small Tablets packed in blisters should be packed to facilitate easy removal of the tablet without breaking / crushing.
10. Specification of outer cartons should be as per given in their Schedule.
11. In case of any conflict between Carton specifications and packets per carton specification the specification of the packets / carton shall prevail.
12. All plastic containers should be made of virgin grade plastics
13. Injection in vials should have a flip-off seals.
14. Container used for infusions should be as per market standard and must not leak during use.
15. The strips shall be aluminium strip / blisters with aluminium foil back.
16. The outer carton/secondary packaging should be of pearl white duplex board (**off white/grey is not acceptable**) with a minimum of 350 GSM with **Gloss laminated** packing for the strips, blisters, ointments, creams etc. and for ampoules and vials should be with pearl white board of 350 GSM (**off white/grey is not acceptable**)**. The material to be used for carton should be from virgin chemical pulp.**

17. All liquid oral preparations to be provided with a measuring plastic cup, fitted over the cap of the bottle in a mono carton. In case of Paediatric Preparation, all liquid oral has to be provided with a measuring plastic cup, dropper fitted over the cap of the bottle in a mono carton.

18. All primary/secondary/tertiary packaging should have PMBJP logo and drug code mentioned as per purchase order.

16. Two Horizontal/vertical/standing lines in two different colour will be there on Primary and secondary packaging, to differentiate therapy groups. The colours of lines will be intimated during Artwork approval.

The primary packing should be decided by the party depending on the drug category as per Drug & Cosmetic act. For e.g if drug is hygroscopic then tablet should be packed in Alu/Alu blister or if it is light sensitive then to be packed in Amber colour PVC e.t.c.

Shipper size or corrugated box specification with weights

S. N	Particulars	Weight	Ply	Grammage	Bursting strength
1	Tablets	Not more than 12.0 Kg	7	Outer box should be 150 GSM and inside partition/ lining should be 120 GSM.	Not less than 10 Kg/cm^2.
2	Capsules (Hard gel and soft gel)	Not more than 12.0 Kg	7		
3	Syrups	Not more than 12 to14.0 Kg	7		
4	Ointment/gel/cream	Not more than 12.0 Kg	7		
5	Injection (vial, respules and ampules)	Not more than 8-12.0 Kg	7		
6	IV fluids	Not more than 12.0 Kg	7		
7	Bottles/Jars	Not more than 12.0 Kg	7		

(4) In the case of 10 ml Ampoules, 20 or 25 ampoules may be packed in a mono carton. Multiples of mono carton boxes should be packed in CB.

(5) If the vial is packed in individual carton, there is no necessity for grey board box packing. The individual carton may be packed as such in the CB with center pad.

(6) In case of ampoules less than 10 ml, every 10 or 5 ampules should be inside the tray with printed white board box.

(7) Vials of eye, ear drops, and nasal drops should be packed in an individual mono carton with a dispensing device. If the vial is of FFS/BFS technology, they should be packed as per approved artwork and market standard.

ANNEXURE IX
(BARCODE REQUIREMENTS}

Reference clause 3(R)

GS1 barcode requirements on Drugs procured by Bureau of Pharma Public Sector undertakings of India (BPPI)

These requirements cover medicines/drugs procured by Bureau of Pharma Public Sector Undertakings of India (BPPI), New Delhi meant for supply and distribution through BPPI regulated distribution channel.

Barcode based on GS1 identification standards are provided below at various levels of product packaging which includes primary, secondary and shipper/carton levels and need to be complied with while supplying medicines/drugs to BPPI.

GS1 India is unique identification & barcoding standards body setup by Ministry of Commerce & Industry, Govt. of India along with APEDA, BIS, Spices board, IIP and apex industry chambers like CII, FICCI, ASSOCHAM to assist India industry and govt. bodies on adoption of global standards.

Suppliers are also required to provide GS1 subscription validity certificate at the time of supply of medicines/drugs issued by GS1 India. For validity certificate suppliers can contact GS1 India at 011-42890-846.

Barcodes based on GS1 global standards are required to be printed on product packaging at primary, secondary and tertiary packaging levels **in addition** to other, existing statutory labelling & marking requirements.

Tertiary Level Pack:

Is defined as a level of packaging that shall contain one or more secondary/primary levels of packaging and is also considered as the final logistics unit like shippers/pallets.

The Tertiary label will carry two barcodes in GS1-128 format

First Barcode

a) Unique product identification code (GTIN - Global Trade Identification Number)
b) Manufacturing Date
c) Expiry date
d) Batch no.
e) Quantity

Second Barcode

f) Serial Shipping Container Code (SSCC) –

Note-

1) *While encoding Manufacturing and expiry date in the barcode, if a specific Manufacturing or expiry date is not printed on the finished pack/drug then Supplier should select first day of the month as the Manufacturing date and Last day of the month as expiry date.*

   Example- If Shelf life is 24 months, April 2019 manufacturing date should be encoded as 190401 and March 2021 expiry date as 210331.

2) *SSCC number of the Tertiary pack should never be reused on another Tertiary pack irrespective the Item, Batch or expiry is different.*

3) *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*Unique Product Number-GTIN-14*	*14*	*Fixed*	*Numeric*
(11)	*Application Identifier to indicate Manufacturing date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
180101	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*
(17)	*Application Identifier to indicate Expiry date Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
220131	*Expiry Date in YYMMDD format*	*6*	*Fixed*	*Date*

(10)	*Application identifier to indicate Lot/batch number Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*20*	*Variable*	*Alphanumeric*
(37)	*Application identifier to indicate Quantity in Outer Carton*	*2*	*Fixed*	*Numeric*
500	No of Primary packs like number of strips/Bottles in the tertiary.	*Upto 8*	*Variable*	*Numeric*
(00)	*Application identifier to indicate the SSCC Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
1 8901072 000000000 6	*Unique number of the tertiary pack. It should never be reused.*	*18*	*Fixed*	*Numeric*
Recommended Barcode – GS-128				

Secondary Level Pack:

Is defined as a level of packaging that may contain one or more primary packages usually termed as Mono-carton/carton

Secondary level barcode can be generated using 2D- GS1 Datamatrix or 1D- GS1-128 format.

Note-

1) Shrink wrap packaging will not be considered as Secondary level packaging.
2) *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Data Attributes Captured in GS1 Datamatrix format

1) *Unique product identification code (GTIN)*

2) *Batch No.*
3) *Qty- No of strips/bottle*

Attribute	Description	Length	Nature	Data Type
(02)	*Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14- Unique product code with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
(10)	*Application identifier to indicate Lot/batch Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*Upto 20*	*Variable*	*Alphanumeric*
(37)	*Application Identifier to indicate serial number Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
5	*Quantity/Units in Secondary pack*	*Upto 8*	*Variable*	*Alphanumeric*
Recommended Barcode depending upon the space available – GS1 Data matrix Or *GS1-128*	 (02) 0 8901072 00255 3 (10) BATCH123 (37) 5 *or*  (02) 0 8901072 00255 3 (10) BATCH123 (37) 5			

Primary Level Pack:

Is defined as the first level of packaging in direct contact with the product like Strip, Vial, Bottle etc

<u>Scenario-I</u> Primary pack with a Mono-carton/Carton/Secondary level pack

For primary packaging packed in a Mono-carton/Secondary pack carton

Unique product identification code (GTIN)

Note-

- *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

Attribute	Description	Length	Nature	Data Type
(01)	*Application Identifier to indicate GTIN-14 Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14 with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
Recommended Barcode – GS1 Datamatrix,	 (01) 0 8901072 00255 3			

<u>Scenario-II</u> Primary pack without Mono-carton/Secondary level pack

For Primary packaging going directly into Tertiary pack without a Carton/Mono-carton/Secondary pack

- *Unique product identification code (GTIN)*
- *Batch No.*

Note-

- *For converting, GTIN-13 into GTIN-14, kindly use "0" as a prefix for all levels of packaging.*

(01)08901072002533
(10)BATCH123

Attribute	Description	Length	Nature	Data Type
(01)	*Application Identifier to indicate GTIN-14. Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
0 8901072 00253 3	*GTIN-14- Unique product code with first digit being the packaging indicator*	*14*	*Fixed*	*Numeric*
(10)	*Application identifier to indicate Lot/batch Brackets not encoded in the barcode*	*2*	*Fixed*	*Numeric*
BATCH123	*Batch No / Lot No*	*Upto 20*	*Variable*	*Alphanumeric*

Mapping of Manufacturer GTIN with BPPI Drug code-

- GS1 has facilitated an online application to link Manufacturer GTIN code with BPPI Drug code. The manufacturer must update the same before sending the physical consignment to BPPI.
- Kindly contact Mr. Ankit Arora or Mr. Amrit Garg for the same at 011-42890846/42890818 or write email at ankit@gs1india.org or amrit@gs1india.org

Barcode Design and Printing-

- For BPPI suppliers, GS1 India has facilitated an online application to generate the barcode designs for each level of packaging.
- Using the same, the supplier will be able to generate Primary, secondary and Tertiary barcodes as per BPPI format.
- Kindly contact Mr. Ankit Arora or Mr. Amrit Garg for the same at 011-42890846/42890818 or write email at ankit@gs1india.org or amrit@gs1india.org

Please contact GS1 India office for any further assistance –

GS1 India
(Under Min. of Commerce, Govt. of India)
330, 2nd Floor, 'C' Wing, August Kranti Bhawan,
Bhikaji Cama Place, New Delhi - 110066
T +91-11-42890890, (D) +91-11-42890846
F +91-11-26168730
E ankit@gs1india.org
W http://www.gs1india.org

ANNEXURE –X

(Ref: -Clause 6.A)

MODEL BANK GUARANTEE FORMAT FOR FURNISHING EMD

Whereas …… (hereinafter called the

"tenderer") has submitted their offer dated…….…… for the supply

Of Drugs (hereinafter called the "tender") against the purchaser's tender enquiry No. BPPI/Drug/RC-098/2019 KNOW ALL MEN by these presents that WE …….
of …….. having our registered office at ……. are bound unto Bureau of Pharma Public
Sector Undertakings of India New Delhi(hereinafter called the "Purchaser) in the sum of Rs. Ten lakh only for which payment will and truly to be made to the said Purchaser, the Bank binds itself, its successors and assigns by these presents. Sealed with the Common Seal of the said Bank this…… day of …….201..

THE CONDITIONS OF THIS OBLIGATION ARE:

(1) If the tenderer withdraws or amends, impairs or derogates from the tender in any respect within the period of validity of this tender.

(2) If the tenderer having been notified of the acceptance of his tender by the Purchaser during the period of its validity: -

(a) Fails or refuses to accept/execute the contract.

WE undertake to pay the Purchaser up to the above amount upon receipt of its first written demand, without the Purchaser having to substantiate its demand, provided that in its demand the Purchaser will note that the amount claimed by it is due to it owing to the occurrence of one or both the two conditions, specifying the occurred condition or conditions.

This guarantee will remain in force up to 12 months from the due date of tender i.e. .....and any
demand in respect thereof should reach the Bank not later than the above date.

……

(Signature of the authorized officer of the Bank)

…….
…….

Name and designation of the officer

…….

Seal, name & address of the Bank and address of the Branch

ANNEXURE-XI

Ref: Clause No. 15.E

Letter of acceptance of tender for Rate Contract

Speed post/e-mail

Ref. No. BPPI/Drug/RC- 098/2019 **Date: ……..**

To,
M/S ----------

Sub: Tender for the Supply of Drugs and Medicines to BPPI for two years: Acceptance tender for Rate Contract.

Ref: Your quotation against BPPI e-Tender No. BPPI/DRUG/RC-098/2019 dated: 11/03/2019 opened on ……. (Technical Bid) & on …… (Price bid).

Please refer to your quotation i.e. technical and price bid (BOQ) along with enclosures/Annexure against subject tender read with your subsequent clarification/confirmation for the supply of Drugs to BPPI, the rate offered/accepted by your firm has been approved for Rate Contract for two years from the date of issue of this letter.

S. N.	Drug Code	Drug Name	Unit Size	Rates in Rs. Per unit exclusive of GST	Rate of GST (%)	Rates in Rs. Per unit inclusive of GST

2. The contract will be with financial limit and BPPI can place the Purchase Order with unlimited variation in quantities indicated in the tender.
3. The estimated value of the contract awarded to you is Rs.....(in word).
4. Performance Security Deposit @5% will be deducted from each bills and accumulated security deposit will be refunded by BPPI to the tenderer within 60 days following the date of completion of tenderers performance obligations under the contract including the shelf life obligation.
5. Approval for Artwork should to be obtained from our Quality Control department by you within 30 days of release of this letter. (e-mail id: regulatory@janaushadhi.gov.in)
6. STP (Standard Testing Procedure) for Non- Pharmacopoeia awarded drugs are required to submit to Quality Control department (e-mail id: regulatory@janaushadhi.gov.in)within 15 days from the date of Letter of Acceptance
7. As per clause 8.6 of Tender document, the Rate Contract validity period may be extended for period up to further one year at same rate, terms & conditions with the consent of the supplier.
8. The terms and conditions of Rate Contract shall be applicable as mentioned in tender document. By issue of this acceptance letter, the Rate Contract is hereby concluded.

Please acknowledge receipt.

, BPPI

Annexure -XII
Clause 18 E & (F)

Bureau of Pharma Public Sector Undertakings of India, New Delhi
Tender for supply of drugs (Tender No. BPPI/DRUG/RC-116/2019 dated 04/10/2019)

(1)	(2)	(3)	(4)	(5)	(6)	(7)
S.N.	**Drug Code**	**Generic Name of Drug**	**Composition / Strength**	**Unit Size**	**Pack Size**	**Indicative Requirement in Unit Size**
1	1	Aceclofenac 100mg and Paracetamol 325 mg Tablets	Each film-coated tablet contains: Aceclofenac 100mg Paracetamol 325 mg	10's	10's X 10	7000000
2	9	Diclofenac Sodium Sustained Release Tablets IP 100mg	Each sustained release film-coated tablet contains: Diclofenac Sodium IP 100 mg	10's	10 X 10's	1200000
3	10	Diclofenac Sodium Injection IP 25mg/ml	Each ml contains: Diclofenac Sodium IP 25mg	3 ml	1's X 10	6200000
4	14	Ibuprofen and Paracetamol Tablets IP (400mg + 325mg)	Each uncoated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325 mg	10's	10's X 10	2700000
5	16	Ibuprofen Tablet IP 400 mg	Each film-coated tablet contains: Ibuprofen IP 400mg	15's	15's X 10	250000
6	17	Indomethacin capsule IP 25 mg	Each capsule contains: Indomethacin IP 25mg	10's	10's X 10	500000
7	21	Diclofenac Sodium and Paracetamol Tablets IP (50mg + 325mg)	Each uncoated tablet contains: Diclofenac Sodium IP 50mg Paracetamol IP 325 mg	10's	10's X 10	2200000
8	24	Pentazocine Injection IP 30mg/ml	Each ml contains: Pentazocine 30 mg	1 ml	1's X 10	500000
9	26	Tramadol Hcl Injection 100 mg/2 ml	Each ml contains: Tramadol Hcl 50 mg	2ml	2ml X 10	400000
10	28	Tramadol 50 mg Tablet	Each Film-coated tablet contains: Tramadol Hydrochloride 50mg	10's	10's X 10	470000
11	29	Acyclovir Tablets IP 400mg	Each uncoated tablet contains: Acyclovir IP 400mg	10's	10's X 10	350000
12	31	Amikacin Injections IP 250mg/2ml	Each ml contains: Amikacin sulphate Ip equivalent to Amikacin 125 mg	2ml Vial	2ml X 10	170000
13	32	Amikacin Injections IP 500mg/2ml	Each ml contains: Amikacin sulphate Ip equivalent to Amikacin 250 mg	2ml Vial	2ml x 10	120000
14	34	Glimepiride and Extended Release Metformin	Each uncoated tablet contains: Glimepiride 2mg Metformin Hydrochloride	15's	15's X 10	3400000

		Hydrochloride Tablets (2mg + 500mg)	500mg (as extended release)			
15	37	Amoxycillin and Potassium Clavulanate Injection 300 mg	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 250 mg Potassium Clavulanate IP equivalent to Clavulanic Acid 50 mg	Vial with WFI	1's x 10	135000
16	38	Amoxycillin and Potassium Clavulanate Injection 600 mg	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 500 mg Potassium Clavulanate IP equivalent to Clavulanic Acid 100 mg	Vial with WFI	1's x 10	110000
17	39	Amoxycillin and Potassium Clavulanate tablets IP (500mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 500mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg Colour: Titanium Dioxide IP	6's	6's X 10	4350000
18	40	Amoxycillin and Cloxacillin Capsules (250mg+250mg)	Each hard gelatin capsule contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 250mg Cloxacillin Sodium IP equivalent to Cloxacillin 250mg	10's	10's X 10	210000
19	42	Amoxicillin Trihydrate Dispersible Tablets IP 125mg	Each uncoated dispersible tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 125mg	10's	10's X 10	245000
20	48	Azithromycin 100 mg Dispersible Tablets	Each uncoated dispersible tablet contains: Azithromycin 100mg	10's	10's X 10	120000
21	51	Cefadroxil Dispersible Tablets 250mg	Each uncoted dispersible tablet contains: Cefadroxil equivalent to Cefadroxil Anhydrous 250mg	10's	10's X 10	600000
22	64	Cefotaxime Sodium Injection 500 mg	Each Vial contains: Cefotaxime Sodium 500 mg	Vial & wfi	1's x 10	245000
23	68	Ceftazidime Injection IP 250mg	Each Vial contains: Ceftazidime 250 mg	Vial & wfi	1's x 10	100000
24	83	Ciprofloxacin and Tinidazole Tablets (250mg+300mg)	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg	10's	10's X 10	180000

			Tinidazole IP 300mg			
25	85	Ciprofloxacin Hydrochloride Tablets IP 250 mg	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Colour: Titanium Dioxide IP	10's	10's X 10	350000
26	92	Doxycycline Capsules IP 100mg	Each hard gelatin capsule contains: Doxycycline Hydrochloride IP equivalent to Doxycycline 100mg	10's	10's X 10	840000
27	104	Roxithromycin Oral Suspension (50 mg/ 5ml)	Each 5ml contains: Roxithromycin 50mg Flavoured Syrupy Base q.s.	30ml	1's x 10	100000
28	106	Roxithromycin Tablets IP 300 mg	Each film-coated tablet contains: Roxythromycin IP 300mg Colours: Lake of Ponceau 4R & Titanium Dioxide IP	10's	10's X 10	250000
29	113	Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream	Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream	15g tube	1's x 10	680000
30	124	Povidone Iodine 5% w/w Ointment USP	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/Jar	1's X 10	155000
31	126	Povidone-Iodine Solution IP 10 % w/v	Povidone-Iodine Solution IP 10 % w/v	500 ml	500 ml x 1	175000
32	127	Povidone-Iodine Solution IP 5 % w/v	Povidone-Iodine Solution IP 5 % w/v	100 ml	100 ml X 6	370000
33	130	Chlorhexidine Gluconate and Cetrimide Solution (1.5% w/v and 3% w/v)	Chlorhexidine Gluconate 1.5% w/v, Cetrimide 3% w/v Solution	100ml Bottle	1 x 100 ml	120000
34	133	Glibenclamide Tablet IP 2.5 mg	Each uncoated tablet contains: Glibenclamide IP 2.5 mg	10's	10's X 10	810000
35	142	Insulin Injection IP Soluble Insulin, Neutral (Regular)	Each ml contains: Human Insulin IP 40 IU (Human Insulin of recombinant DNA origin) m-cresol 0.25% w/v	10 ml Vial	10 ml Vial X10	550000
36	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	10's X 10	4950000
37	153	Cisplatin Injection IP 10 mg/10ml	Each ml contains: Cisplatin 1 mg	Vial	1's x 10	36000
38	158	Etoposide Injection IP 100 mg/5 ml	Each ml contains: Etoposide IP 20 mg	Vial	1's x 10	100000
39	165	Ciprofloxacin infusion IP 200mg (2mg/ml)	Each ml contains: Ciprofloxacin 2 mg	100 ml	100 ml X 6	87000
40	170	MANNITOL Injection IP 20% w/v	Each 100 ml contains: Mannitol 20 g	100 ml	100 ml X 6	185000
41	172	Metronidazole Infusion IP 500 mg	Each ml contains: Metronidazole 5 mg	100 ml	100 ml X 6	875000

42	186	Domperidone Tablets IP 10 mg	Each film-coated tablet contains: Domperidone Maleate IP equivalent to Domperidone 10mg	10's	10's X 10	750000
43	194	Hyoscine Butylbromide Tablets IP 10 mg	Each sugar coated tablet contains: Hyoscine Butylbromide IP 10 mg	10's	10's X 10	84000
44	196	Lactic Acid Bacillus Tablets (60 M)	Each uncoated tablet contains: Lactic Acid Bacillus not less than 60 million spores.	10's	10's X 10	955000
45	197	Lactulose Solution	Each 15ml contains: Lactulose solution equivalent to Lactulose 10g	100 ml	100 ml X 6	440000
46	198	Dried Aluminium Hydroxide 250mg, Magnesium Hydroxide 250mg, Activated Methyl Polysiloxane Suspension 50mg/ 5ml	Each 5ml contains: Dried Aluminium Hydroxide 250mg Magnesium Hydroxide 250mg Activated Methyl Polysiloxane 50mg	170 ml	1's X 10	630000
47	200	Metoclopramide Injection IP 5mg/ml	Each ml contains: Metoclopramide 5 mg	2ml	2ml X 10	345000
48	201	Metronidazole Tablets IP 200mg	Each film-coated tablet contains: Metronidazole Tablets IP 200mg Excipients q.s.	10's	10's X 10	550000
49	202	Metronidazole Tablets IP 400mg	Each film-coated tablet contains: Metronidazole Tablets IP 400mg Excipients q.s.	10's	10's X 10	1860000
50	208	Ondansetron injection IP 2mg/ml	Each ml contains: Ondansetron 2 mg	2 ml	2ml x 10	1090000
51	209	Ondansetron Tablets IP 4mg	Each film-coated tablet contains: Ondansetron Hydrochloride IP equivalent to Ondansetron 4mg	10's	10's X 10	620000
52	215	Rabeprazole Gastro-resistant Tablets IP 20mg	Each gastro-resistant tablet contains: Rabeprazole Sodium IP 20mg	10's	10's X 10	4000000
53	217	Ranitidine Tablets IP 150 mg	Each film-coated tablet contains: Ranitidine Hydrochloride IP 167.4mg equivalent to Ranitidine 150mg Excipients q.s.	10's	10's X 10	8600000

54	220	Calcium with Vitamin D3 Tablets IP (500mg+250IU)	Each film-coated tablet contains: 1250mg Calcium Carbonate equivalent to Elemental Calcium IP 500mg Vitamin D3 IP 250IU	10's	10's X 10	4500000
55	227	Polyvitamin Tablets NFI (Prophylactic)	Each film-coated tablet contains: Vitamin A 2500 IU Vitamin D3 200IU Vitamin B1 2mg Vitamin B6 0.5mg Vitamin B12 2mg Niacinamide 25mg Calcium Pantothenate 1mg Vitamin C 50mg Folic Acid 0.2mg	10's	10's X 10	1535000
56	230	Vitamin B-Complex fort Zinc Capsule"	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 45mg Pyridoxine Hydrochloride 3mg Cynocobalamine 15mcg Folic acid 1.5mg Ascorbic acid 150mg Zinc Sulfate Monohydrate 61.8mg (Eq. to 22.5 mg of Elemental Zinc)	10's	10's X 10	1800000
57	232	Vitamin B-Complex Syrup	Each 5ml contains: Pyridoxine Hydrochloride IP 0.75 mg Thiamine Hydrochloride IP 2.5 mg Riboflavin Sodium Phosphate IP 2.5 mg Cynocobalamine IP 2.5 mcg Nicotinamide IP 22.5 mg D-Panthenol IP 3.0 mg	200 ml	1's x 10	610000
58	233	Vitamin-C Chewable 100mg Tablet	Vitamin-C Chewable 100mg Tablet	10's	10's X 10	1380000
59	236	Budesonide Inhaler 100mcg	Each activation delivers Budesonide IP 100mcg	200 MDI	1's X 10	80000
60	238	Budesonide Inhaler 200mcg	Each activation delivers Budesonide IP 200mcg	200 md	1's X 10	45000
61	239	Cetirizine Syrup IP (5 mg/ 5 ml)	Each 5ml contains: Cetrizine Hydrochloride IP 5mg	60 ml	60ml X 10	575000
62	240	Cetrizine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Cetrizine Hydrochloride IP 10mg	10's	10's X 10	5035000

63	244	Etophyllin and Theophylline Injection (84.7mg+25.3 mg)	Each ml contains: Etofylline 84.7 mg Theophylline anhydrous equivalent to Theophylline hydrate 25.3 mg	2 ml	2ml x 10	945000
64	245	Etophylline and Theophylline Tablets 100 mg	Each uncoated tablet contains: Etophylline 77 mg Theophylline (Hydrated) 23 mg	10's	10's X 10	1150000
65	255	Salbutamol Inhalation IP 100 mcg/puff	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg	200 md	1's X 10	145000
66	256	Salbutamol Tablets IP 2mg	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg	10's	10's X 10	125000
67	265	Atenolol Tablets IP 50 mg	Each uncoated tablet contains: Atenolol IP 50mg	14's	14's x 10	3460000
68	268	Clonidine Tablets IP 0.1 mg	Each uncoated tablet contains: Clonidine Hydrochloride IP 100mcg	10's	10's X 10	1060000
69	270	CLOPIDOGREL AND ASPIRIN Tablets (75mg + 75mg)	Each film-coated tablet contains: Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg Aspirin 75mg	10's	10's X 10	5035000
70	273	Dobutamine Injection 250mg/20ml	Each vial (20ml) contains: Dobutamine 250 mg	Vial	1's x 10	58000
71	274	Dopamine HCl Injection 200 mg/5ml	Each ml contains: Dopamine Hydrochloride 40mg	5 ml	5 ml X10	90000
72	275	Enalapril Tablets IP 5 mg	Each uncoated tablet contains: Enalapril Maleate IP 5 mg	10's	10 X 10's	2810000
73	277	Enoxaparin Injection IP 60 mg/0.6 ml	Each pre-filled syringe contains: Enoxaparin sodium IP 60 mg equivalent to 6,000 IU anti-Xa activity.	0.6 ml	1's X 10	75000
74	281	Heparin Sodium Injection IP 5000 IU/ml	Each ml contains: Heparin Sodium 5000 IU	5 ml	5 ml X 10	10000
75	295	Simvastatin Tablets IP 10mg	Each film-coated tablet contains: Simvastatin IP 10mg	10's	10's X 10	150000
76	296	Simvastatin Tablets IP 20mg	Each film-coated tablet contains: Simvastatin IP 20mg	10's	10's X 10	116000
77	298	Telmisartan and Hydrochlorothiazide Tablets IP (40mg+12.5 mg)	Each uncoated bilayer tablet contains: Telmisartan IP 40mg Hydrochlorthiazide IP 12.5mg	10's	10's X 10	4850000
78	300	Telmisartan Tablets IP 40mg	Each uncoated tablet contains: Telmisartan IP 40 mg	10's	10 X 10's	13200000

79	304	α-β Arteether Injection 150 mg	Each 2 ml contains: α-β Arteether 150 mg	2ml Vial	2ml x 5	70000
80	305	Chloroquine Phosphate Tablets IP 250 mg	Each film-coated tablet contains: Chloroquine Phosphate IP 250mg	10's	10's X 10	110000
81	312	Oral Rehydration Salts 20.5 GM Sachet (WHO Formula)	Each pack contains: Sodium Chloride IP 2.6 mg Potassium Chloride IP 1.5 mg Sodium Citrate IP 2.9 mg Dextrose IP (anhydrous) 13.5 mg Excipients q.s.	1's	1's x 10	2360000
82	326	Methyl Ergometrine Tablets IP 0.125mg	Each sugar coated tablet contains: Methylergometrine Maleate IP 0.125mg	10's	10's X 10	130000
83	330	Prednisolone Tablets IP 10 MG	Each uncoated tablet contains: Prednisolone IP 10 mg	10's	10's X 10	1050000
84	333	Dexamethasone Tablets IP 0.5 mg	Each uncoated tablet contains: Dexamethasone IP 0.5mg	10's	10's X 10	960000
85	334	Dexamethasone Injection 4mg/ml	Each ml contains: Dexamethasone Sodium Phosphate IP equivalent to Dexamethasone Phosphate 4mg	2 ml	2ml X 10	1365000
86	336	Allopurinol Tablets IP 100 mg	Each uncoated tablet contains: Allopurinol IP 100 mg	10's	10 X 10's	890000
88	352	Bupivacaine Hydrochloride Injection IP 5 mg/ml	Each ml contains: Bupivacaine Hydrochloride 5 mg	20ml	20 ml x 5	100000
89	357	Lignocaine and Adrenaline Injection IP (2%w/v and 1:80000)	Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Adrenaline Bitartrate IP 0.0225 mg equivalent to (Adrenaline 0.0125 mg)	30 ml Vial	1's x 10	100000
90	358	Propofol Injection 10 mg/ml	Each ml contains: Propofol 10 mg	10ml Vial	10 ml Vial X10	115000
91	359	Tetanus Vaccine	Each 0.5 ml contains: Tetanus Toxoid ≥ 5 LF	0.5 ml Amp.	1's x 10	500000
92	362	BIPHASIC ISOPHANE INSULIN INJECTION IP (50:50) 4O IU/ML	Each ml contains: Human Insulin IP 40 IU (50% as Soluble Insulin Injection and 50% as Isophane Insulin Injection) (Human Insulin od recombinant DNA origin)	10 ML VIAL	1's x 10	410000
93	373	ARTESUNATE INJECTION 60 MG	Each vial contains: Artesunate 60 mg The pack also contains: 1 ml ampoule of Sodium Bicarbonate 5% w/v 5 ml ampoule of Sodium	1 vial with diluent	1's X 10	25000

			Chloride 0.9% w/v			
94	377	CLINDAMYCIN CAPSULES 300 MG	Each hard gelatin capsule contains: Clindamycin Hydrochloride equivalent to Clindamycin 300mg	10's	10's X 10	265000
95	384	ITRACONAZOLE Capsules 100 mg	Each hard gelatin capsule contains: Itraconazole 100mg	4's	4's x 10	6200000
96	386	Diethylcarbamazine Tablets IP 50 mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 50mg Excipients q.s.	30's	10's X 10	120000
97	392	GRISEOFULVIN TABLETS IP 250 MG	Each uncoated tablet contains: GRISEOFULVIN IP 250 MG	10's	10's X 10	100000
98	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	Each dispersible uncoated tablet contains: Aciclovir IP 800mg	5's	5's X 10	50000
99	395	CEFUROXIME and POTASSIUM CLAVULANATE Tablets (500MG + 125MG)	Each film-coated tablet contains: Cefuroxime Axetil IP equivalent to Anhydrous Cefuroxime 500mg Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 125mg	6's	(6's X 10)	220000
100	396	AMPHOTERICIN B INJECTION IP 50 mg/vial	Each Vial contains: AMPHOTERICIN B 50 mg	Vial	1's x 10	30000
101	401	Amoxycillin and Potassium Clavulanate tablets (250mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 250mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg	6's	(6's X 10)	470000
102	402	Amoxycillin and Potassium Clavulanate tablets (875mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 875mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg	6's	(6's X 10)	410000
103	405	OFLOXACIN INFUSION IP 200 mg /100 ml	Each 100 ml contains: OFLOXACIN IP 200mg	100 ml	100 ml X 6	60000
104	417	TELMISARTAN AND AMLODIPINE Tablets IP (40 mg +5 mg)	Each uncoated tablet contains: Telmisartan IP 40mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	15's	15's X 10	5100000

105	419	Ointment of Heparin Sodium and Benzyl Nicotinate	Each gram contains: Heparin Sodium 50 IU Benzyl Nicotinate 2mg	20 GM	1's x 20	100000
106	423	BISOPROLOL TABLETS 5 MG	Each film-coated tablet contains: Bisoprolol Fumarate 5mg	10's	10's X 10	1430000
107	425	Diltiazem Sustained Release Tablets 90mg	Each uncoated sustained release tablet contains: Diltiazem Hydrochloride IP 90mg	10's	10's X 10	385000
108	427	S(-)AMLODIPINE TABLETS IP 2.5 MG	Each uncoated tablet contains: S(-)AMLODIPINE Besylate IP equivalent to S(-)AMLODIPINE 2.5 MG	10's	10's X 10	2068000
109	428	DIGOXIN Tablets IP 0.25 mg	Each uncoated tablet contains: DIGOXIN IP 0.25 mg	10's	10's X 10	560000
110	429	ATORVASTATIN and FENOFIBRATE Tablets (10mg + 160mg)	Each film-coated tablet contains:Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Fenofibrate 160mg	15's	15's X 10	1035000
111	430	AMIODARONE Tablets IP 200 mg	Each uncoated tablet contains: Amiodarone Hydrochloride IP 200mg	10's	10's X 10	242000
112	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	Each uncoated tablet contains: Ramipril IP 5mg Hydrochlorothiazide IP 12.5mg	10's	10's X 10	675000
113	432	OLMESARTAN MEDOXOMIL Tablets IP 40 mg	Each film-coated tablet contains: OLMESARTAN MEDOXOMIL IP 40 mg	10's	10 X 10's	1410000
114	434	PROPRANOLOL Tablets IP 40 mg	Each uncoated tablet contains: Propranolol Hydrochloride IP 40mg	10's	10's X 10	945000
115	437	NIFEDIPINE SUSTAINED RELEASE Tablets IP 20 mg	Each sustained release film coated tablet contains: Nifedipine IP 20mg	10's	10's X 10	990000
116	438	INDAPAMIDE TABLETS IP 1.5 MG	Each film-coated tablet contains: Indapamide IP 1.5mg	10's	10's X 10	360000
117	439	OLMESARTAN MEDOXOMIL AND HYDROCLORTHIAZIDE Tablets IP (40 mg+12.5 mg)	Each film-coated tablet contains: Olmesartan Medoxomil IP 40mg Hydrochlorothiazide IP 12.5mg	10's	10's X 10	1360000
118	440	METOPROLOL (ER) AND AMLODIPINE TABLETS (50mg + 5mg)	Each film-coated bilayered tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol Tartrate 50mg Amlodipine Besilate IP equivalent to Amlodipine	7's	(7's X 10)	1480000

			5mg			
119	441	LOSARTAN and AMLODIPINE TABLETS IP (50mg + 5mg)	Each film-coated tablet contains: Losartan Potassium IP 50mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	10's X 10	1330000
120	442	FENOFIBRATE TABLETS IP 160 MG	Each film-coated tablet contains: FENOFIBRATE IP 160 MG	10's	10's X 10	385000
121	444	ENALAPRIL and HYDROCHLOROTHIAZIDE TABLETS IP (10mg + 25mg)	Each uncoated tablet contains: Enalapril Maleate IP 10 mg Hydrochlorothiazide IP 25 mg	30's	30's X 10	200000
122	445	OLMESARTAN and AMLODIPINE Tablets (20mg + 5mg)	Each film-coated tablet contains: Olmesartan Medoxomil IP 20mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	10's X 10	870000
123	446	AMLODIPINE and HYDROCHLOROTHIAZIDE TABLETS (5mg + 12.5mg)	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Hydrochlorthizide IP 12.5mg	10's	10's X 10	920000
124	448	RAMIPRIL AND AMLODIPINE TABLETS (5mg + 5mg)	Each uncoated tablet contains: Ramipril IP 5mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	10's X 10	500000
125	449	SPIRONOLACTONE TABLETS IP 25 MG	Each uncoated tablet contains: Spirinolactone IP 25mg	15's	15's X 10	735000
126	451	STREPTOKINASE INJECTION IP 15,00,000 IU	Each vial contains: STREPTOKINASE IP 15,00,000 IU	10 ml & wfi	1's x 10	50000
127	452	WARFARIN TABLETS IP 5 MG	Each uncoated tablet contains: Warfarin Sodium Clathrate IP equivalent to Warfarin sodium (anhydrous) 5mg	10's	10's X 10	335000
128	453	BISOPROLOL and HYDROCHLOROTHIAZIDE TABLETS IP (5mg + 6.25mg)	Each film-coated tablet contains: Bisoprolol Fumarate IP 5mg Hydrochlorthizide IP 6.25mg	10's	10's X 10	200000
129	454	VALSARTAN TABLETS IP 80 MG	Each film-coated tablet contains: Valsartan IP 80 mg	10's	10's X 10	275000
130	455	VERAPAMIL TABLETS IP 80 MG	Each film-coated tablet contains: Verapamil Hydrochloride IP 80 mg	10's	10's X 10	100000
131	457	TORSEMIDE TABLETS IP 20 MG	Each uncoated tablet contains: Torsemide IP 20mg	10's	10's X 10	960000

132	458	LABETALOL INJECTION IP 5 mg/ml	Each ml contains: Labetalol 5 mg	4 ml Vial	4 ml X 10	55000
133	461	BETAMETHASONE VALERAT and NEOMYCIN SULFATE CREAM (0.1% w/w and 0.5% w/w)	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	1's x 20	635000
134	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12% w/w+ 3% w/w)	BETAMETHASONE VALERATE 0.12% w/w CLIOQUINOL CREAM BP 3% w/w)	30 GM	1's X 20	200000
135	468	BACILLUS CLAUSII SPORES SUSPENSION 2 Billion/5ml	Each 5ml oral suspension contains: Spores of polyantibiotic resistant Bacillus Clausii 2 billion (Strains: O/C, N/R, SIN and T)	5 ML	5 ml X 10	50000
136	470	DIASTASE and PEPSIN LIQUID	Each 5ml contains: Diastase IP (1:1200) 50mg Pepsin IP (1:3000) 10mg	200 ML	1's x 10	180000
137	471	OXETACAINE, ALUMINIUM HYDROXIDE AND MAGNESIUM HYDROXIDE GEL	Each 5ml contains: Oxetacaine 10 mg Aluminium Hydroxide 0.291 g Magnesium Hydroxide 96 mg	200 ML	1's x 10	320000
138	472	Enteric-Coated Esomeprazole and Sustained Release Domperidone Capsules (40mg+30mg)	Each hard gelatin calsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Domperidome (as sustained release) 30mg	10's	10's X 10	1950000
139	476	LIQUID PARAFFIN, MILK OF MAGNESIA and SODIUM PICOSULPHATE SUSPENSION 170ml	Each 5ml contains: LIQUID PARAFFIN 1.25ml MILK OF MAGNESIA 3.75ml SODIUM PICOSULPHATE3.33mg	170 ml Bottle	1's X 10	510000
140	477	CHLORDIAZEPOXIDE AND CLIDINIUM BROMIDE TABLETS (5mg+2.5mg)	Each sugar-coated tablet contains: Chlordiazepoxide 5mg Clidinium Bromide 2.5mg	10's	10's X 10	268000
141	479	Solution of SORBITOL and TRICHOLINE CITRATE	Each 10ml contains: TRICHOLINE CITRATE 0.55g SORBITOL Solution (70%) IP 7.15g	200 ML	1's x 10	229000
142	480	Enteric-Coated Esomeprazole and Sustained Release Levosulpiride Capsules (40mg+75mg)	Each hard gelatin capsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Levosulpiride (as sustained	10's	10's X 10	630000

			release) 75mg			
143	481	RIFAXIMIN TABLETS 400 MG	Each film-coated tablet contains: Rifaximin 400mg	10's	10's X 10	50000
144	483	LOPERAMIDE Capsules IP 2 mg	Each hard gelatin calsule contains: LOPERAMIDE HYDROCHLORIDE IP 2 mg	10's	10's X 10	720000
145	486	PANCREATIN and Activated DIMETHICONE TABLETS (170mg+80mg)	Each enteric-coated tablet contains: PANCREATIN IP 170mg Activated DIMETHICONE TABLETS IP 80mg	10's	10's X 10	100000
146	487	Dicyclomine Hydrochloride and Dimethicone Suspension (10mg+40mg)	Each 5ml contains: Dicyclomine Hydrochloride IP 10mg Simethicone IP 40mg	30 ML	1's x 10	112000
147	488	LANSOPRAZOLE CAPSULES IP 15 MG	Each capsule contains: Lansoprazole IP 15 mg (as enteric coated granules)	10's	10's X 10	122000
148	489	Sulfasalazine Delayed Release Tablets 1000mg	Each enteric-coated tablet contains: Sulfasalazine 1000mg	10's	10's X 10	50000
149	492	Sulfasalazine Delayed Release Tablets 500mg	Each enteric-coated tablet contains: Sulfasalazine 500mg	10's	10's X 10	402000
150	496	DYDROGESTERONE TABLETS IP 10 MG	Each film-coated tablet contains: DYDROGESTERONE IP 10 MG	10's	10's X 10	50000
151	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	Each film-coated tablet contains: BETAMETHASONE SODIUM PHOSPHATE TABLETS IP equivalent to Betamethasone 0.5 MG	20's	20's x 10	490000
152	504	NANDROLONE DECANOATE INJECTION IP 25 MG/ML	Each ml contains: NANDROLONE DECANOATE IP 25 mg	1 ML	1's X 10	175000
153	505	CARBIMAZOLE TABLETS 10 MG	Each uncoated tablet contains: CARBIMAZOLE 10 MG	100's	1's X 10	150000
154	507	CARBIMAZOLE TABLETS IP 5 MG	Each uncoated tablet contains: CARBIMAZOLE IP 5 MG	10's	10's X 10	650000
155	521	Tramadol Sustained release Tablets 100 mg	Each sustained release tablet contains: Tramadol 100mg	10's	10's X 10	233000
156	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	Each soft gelatin capsule contains: Alfacalcidol 0.25mcg	10's	10's X 10	443000
157	523	NAPROXEN TABLETS IP 500 MG	Each uncoated tablet contains: NAPROXEN IP 500 MG	15's	15's X 10	150000

158	524	LIGNOCAINE INJECTION IP 2%	Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Sodium chloride IP 6.0 mg Methyl Paraben IP 1.0 mg (as preservative)	30 ML VIAL	1's x 10	100000
159	528	PARACETAMOL, PHENYLEPHRINE and CHLORPHENIRAMINE Tablets (325mg+10mg+2mg)	Each uncoated tablet contains: PARACETAMOL IP 325 mg PHENYLEPHRINE HYDROCHLORIDE IP 10 mg CHLORPHENIRAMINE MALEATE IP 2 mg	10's	10's X 10	1035000
160	529	LEVOSALBUTAMOL AND IPRATROPIUM RESPULES (1.25mcg+500mcg)	Each 2.5ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25mcg	2.5 ML	2.5 ml x 5	250000
161	530	FORMOTERAL and BUDESONIDE ROTACAPS (6mcg+200mcg)	Each capsule contains: Formoterol Fumarate (as Formoterol Fumarate dihydrate IP) 6mcg Budesonide IP 200mcg	30's	30's X 10	150000
162	532	SALMETEROL and FLUTICASONE ROTACAPS (50mcg+250mcg)	Each capsule contains: Salmeterol Fumarate (as Formoterol Xinafoate IP) 50mcg Fluticasone Propionate IP 250mcg	30's	30's X 10	150000
163	537	Ambroxol Hydrochloride and Levosalbutamol Sulphate Syrup	Each 5ml contains: Ambroxol Hydrochloride15mg Levosalbutamol Sulphate equivalent to Levosalbutamol 0.5mg	100 ML	100 ml X 6	200000
164	540	Levosalbutamol and BUDESONIDE Respules (1.25mg+1mg)	Each 2ml respule contains: Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25 mg Budesonide 1 mg	2 ML	2ml x 5	250000
165	543	MENTHOL (55 mg ± 5.) CINNAMON (12.5 mg ± 2) and PINE OIL (112.5 mg ± 1) SOFT CAPSULES	MENTHOL (55 mg ± 5.) CINNAMON (12.5 mg ± 2) and PINE OIL (112.5 mg ± 1) SOFT CAPSULES	10's	10's X 10	200000
166	559	SALBUTAMOL AND THEOPHYLLINE TABLETS (2mg+100mg)	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg Theophylline (anhyd.) IP 100mg	30's	30's X 10	200000
167	560	FLUTICASONE PROPIONATE NASAL SPRAY 50 mcg	Each spray delivers: Fluticasone Propionate IP 50 mcg	120 MD	1's x 10	50000

168	561	LEVOSALBUTAMOL SYRUP (1mg/5ml)	Each 5ml contains: Levosalbutamol Sulphate IP equivalent to Salbutamol 1mg Flavoured syrup base q.s.	100 ML	100 ml X 6	200000
169	564	Tiotropium Bromide and Formoterol Fumarate Dihydrate Rotacaps (18mcg+12mcg)	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg	15's	15's X 10	50000
170	565	Tiotropium Bromide, Formoterol Fumarate Dihydrate and Ciclesonide Rotacaps (18mcg+12mcg+400mcg)	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg Ciclesonide IP 400mcg	15's	15's X 10	50000
171	566	Ipratropium Bromide Respirator Solution 250mcg	Each ml contains: Ipratropium bromide IP 250mcg	15 ML	1's X 10	50000
172	567	SALBUTAMOL AND IPRATROPIUM INHALER (100mcg+20mcg)	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg Ipratropium bromide IP 20mcg	200 MDI	1's X 10	137000
173	568	Salmeterol and Fluticasone Propionate Inhaler IP (25mcg+250mcg)	Each activation delivers: Salmeterol (as Salmeterol Xinofoate) 25mcg Fluticasone Propionate 250mcg	100 MD	30's x 10	50000
174	571	Tamsulosin Hydrochloride and Dutasteride Tablets (0.4mg+0.5mg)	Each film-coated tablet contains: Tamsulosin Hydrochloride IP 0.4mg (as modified release tablets) Dutasteride IP 0.5mg	15's	15's X 10	1630000
175	574	Rabies Vaccine, Human IP	Purified lyophilized Rabies antigen derived from Rabies virus (L.Pasteur 2061/ Vero strain propogated in Vero cells), Inactivated. Potency: ≥ 2.5 IU per Vial Stabilizers: Maltose and Human Albumin q.s. Preservatives: Thiomersal ≤ 0.015% w/v	1 ml with Diluent (0.9% w/v Sodium Chloride inj. IP)	1's X 10	2500000

176	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	Each 15ml contains: Vitamin A 2500 IU Thiamine Hydrochloride 1.5 mg Riboflavin Sodium Phosphate 1.7 mg Pyridoxine Hydrochloride 1.5 mg Cyanocobalamine 1 mcg Vitamin C 25 mg Vitamin D3 200 IU Vitamin E 10 IU Nicotinamide 20 mg D-Panthenol 5 mg Biotin 10 mcg Zinc 3 mg Iodine 50 mcg Iron 5 mg Manganese 0.8 mg Chromium 8 mcg Molybdenum 8 mcg in a flavoured base q.s.	200 ML	1's x 10	708000
177	583	CYPROHEPTADINE Tablets IP 4 mg	Each uncoated tablet contains: Cyproheptadine Hydrochloride IP 4mg	10's	10's X 10	250000
178	586	METHYLCOBALAMIN, L- CARTININE L-TARTRATE and FOLIC ACID TABLETS (1500mcg+500mg+1.5mg)	Each film-coated tablet contains: L- CARTININE L-TARTRATE equivalent to L-carnitine 500 mg Methylcobalamine 1500 mcg Folic acid 1.5 mg	10's	10's X 10	200000
179	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	Each 5ml contains: Thiamine Hydrochloride 2.25 mg Riboflavin Sodium Phosphate 2.5 mg Nicotinamide 22.5 mg D-panthenol 3.0 mg Pyridoxine Hydrochloride 0.75 mg Lysine Hydrochloride 375 mg	200 ML	1's x 10	783000
180	593	Folic Acid, Cyanocobalamine and Nicotinamide Injection (15mg+500mcg+200mg)	Each ml contains: Folic Acid 15 mg Cyanocobalamine 500 mcg Nicotinamide 200 mg Benzyl Alcohol 2.5% v/v Phenol 0.5% w/v (As preservative)	10 ML	10 ml Vial X10	50000
181	595	THIAMINE, PYRIDOXINE HCl and CYANOCOBALAMIN INJECTION (100mg+50mg+1000mcg)	Each 2 ml ampoule contains: Mecobalamin IP 1000 mcg Pyridoxine HCl IP 50 mg Thiamine 100 mg	2 ML	2ml x 10	100000

182	597	PYRIDOXINE TABLETS 50 MG	Each uncoated tablet contains: Pyridoxine Hydrochloride 50mg	10's	10's X 10	65000
183	601	Disulfiram Tablets 500 mg	Each uncoated tablet contains: Disulfiram 500 mg	4's	(4's X 10)	305000
184	603	Cetirizine Dihydrochloride, Phenylephrine HCl and Paracetamol Tablets (5mg+10mg+325mg)	Each uncoated tablet contains: Cetirizine Dihydrochloride 5mg Phenylephrine Hydrochloride 10mg Paracetamol 325mg	10's	10's X 10	1710000
185	608	Betamethasone Dipropionate and Salicylic acid Ointment	Contains: Betamethasone Dipropionate 0.05% w/w Salicylic acid 3% w/w	20gm	1's x 20	540000
186	609	Silver Nitrate and Chlorhexidine Gluconate Cream	Contains: Silver Nitrate 0.20% w/w Chlorhexidine Gluconate Solution 0.20%w/w Preservative: Chlorocresol 0.12%w/w	15g Tube	1's x 10	100000
187	610	Paracetamol, Phenylephrine Hydrochloride and Cetirizine Dihydrochloride Suspension (125mg+5mg+2mg)	Each 5ml contains: Paracetamol IP 125mg Phenylephrine Hydrochloride IP 5mg Cetirizine Dihydrochloride 2mg	60 ML	60ml X 10	176000
188	611	Cyproheptadine Hydrochloride Syrup IP 2mg	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg	200 ml	1's x 10	290000
189	612	Povidone-Iodine Powder 5% w/w	Povidone-Iodine Powder 5% w/w	10gm Container	10gm X 20	275000
190	613	Diclofenac Potassium, Paracetamol and Serratiopeptidase Tablets (50mg+325mg+10mg)	Each film-coated tablet contains: Diclofenac Potassium 50 mg Paracetamol 325 mg Serratiopeptidase 10mg (20,000 serratiopeptidase unit as enteric coated granules)	10's	10's X 10	1364000
191	621	Carbonyl Iron, Zinc and Folic Acid Capsules	Each capsule contains: Elemental Iron 50 mg (in the form of Carbonyl Iron) Zinc Sulphate Monohydrate 61.8 mg (equivalent to 22.5 elemental Zinc) Folic Acid 0.5 mg	15's	10 x 15's	1815000
192	626	Ketoconazole Shampoo 2% W/V	Ketoconazole Shampoo 2% W/V	100ml Bottle	10 x 100ml	455000

193	627	Etophylline and Theophylline Prolonged Release Tablets IP (115mg+35mg)	Each film-coated prolonged release tablet contains: Etophylline 115mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 35mg	10's	10's X 10	2000000
194	628	Etophylline and Theophylline Prolonged Release Tablets (231mg+69mg)	Each film-coated prolonged release tablet contains: Etophylline 231mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 69mg	10's	10's X 10	708000
195	632	Etamsylate Tablets 250 mg	Each uncoated tablet contains: Etamsylate 250 mg	10's	10's X 10	140000
196	635	Clobetasol Propionate, Neomycin Sulphate, Miconazole Nitrate and Chlorhexidine Gluconate Cream	Contains: Clobetasol Propionate 0.05% w/w Neomycin Sulphate 0.50% w/w Miconazole Nitrate 2.00% w/w Chlorhexidine Gluconate Solution 0.20% w/w Chlorocresol (as preservative) 0.10% w/w In a cream base q.s.	10 gms tube	1's x 20	200000
197	640	Nimesulide Gel 1% w/w	Nimesulide Gel 1% w/w	20gm Tube	1's x 20	265000
198	645	Nimesulid, Paracetamol and Chlorzoxazone Tablets (100mg+325mg+375mg)	Each uncoated tablet contains: Nimesulide 100mg Paracetamol 325mg Chlorzoxazone 375mg	10's	10's X 10	100000
199	649	Dicyclomine Hydrochloride and Simethicone Oral Drops (10mg+40mg)	Each ml contains: Dicyclomine Hydrochloride 10mg Simethicone 40mg	10ml Bottle	10ml X 10	125000
200	650	Mefenamic Acid and Paracetamol Tablets (500mg+325mg)	Each uncoated tablet contains: Mefenamic Acid 500mg Paracetamol 325mg	10's	10's X 10	23000
201	656	Diastase and Pepsin Enzyme Drops	Each ml contains: Diastase (1:1200) 33.33 mg Pepsin (1:3000) 5mg Vit B1 1 mg Vit B2 1 mg Vit B6 1 mg Vit B12 1 mcg Niacinamide 10 mg	15 ml	1's X 10	100000
202	659	Chlorhexidine Gluconate and Cetrimide Solution (0.3% w/v and 0.6% w/v)	Chlorhexidine Gluconate 0.3% w/v + Cetrimide 0.6%w/v	200 ml	1x 200 ml	275000

203	662	Gamma Benzene Hexachloride and Cetrimide Lotion	contains: Gamma Benzene Hexachloride 1% w/v Cetrimide 0.1% w/v	200ML	24 x 1 x 200ml	100000
204	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	Choline Salicylate sodium 9% w/v Benzalkonium Chloride 0.01% w/w	10gm	10gm X 20	665000
205	665	Vitamin B complex & Ascorbic Acid Capsules	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 50mg Pyridoxine Hydrochloride 3mg Cynocobalamine 50mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid 150mg	10's	10's X 10	410000
206	666	Pheniramine Maleate Injection IP 22.75 mg	Each ml contains: Pheniramine Maleate IP 22.75 mg	2 ML	2ml x 10	100000
207	668	Multivitamin Drops	Each ml contains: Vitamin A (as Palmitate) 2500 IU Vitamin E acetate 25 IU Vitamin D3 200 IU Ascorbic Acid 40 mg Thiamine Hydrochloride 1 mg Riboflavin Sodium Phosphate 1.5 mg Niacinamide 10 mg D-Panthenol 3 mg D-Biotin 50mcg Lysine Hydrochloride 18 mcg	15ml	1's x 10	245000
208	670	Glucosamine, Diacerein and Methylsulfonylmethane Tablets (750mg+50mg+250mg)	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 750 mg Diacerein 50 mg Methylsulfonylmethane 250mg	10's	10's X 10	435000
209	671	Glucosamine and Diacerein Tablets (500mg+50mg)	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 500 mg Diacerein 50 mg	10's	10's X 10	400000
210	677	Flupentixol Tablets 0.5 mg	Each film-coated tablet contains: Flupentixol Hydrochloride equivalent to Flupentixol 0.5 mg	10's	10's X 10	110000
211	679	Nalidixic Acid Tablets IP 500 mg	Each tablet contains: Nalidixic Acid Tablets IP 500 mg	10's	10's X 10	100000

212	681	Phenazopyridine Hydrochloride tablet 100mg	Each sugar coated tablet contains: Phenazopyridine Hydrochloride 100mg	10's	10's X 10	20000
213	682	Rabeprazole 20mg + Domperidone 10mg Capsule	Each hard gelatin capsule contains: Rabeprazole sodium Ip (as enteric coated pellets) 20mg Domperidone Ip (as immediate release pellets) 10mg	10's	10's X 10	2720000
214	686	Magaldrate 400mg + Simethicone 20mg/5ml Oral Suspension IP	Each 5 ml contains: Magaldrate 400 mg Simethicone 20 mg	170 ml	1's X 10	205000
215	691	Ofloxacin Eye Drops 0.3%w/v	Ofloxacin Eye Drops 0.3%w/v	10ml	1's x 10	500000
216	692	Olopatadine Hydrochloride Ophthalmic Solution 0.1% w/v	Contains: Olopatadine Hydrochloride equivalent to Olopatadine 0.1% w/v Benzalkonium Chloride 0.01% w/v (as preservative)	10ml	10 ml Drops X10	305000
217	693	Tropicamide Eye Drops IP 1% w/v	Contains: Tropicamide IP 1% w/v Chlorbutol IP 0.5% w/v (as preservative)	5ml	5ml x 10	50000
218	697	Sulphacetamide eye drop 10 % w/v	Contains: Sulphacetamide Sodium 10 % w/v Phenylethyl Alcohol 0.5% v/v (as preservative)	10 ml	1's x 10	100000
87	699	Acyclovir Eye Ointment IP 3% w/w	Contains: Aciclovir IP 3% w/w Benzalkonium chloride IP 0.01% w/w	5gm	12 x1 x 5 g	200000
219	701	Pilocarpine Eye Drops IP 2% w/v	Contains: Pilocarpine Nitrate IP 2% w/v Hydroxypropylmethylcellulose IP 0.35% w/v Chlorbutol IP 0.5% w/v (As preservative)	10 ml	10ml X 10	20000
220	705	Levofloxacin INFUSION IP 500 mg/100 ml	Each ml contains: Levofloxacin 5 mg	100 ML	100 ml X 6	95000
221	707	Piroxicam Dispersible Tablets 10 mg	Each dispersible uncoated tablet contains: Piroxicam 10mg	10's	10's X 10	100000
222	708	Piroxicam Dispersible Tablets 20 mg	Each dispersible uncoated tablet contains: Piroxicam 20mg	10's	10's X 10	110000
223	709	Piroxicam Injection 20 mg	Each ml contains: Piroxicam 20 mg Benzyl Alcohol 20 mg (as preservative)	1ml	1 ml x 10	200000

224	715	Glycerin IP 98%w/w	Contains: Glycerin IP 98%w/w	50 GM	50gm x 10	153000
225	717	Etodolac Tablets IP 300mg	Each film-coated tablet contains: Etodolac IP 300mg	10's	10's X 10	170000
226	720	Ringer Lactate Infusion	Sodium chloride (600mg), Sodium Lactate (320mg), Potassium Chloride (40mg), Calcium Chloride (27mg)	500ml in FFS bottle	500 ml x 1	310000
227	725	Dextrose IV fluid IP 5% w/v	Dextrose IV fluid IP 5% w/v	500ml	500 ml x 1	166000
228	728	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	500ml	500 ml x 1	435000
229	732	Sodium Chloride Injection IP 0.9%w/v	Sodium Chloride Injection IP 0.9%w/v	100ml IV fluid plastic container	1's X 20	258000
230	733	Progesterone Sustained Release Tablets 200 mg	Each film-coated sustained release tablet contains: Progesterone 200mg	10's	10's X 10	180000
231	734	Dehydroepiandrosterone (Micronized) 25 mg Capsule	Each hard gelatin capsule contains: Dehydroepiandrosterone (Micronized) 25 mg	10's	10's X 10	36000
232	740	Clarithromycin Tablets IP 250 mg	Each film-coated tablet contains: Clarithromycin IP 250mg	10's	10's X 10	240000
233	747	Glimepiride Tablets IP 3mg	Each uncoated tablet contains: Glimepiride IP 3 mg	10's	10 X 10's	1945000
234	753	Clotrimazole and Beclometasone Dipropionate lotion (1%w/v + 0.025%w/v)	Contains: Clotrimazole 1% w/v Beclometasone Dipropionate 0.025% w/v	15ml	12 x 1 x 15 ml	281000
235	769	Acetyl Salicylic Acid (Aspirin)Tablet 325mg	Each gastro-resistant tablet contains: Aspirin 325mg	14's	14's x 10	298000
236	785	Amitriptyline hydrochloride Tablets IP 25mg	Each film-coated tablet contains: Amitriptyline hydrochloride IP 25mg	15's	15's X 10	656000
237	791	Atenolol and Amlodipine Tablets (25mg+5mg)	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Atenolol IP 25mg	14's	14's x 10	1242000
238	793	Atenolol Tablets 25 mg	Each uncoated tablet contains: Atenolol 25mg	14's	14's x 10	1270000
239	796	Atorvastatin 10mg, Aspirin (EC) 75mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP	10's	10's X 10	2815000

			equivalent to Atorvastatin 10mg Aspirin IP 75mg (as gastro-resistant tablet IP 75mg)			
240	800	Bacitracin-Neomycin Sulphacetamide Dusting Powder	Each gram contains: Neomycin Sulphate 5 mg Bacitracin 250 units Sulphacetamide 60mg	10gm Powder	10gm X 20	46000
241	804	Betamethasone Injection IP 4 mg/ml	Each ml contains: Betamethasone Sodium Phosphate 4 mg	1 ml	1's X 10	568000
242	806	Bicalutamide Tablets IP 50mg	Each film-coated tablet contains: Bicalutamide IP 50mg	10's	10's X 10	156000
243	807	Biphasic Isophane Insulin Injection I.P 100 IU/ml (30:70) (30% Soluble Insulin & 70% Isophane Ins)	Each ml contains: Human Insulin IP 100 IU (30% Soluble Insulin Injection and 70% Isophane Insulin Injection) Preservative: m-cresol, phenol	3ml Cartridge/Penfill	3 ml X 5	653000
244	815	Calcitriol Capsules IP 0.25mcg	Each soft gelatin capsule contains: Calcitriol IP 0.25 mcg	10's	10's X 10	485000
245	816	Calcium Acetate Tablets 667mg	Each uncoated tablet contains: Calcium Acetate 667mg	10's	10's X 10	485000
246	818	Calcium Gluconate Injection IP 10 %	Contains: Calcium Gluconate IP 10 % w/v	10 ml	1's x 5	100000
247	829	Chloramphenicol Eye Ointment IP 1%w/w	Contains: Chloramphenicol IP 1%w/w	5 gm	1's x 10	110000
248	832	Chlorthalidone Tablets 12.5mg	Each uncoated tablet contains: Chlorthalidone 12.5mg	10's	10's X 10	925000
249	835	Glucosamine Sulphate and Chondroitin Tablets (500mg+400mg)	Each film-coated tablet contains: Chondroitin Sulphate 400mg Glucosamine Sulphate 500mg	10's	10's X 10	165000
250	838	Cilostazol Tablets IP 50mg	Each uncoated tablet contains: Cilostazol IP 50mg	10's	10's X 10	140000
251	844	Clonazepam Tablets IP 1mg	Each uncoated tablet contains: Clonazepam IP 1mg	10's	10's X 10	309000
252	860	Dextromethorphan Hydrobromide Syrup IP	Each 5 ml contains: Dextromethorphan Hydrobromide IP 13.5mg Flaoured base syrup q.s.	50ml	50 ml x 10	380000
253	868	Dicyclomine HCl (Dicycloverine) Injection IP 10mg/ml	Each ml contains: Dicyclomine Hydrochloride IP 10mg	2ml	2ml x 10	109000
254	875	Donepezil Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Donepezil Hydrochloride IP 10mg	10's	10's X 10	100000

255	881	Ebastine Tablets IP 10mg	Each film-coated tablet contains: Ebastine IP 10mg	10's	10's X 10	340000
256	885	Ethinylestradiol and Levonorgestrel Tablets IP (0.05mg+0.25mg)	Each uncoated tablet contains: Ethinylestradiol IP 0.05mg Levonorgestrel IP 0.25mg	21's	21's x 10	92000
257	899	Frusemide and Spironolactone Tablets (20mg+50mg)	Each film-coated tablet contains: Frusemide IP 20mg Spironolactone IP 50mg	10's	10's X 10	697000
258	900	Gabapentin and Methylcobalamine Tablets (100mg+500mcg)	Each film-coated tablet contains: Gabapentin 100 mg Methylcobalamine 500 mcg	10's	10's X 10	495000
259	904	Glimepiride and Metformin SR Tablets (1mg + 500mg)	Each uncoated bi-layer tablet contains: Glimepiride IP 1 mg Metformin Hydrochloride 500 mg (as extended release)	10's	10 X 10's	1266800 0
260	906	Glyceryl Trinitrate Controlled Release Tablets 2.6mg (Nitroglycerin CR Tablets)	Each uncoated tablet contains: Diluted Nitroglycerin equivalent to Nitroglycerin 2.6 mg (in a controlled release system)	30's	30's X 10	1108000
261	912	Hydroclorthiazide Tablets 12.5mg	Each uncoated tablet contains: Hydroclorthiazide 12.5mg	10's	10's X 10	1038000
262	915	Hydroxyzine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Hydroxyzine Hydrochloride IP 10mg	10's	10's X 10	411000
263	917	Imipramine Hydrochloride Tablets IP 25mg	Each film-coated tablet contains: Imipramine Hydrochloride IP 25mg	10's	10's X 10	141000
264	920	Insulin Regular (R-DNA Origin) Injection 100 IU	Insulin Regular (R-DNA Origin) Injection 100 IU	3ml Cartridge/Penfill	3 ml X 5	50000
265	922	Isopropyl Alcohol (70%) (Spirit)	Isopropyl Alcohol (70% Conc.)	100 ML bottle	100ml X 10	121000
266	931	Lamotrigine Tablets 100mg	Each uncoated tablet contains: Lamotrigine 100 mg	10's	10's X 10	138000
267	932	Latanoprost Eye Drops IP 0.005%w/v (50mcg/ml)	Each ml contains: Latanoprost IP 50 mcg	2.5 ML	2.5 ml x 10	74000
268	933	Leflunomide Tablets IP 20mg	Each film-coated tablet contains: Leflunomide IP 20mg	10's	10's X 10	114000
269	939	Levocarnitine Tablets 500mg	Each film-coated tablet contains: Levocarnitine 500mg	10's	10's X 10	250000
270	944	Levosalbutamol HCl inhaler 50mcg	Each activation delivers: Levosalbutamol tartrate equivalent to Levosalbutamol 50mcg	200 Mdi	1's X 10	83000

271	946	Lignocaine (Lidocaine) Hydrochloride Gel IP 2% w/v	Contains: Lignocaine Hydrochloride IP equivalent to anhydrous Lignocaine Hydrochloride 2% w/v	20g	1's x 20	258000
272	947	Lithium Carbonate Prolonged Release Tablets IP 450mg	Each uncoated prolonged release tablet conatins: Lithium Carbonate IP 450 mg	10's	10's X 10	125000
273	948	Lorazepam Tablets IP 1mg	Each uncoated tablet conatins: Lorazepam IP 1mg	10's	10's X 10	207000
274	951	Lycopene 1000 mcg, Vitamin A 2500 IU, Vitamin E 10 IU, Selenium 35 mcg and Vitamin C 50mg	Each 5 ml contains: Levocarnitine 5% 1000 mcg Vitamin A 2500 IU Vitamin E 10 IU Vitamin C 50 mg Zinc (as Zinc Gluconate) 3 mg Manganese 2 mg Iodine 100 mcg Copper 500 mcg Thiamine HCl 2 mg Riboflavin Sodium Phosphate 3 mg Pyridoxine HCl 1.5 mg	200 ml	1's x 10	146000
275	957	Memantine Hydrochloride Tablets IP 10mg	Each film-coated tablet conatins: Memantine Hydrochloride IP 10mg	10's	10's X 10	240000
276	965	Miconazole and Fluocinolone Acetonide Ointment (2%w/w+0.01%w/w)	Contains: Miconazole Nitrate 2% w/w Fluocinolone Acetonide 0.01% w/w	15gm Tube	1's x 10	58000
277	976	Nebivolol Tablets IP 2.5mg	Each uncoated tablet conatins: Nebivolol Hydrochloride IP 2.5 mg	10's	10's X 10	619000
278	978	Nepafenac Eye Drop 0.1% w/v	Each ml contains: Nepafenac 1mg Benzalkonium Chloride IP (as preservative) 0.005% w/v	5ml	5 ml x 10	178000
279	986	Nitrazepam Tablets I.P 10mg	Each uncoated tablet contains: Nitrazepam IP 10 mg	10's	10's X 10	207600
280	987	Nitrofurantoin Tablets I.P 100mg	Each uncoated tablet contains: Nitrofurantoin IP 100 mg	10's	10's X 10	380000
281	1008	Phytomenadione (Vitamin K1) Injection 1 mg/0.5ml	Each ml contains: Phytonadione 2 mg Polyoxyethylated fatty acid derivative 70 mg, dextrose, hydrous 37.5 mg, benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment.	0.5ml Ampoule	1's x 10	170000
282	1009	Pioglitazone Tablets IP 15 mg	Each uncoated tablet contains: Pioglitazone Hydrochloride IP equivalent to Pioglitazone15 mg	10's	10's X 10	50000

283	1024	Promethazine Injection IP 25 mg/ml	Each ml contains: Promethazine Hydrochloride 25 mg	2ml	2ml x 10	250000
284	1037	Recombinant Human Erythropoietin Injection 4000 IU	Each prefilled syringe contains: Erythropoietin concentrate Solution 4000 IU	Vial	1's x 10	163000
285	1038	Recombinant Human Erythropoietin Injection 2000 IU	Each prefilled syringe contains: Erythropoietin concentrate Solution 2000 IU	Vial	1's x 10	66000
286	1041	Risperidone and Trihexiphenidyl Tablets (4mg+2mg)	Each uncoated tablet contains: Resperidone 4 mg Trihexyphenidyl hydrochloride IP 2 mg	10's	10's X 10	216000
287	1044	Rosuvastatin Tablet I.P 5mg	Each film coated tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 5 mg	10's	10's X 10	2597000
288	1050	Sertraline Tablets I.P 100mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 100 mg	10's	10's X 10	238000
289	1051	Sertraline Tablets I.P 25mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 25 mg	10's	10's X 10	211000
290	1060	Sodium Valproate Gastro-resisTablets IP 300mg	Each gastro-resistant tablet contains: Sodium Valproate IP 300mg	10's	10 X 10's	797000
291	1069	Sulphacetamide Sodium Eye Drop I.P 20% w/v	Each ml contains: Sulfacetamide Sodium IP 20 % w/v Phenylethyl alcohol IP 0.5 % v/v (as preservative)	10ml	1's x10	50000
292	1074	Telmisartan and Hydroclorthiazide Tablets (80mg+12.5mg)	Each uncoated bilayer tablet contains: Telmisartan IP 80 mg Hydrochlorthiazide IP 12.5 mg	10's	10's X 10	1417000
293	1076	Tenofovir Disoproxil Fumarate Tablets 300 mg	Each film coated tablet contains: Tenofovir Disoproxil fumarate IP 300 mg	10's	10's X 10	35000
294	1087	Trihexyphenidyl Hydrochloride Tablets 2mg (benzhexol HCl Tablets IP 2mg)	Each uncoated tablet contains: Trihexyphenidyl Hydrochloride IP 2 mg	10's	10's X 10	605000

295	1088	Trimetazidine Hydrochloride Modified Release Tablets 35 mg	Each film-coated modified release tablet contains: Trimetazidine Hydrochloride IP 35 mg	10's	10's X 10	730000
296	1097	Vitamin A Capsule 25000 IU	Each soft gelatin capsule contains: Vitamin A IP (as Palmitate) 25000 IU (equivalent to Retinol 7.5 mg) in water soluble form.	30's	(30's X 10)	503000
297	1099	Voglibose and Metformin Tablets (0.3mg+500mg)	Each uncoated tablet contains: Voglibose IP 0.3 mg Metformin Hydrochloride IP 500 mg	10's	10's X 10	2885000
298	1106	Metoprolol Succinate ER 50 mg & Telmisartan 40mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate IP equivalent to Metoprolol Tartarate 50 mg (as extended release form) Telmisartan IP 40 mg	10's	10's X 10	1870000
299	1110	Clobazam Tablet IP 5mg	Each uncoated tablet contains: Clobazam IP 5 mg	10's	10's X 10	140000
300	1112	Cinnarizine Tablets IP 25mg	Each uncoated tablet contains: Cinnarizine IP 5 mg	10's	10's X 10	815000
301	1123	Clomipramine Hydrochloride SR Tablets 75mg	Each film coated sustained release tablet contains: Clomipramine Hydrochloride 75 mg	10's	10's X 10	130000
302	1124	Fluvoxamine Maleate Tablets IP 100mg	Each film coated sustained release tablet contains: Fluvoxamine Maleate IP 100 mg	10's	10's X 10	117000
303	1125	Aripiprazole Tablets IP 5mg	Each uncoated tablet contains: Aripiprazole IP 5 mg	10's	10's X 10	136000
304	1149	Lisinopril Tablets IP 10mg	Each uncoated tablet contains: Lisinopril IP equivalent to anhydrous Lisinopril 2 mg	15's	15's X 10	95000
305	1152	Carbamazepine Sustained Release Tablets IP 200mg	Each film coated prolonged release tablet contains: Carbamazepine IP 200 mg	10's	10's X 10	117000
306	1154	Diethylcarbamazine Citrate Tablets IP 100mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 100mg Excipients q.s.	30's	(30's X 10)	100000
307	1156	Metoprolol Succinate ER 25 mg & Amlodipine Besylate 5 mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate IP equivalent to Metoprolol Tartarate 25 mg (as extended release form) Amlodipine besylate IP equivalent to Amlodipine 5 mg	7's	7's x 10	388000

308	1157	DOXYLAMINE SUCCINATE 20 MG+ PYRIDOXINE HCl 20 MG TABLETS	Each enteric coated tablet contains: Doxylamine Succinate 20 mg Pyridoxine Hydrochloride 20 mg	10's	10's X 10	115000
309	1164	NANDROLONE DECANOATE INJECTION IP 50 mg/ml	Each ml contains: Nandrolone decanoate 50mg	2 ml	2ml x 10	125000
310	1166	MEFENAMIC ACID 250 MG TABLETS	Each uncoated tablet contains: Mefenamic Acid 250 mg	10's	10's X 10	115000
311	1168	KETOROLAC Inj. IP 30mg/ml	Each vial contins: Ketorolac tromethamine 30 mg	1 ml	1's X 10	212000
312	1170	ACETYLCYSTEINE Injection 200 mg/ml	Each ml contains: Acetylcystein 200 mg	2ml Ampoules	1ml x 5	107000
313	1187	Cyclosporine Capsules IP 100 mg	Each soft gelatin capsule contains: Cyclosporine IP 100 mg	5's	5's X 10	10000
314	1191	Glycopyrrolate Inj IP 0.2mg	Each ml contains: Glycopyrrolate 0.2 mg Benzyl alcohol 0.9 % WFI q. s.	1 ml	1's X 10	108000
315	1203	Protamine Inj 10mg/ml	Each ml contains: Protamine Sulphate 10 mg	5ml vial/ampoule	5 ml Vial X10	50000
316	1219	Amino Acid Solution for IV 200 ml bottle	Nutritive infusion of Pure Crystalline Amino Acids	200 ml Glass Bottle	1's x 10	35000
317	1220	Oseltamivir Capsules 75mg	Each hard gelatin capsule contains: Oseltamivir Phosphate IP 98.5 mg equivalent to Oseltamivir 75mg	10's	10's X 10	20000
318	1225	Orlistat Capsules 120 mg	Each hard gelatin capsule contains: Orlistat 120 mg (as pellets 50 % w/w)	10's	10's X 10	113000
319	1226	Triamcinolone Injection 40mg/ml	Each ml contains: Triamcinolone Acetonide IP 40 mg Benzyl Alcohol IP 0.9%w/v (as preservative)	1 ml	1's X 10	140000
320	1231	Vitamin E Acetate & Levocarnitine Tablets (200 mg + 150 mg)	Each film coated tablet contains: Tocopheryl Acetate IP 200 mg (as 50% powder) L-Carnitine-L-Tartarate equivalent to Levocarnitine USP 150 mg	10's	10's X 10	100000
321	1237	Methyldopa tablets IP 500 mg	Each film coated tablet contains: Methyldopa IP equivalent to anhydous Methyldopa 500 mg	10's	10's X 10	20000

322	1238	Prazosin Hydrochloride Sustained Release Tablets 2.5 mg	Each film coated sustained release tablet contains: Prazosin Hydrochloride IP equivalent to Prazosin 2.5 mg	30's	30's X 10	20000
323	1241	Cefaclor Dispersible Tablets 250 mg	Each dispersible tablet contains: Cefaclor IP equivalent to anhydous Cefaclor 250 mg	10's	10's X 10	50000
324	1243	Betamethasone Valerate & Salicylic Acid (0.05% w/w + 3.0% w/w) Ointment	Contains: Betamethasone Valerate IP equivalent to betamethasone 0.05% w/w Salicylic Acid IP 3.0%w/w in a greasy base	20gm Tube	1's x 20	50000
325	1248	Haematinic syrup of Iron,Folic acid and Vitamin B12(32mg+0.5mg+7.5mcg) 200 ml	Each 15 ml contains: Ferric Ammonium Citrate equivalent to Elemental Iron 32 mg Folic Acid IP 0.5 mg Cyanocobalamin IP 7.5 mg	200ml bottle	1's x 10	210000
326	1252	Suspension of Calcium Phosphate with Vitamin D3 & Viatmin B12 (82 mg + 200 IU + 2.5 mcg)	Each 5ml contains: Vitamin D3 (Cholecalciferol IP) 200 IU Vitamin B12 IP 2.5 mcg Calcium Phosphate equivalent to elemental Calcium 82 mg	200 ml	1's x 10	100000
327	1255	Montelukast & Acebrophylline Sustained Release (10 mg +200 mg) Tablets	Each film coated bilayered tablet contains: Montelukast Sodium IP equivalent to Montelukast 10mg (in immediate release form) Acebrophylline 200 mg (in sustained release form)	10's	10's X 10	132000
328	1284	Cilnidipine & Telmisartan Tablets (10 mg + 40 mg)	Each film coated tablet contains: Cilnidipine 10 mg Telmisartan IP 40 mg	10's	10's X 10	770000
329	1308	Ethinylestradiol IP 0.03mg+ Levonorgestrel IP 0.15mg Tablet	Each uncoated tablet contains: Levonorgestrel IP 0.15 mg Ethinyloestradiol IP 0.03 mg	21's	21's x 10	100000
330	1328	Isoxsuprine Injection IP 5 mg	Each ml contains: Isoxsuprine Hydrochloride IP 5 mg WFI IP q. s.	2ml Vial	2ml x 10	50000
331	1342	Mebeverine Hydrochloride Tablets	Each sugar-coated tablet contains: Mebeverine Hydrochloride IP 200 mg	10's	10's X 10	20000
332	1368	Olmesartan Medoxomil & Hydrochlorthiazide Tablets (20 mg + 12.5 mg)	Each film coated tablet contains: Olmesartan Medoxomil 20 mg Hydrochlorothiazide IP 12.5 mg	10's	10's X 10	472000

333	1409	Teicoplanin Injection 400 mg	Each ml contains (as lyophilisate) Teicoplanin 400 mg Sterile powder for preparation of intramuscular or intravenous injection.	1 ml Vial	10ml Vial X10	50000
334	1414	Terlipressin Injection 1000 mcg (1 mg)/10ml	Each 10ml contains: Terlipressin 1 mg	10 ml Vial	10 ml Vial X10	50000
335	1427	Trypsin, Bromelain & Rutoside Trihydrate Tablets (48 mg + 90 mg + 100 mg)	Each enteric coated tablet contains: Trypsin 48 mg Bromelain 90 mg Rutoside Trihydrate 100 mg	10's	10's X 10	100000
336	1431	Valethamate Injection 8 mg/ml (For IM/IV use)	Each ml contains: Valethamate Bromide 8 mg Sodium Chloride IP 8 mg WFI q.s.	1 ml Vial	1ml X 10	50000
337	1432	Tobramycin Eye Drops 0.3%	Each ml contains: Tobramycin Sulfate equivalent to Tobramycin 3mg Benzalkonium Chloride 0.0001 ml (as preservative)	5ml	5 ml X10	50000
338	1441	Nirmal (Nicotine Polacrilex chewing gum 2 mg)	Each gum contains: Nicotine Polacrilex equivalent to Nicotine 2 mg	1 x 9's (mono carton pack)	10 x 1 x 9's	395000
339	1449	Enzyme Syrup Mixed Fruit Flavour (Diastase and Pepsin)	Each 5ml contains: Diastase (1:1200) 50mg Pepsin (1:3000) 10mg	200 ml	1's x 10	500000
340	1450	PYRANTEL PAMOATE ORAL SUSPENSION IP 250mg/5ml	Each 5ml contains: Pyrantel Pamoate 250 mg	10 ML	1's x 10	100000
341	1451	THEOPHYLLINE Controlled release TABLETS 400 MG	Each uncoated tablet contains: Theophylline Anhydrous IP 400mg (in controlled release form)	10's	10's X 10	100000
342	1452	Pyridoxine Hydrochloride Sustained Release Tablets 100 mg	Each Sustained release tablet contains: Pyridoxine Hydrochloride IP 100 mg	10's	10's X 10	200000
343	1453	Levetiracetam Syrup 100 Mg	Each ml contains: Levetiracetam 100mg	100ml	100 ml X 6	200000
344	1454	Terbutaline Sulphate and Bromhexine Hydrochloride Syrup	Each 5ml contains: Terbutaline Sulphate 2.5mg Bromhexine Hydrochloride 8mg	100 ML	100 ml X 6	200000
345	1455	L-Arginine Granules	Each sachet of 5 g contains: L-Arginine 3 g Excipients q.s	5 gm	10x 5gm	200000
346	1456	Itraconazole Capsules 200 mg	Each hard gelatin capsule contains: Itraconazole BP 200 mg (As pellets)	4's	10 X 4's	500000

347	1457	Luliconazole Cream 1% w/w	Contains: Luliconazole 1% w/w Preservatives: Methylparaben 0.14% w/w Benzyl Alcohol 1% w/w in a Cream base q.s.	10 g	20 x 1's	500000
348	1458	Sodium Chloride Injection IP 0.9%w/v	Sodium Chloride Injection IP 0.9%w/v	500ml IV fluid plastic container	1's X 20	200000

Note: For Drug Codes 807 and 920 bidders must quote their basic price in unit size considering one Pen free with per 10 cartridge/ pen fill.

Annexure – XIII

{Ref:- clause 19(K)}

(1)	(2)	(3)	(4)	(5)	(6)
S. N.	**Drug Code**	**Generic Name of Drug**	**Composition/Strength**	**Unit Size**	**Minimum Shelf Life Quoted (Months)**
1	1	Aceclofenac 100mg and Paracetamol 325 mg Tablets	Each film-coated tablet contains: Aceclofenac 100mg Paracetamol 325 mg	10's	30
2	9	Diclofenac Sodium Sustained Release Tablets IP 100mg	Each sustained release film-coated tablet contains: Diclofenac Sodium IP 100 mg	10's	24
3	10	Diclofenac Sodium Injection IP 25mg/ml	Each ml contains: Diclofenac Sodium IP 25mg	3 ml	24
4	14	Ibuprofen and Paracetamol Tablets IP (400mg + 325mg)	Each uncoated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325 mg	10's	24
5	16	Ibuprofen Tablet IP 400 mg	Each film-coated tablet contains: Ibuprofen IP 400mg	15's	24
6	17	Indomethacin capsule IP 25 mg	Each capsule contains: Indomethacin IP 25mg	10's	24
7	21	Diclofenac Sodium and Paracetamol Tablets IP (50mg + 325mg)	Each uncoated tablet contains: Diclofenac Sodium IP 50mg Paracetamol IP 325 mg	10's	24
8	24	Pentazocine Injection IP 30mg/ml	Each ml contains: Pentazocine 30 mg	1 ml	24
9	26	Tramadol Hcl Injection 100 mg/2 ml	Each ml contains: Tramadol Hcl 50 mg	2ml	24
10	28	Tramadol 50 mg Tablet	Each Film-coated tablet contains: Tramadol Hydrochloride 50mg	10's	24
11	29	Acyclovir Tablets IP 400mg	Each uncoated tablet contains: Acyclovir IP 400mg	10's	24
12	31	Amikacin Injections IP 250mg/2ml	Each ml contains: Amikacin sulphate Ip equivalent to Amikacin 125 mg	2ml Vial	24
13	32	Amikacin Injections IP 500mg/2ml	Each ml contains: Amikacin sulphate Ip equivalent to Amikacin 250 mg	2ml Vial	24
14	34	Glimepiride and Extended Release Metformin Hydrochloride Tablets (2mg + 500mg)	Each uncoated tablet contains: Glimepiride 2mg Metformin Hydrochloride 500mg (as extended release)	15's	30
15	37	Amoxycillin and Potassium Clavulanate Injection 300 mg	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 250 mg Potassium Clavulanate IP	Vial with WFI	24

			equivalent to Clavulanic Acid 50 mg		
16	38	Amoxycillin and Potassium Clavulanate Injection 600 mg	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 500 mg Potassium Clavulanate IP equivalent to Clavulanic Acid 100 mg	Vial with WFI	24
17	39	Amoxycillin and Potassium Clavulanate tablets IP (500mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 500mg Potassium Clavulanate IP equivalent to Clavulanic acid 125mg Colour: Titanium Dioxide IP	6's	24
18	40	Amoxycillin and Cloxacillin Capsules (250mg+250mg)	Each hard gelatin capsule contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 250mg Cloxacillin Sodium IP equivalent to Cloxacillin 250mg	10's	24
19	42	Amoxicillin Trihydrate Dispersible Tablets IP 125mg	Each uncoated dispersible tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 125mg	10's	24
20	48	Azithromycin 100 mg Dispersible Tablets	Each uncoated dispersible tablet contains: Azithromycin 100mg	10's	24
21	51	Cefadroxil Dispersible Tablets 250mg	Each uncoated dispersible tablet contains: Cefadroxil equivalent to Cefadroxil Anhydrous 250mg	10's	24
22	64	Cefotaxime Sodium Injection 500 mg	Each Vial contains: Cefotaxime Sodium 500 mg	Vial & wfi	24
23	68	Ceftazidime Injection IP 250mg	Each Vial contains: Ceftazidime 250 mg	Vial & wfi	24
24	83	Ciprofloxacin and Tinidazole Tablets (250mg+300mg)	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Tinidazole IP 300mg	10's	24
25	85	Ciprofloxacin Hydrochloride Tablets IP 250 mg	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Colour: Titanium Dioxide IP	10's	36
26	92	Doxycycline Capsules IP 100mg	Each hard gelatin capsule contains: Doxycycline Hydrochloride IP equivalent to	10's	36

			Doxycycline 100mg		
27	104	Roxithromycin Oral Suspension (50 mg/ 5ml)	Each 5ml contains: Roxithromycin 50mg Flavoured Syrupy Base q.s.	30ml	24
28	106	Roxithromycin Tablets IP 300 mg	Each film-coated tablet contains: Roxythromycin IP 300mg Colours: Lake of Ponceau 4R & Titanium Dioxide IP	10's	24
29	113	Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream	Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream	15g tube	24
30	124	Povidone Iodine 5% w/w Ointment USP	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/Jar	24
31	126	Povidone-Iodine Solution IP 10 % w/v	Povidone-Iodine Solution IP 10 % w/v	500 ml	24
32	127	Povidone-Iodine Solution IP 5 % w/v	Povidone-Iodine Solution IP 5 % w/v	100 ml	24
33	130	Chlorhexidine Gluconate and Cetrimide Solution (1.5% w/v and 3% w/v)	Chlorhexidine Gluconate 1.5% w/v, Cetrimide 3% w/v Solution	100ml Bottle	24
34	133	Glibenclamide Tablet IP 2.5 mg	Each uncoated tablet contains: Glibenclamide IP 2.5 mg	10's	24
35	142	Insulin Injection IP Soluble Insulin, Neutral (Regular)	Each ml contains: Human Insulin IP 40 IU (Human Insulin of recombinant DNA origin) m-cresol 0.25% w/v	10 ml Vial	24
36	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	24
37	153	Cisplatin Injection IP 10 mg/10ml	Each ml contains: Cisplatin 1 mg	Vial	24
38	158	Etoposide Injection IP 100 mg/5 ml	Each ml contains: Etoposide IP 20 mg	Vial	24
39	165	Ciprofloxacin infusion IP 200mg (2mg/ml)	Each ml contains: Ciprofloxacin 2 mg	100 ml	24
40	170	MANNITOL Injection IP 20% w/v	Each 100 ml contains: Mannitol 20 g	100 ml	18
41	172	Metronidazole Infusion IP 500 mg	Each ml contains: Metronidazole 5 mg	100 ml	24
42	186	Domperidone Tablets IP 10 mg	Each film-coated tablet contains: Domperidone Maleate IP equivalent to Domperidone 10mg	10's	36
43	194	Hyoscine Butylbromide Tablets IP 10 mg	Each sugar coated tablet contains: Hyoscine Butylbromide IP 10 mg	10's	36
44	196	Lactic Acid Bacillus Tablets (60 M)	Each uncoated tablet contains: Lactic Acid Bacillus not less than 60 million spores.	10's	24
45	197	Lactulose Solution	Each 15ml contains: Lactulose solution equivalent to Lactulose 10g	100 ml	24

46	198	Dried Aluminium Hydroxide 250mg, Magnesium Hydroxide 250mg, Activated Methyl Polysiloxane Suspension 50mg/ 5ml	Each 5ml contains: Dried Aluminium Hydroxide 250mg Magnesium Hydroxide 250mg Activated Methyl Polysiloxane 50mg	170 ml	24
47	200	Metoclopramide Injection IP 5mg/ml	Each ml contains: Metoclopramide 5 mg	2ml	24
48	201	Metronidazole Tablets IP 200mg	Each film-coated tablet contains: Metronidazole Tablets IP 200mg Excipients q.s.	10's	24
49	202	Metronidazole Tablets IP 400mg	Each film-coated tablet contains: Metronidazole Tablets IP 400mg Excipients q.s.	10's	24
50	208	Ondansetron injection IP 2mg/ml	Each ml contains: Ondansetron 2 mg	2 ml	24
51	209	Ondansetron Tablets IP 4mg	Each film-coated tablet contains: Ondansetron Hydrochloride IP equivalent to Ondansetron 4mg	10's	36
52	215	Rabeprazole Gastro-resistant Tablets IP 20mg	Each gastro-resistant tablet contains: Rabeprazole Sodium IP 20mg	10's	24
53	217	Ranitidine Tablets IP 150 mg	Each film-coated tablet contains: Ranitidine Hydrochloride IP 167.4mg equivalent to Ranitidine 150mg Excipients q. s.	10's	24
54	220	Calcium with Vitamin D3 Tablets IP (500mg+250IU)	Each film-coated tablet contains: 1250mg Calcium Carbonate equivalent to Elemental Calcium IP 500mg Vitamin D3 IP 250IU	10's	24
55	227	Polyvitamin Tablets NFI (Prophylactic)	Each film-coated tablet contains: Vitamin A 2500 IU Vitamin D3 200IU Vitamin B1 2mg Vitamin B6 0.5mg Vitamin B12 2mg Niacinamide 25mg Calcium Pantothenate 1mg Vitamin C 50mg Folic Acid 0.2mg	10's	24
56	230	Vitamin B-Complex fort Zinc Capsule"	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 45mg Pyridoxine Hydrochloride 3mg Cynocobalamine 15mcg Folic acid 1.5mg Ascorbic acid 150mg Zinc Sulfate Monohydrate 61.8mg	10's	24

			(Eq. to 22.5 mg of Elemental Zinc)		
57	232	Vitamin B-Complex Syrup	Each 5ml contains: Pyridoxine Hydrochloride IP0.75 mg Thiamine Hydrochloride IP 2.5 mg Riboflavin Sodium Phosphate IP 2.5 mg Cynocobalamine IP 2.5 mcg Nicotinamide IP 22.5 mg D-Panthenol IP 3.0 mg	200 ml	24
58	233	Vitamin-C Chewable 100mg Tablet	Vitamin-C Chewable 100mg Tablet	10's	24
59	236	Budesonide Inhaler 100mcg	Each activation delivers Budesonide IP 100mcg	200 MDI	24
60	238	Budesonide Inhaler 200mcg	Each activation delivers Budesonide IP 200mcg	200 md	24
61	239	Cetirizine Syrup IP (5 mg/ 5 ml)	Each 5ml contains: Cetrizine Hydrochloride IP 5mg	60 ml	24
62	240	Cetrizine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Cetrizine Hydrochloride IP 10mg	10's	24
63	244	Etophyllin and Theophylline Injection (84.7mg+25.3 mg)	Each ml contains: Etofylline 84.7 mg Theophylline anhydrous equivalent to Theophylline hydrate 25.3 mg	2 ml	24
64	245	Etophylline and Theophylline Tablets 100 mg	Each uncoated tablet contains: Etophylline 77 mg Theophylline (Hydrated) 23 mg	10's	24
65	255	Salbutamol Inhalation IP 100 mcg/puff	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg	200 md	24
66	256	Salbutamol Tablets IP 2mg	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg	10's	24
67	265	Atenolol Tablets IP 50 mg	Each uncoated tablet contains: Atenolol IP 50mg	14's	24
68	268	Clonidine Tablets IP 0.1 mg	Each uncoated tablet contains: Clonidine Hydrochloride IP 100mcg	10's	24
69	270	CLOPIDOGREL AND ASPIRIN Tablets (75mg + 75mg)	Each film-coated tablet contains: Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg Aspirin 75mg	10's	24
70	273	Dobutamine Injection 250mg/20ml	Each vial (20ml) contains: Dobutamine 250 mg	Vial	24
71	274	Dopamine HCl Injection 200 mg/5ml	Each ml contains: Dopamine Hydrochloride 40mg	5 ml	24

72	275	Enalapril Tablets IP 5 mg	Each uncoated tablet contains: Enalapril Maleate IP 5 mg	10's	24
73	277	Enoxaparin Injection IP 60 mg/0.6 ml	Each pre-filled syringe contains: Enoxaparin sodium IP 60 mg equivalent to 6,000 IU anti-Xa activity.	0.6 ml	24
74	281	Heparin Sodium Injection IP 5000 IU/ml	Each ml contains: Heparin Sodium 5000 IU	5 ml	24
75	295	Simvastatin Tablets IP 10mg	Each film-coated tablet contains: Simvastatin IP 10mg	10's	24
76	296	Simvastatin Tablets IP 20mg	Each film-coated tablet contains: Simvastatin IP 20mg	10's	24
77	298	Telmisartan and Hydrochlorothiazide Tablets IP (40mg+12.5 mg)	Each uncoated bilayer tablet contains: Telmisartan IP 40mg Hydrochlorthiazide IP 12.5mg	10's	24
78	300	Telmisartan Tablets IP 40mg	Each uncoated tablet contains: Telmisartan IP 40 mg	10's	24
79	304	α-β Arteether Injection 150 mg	Each 2 ml contains: α-β Arteether 150 mg	2ml Vial	24
80	305	Chloroquine Phosphate Tablets IP 250 mg	Each film-coated tablet contains: Chloroquine Phosphate IP 250mg	10's	36
81	312	Oral Rehydration Salts 20.5 GM Sachet (WHO Formula)	Each pack contains: Sodium Chloride IP 2.6 mg Potassium Chloride IP 1.5 mg Sodium Citrate IP 2.9 mg Dextrose IP (anhydrous) 13.5 mg Excipients q.s.	1's	24
82	326	Methyl Ergometrine Tablets IP 0.125mg	Each sugar coated tablet contains: Methylergometrine Maleate IP 0.125mg	10's	24
83	330	Prednisolone Tablets IP 10 MG	Each uncoated tablet contains: Prednisolone IP 10 mg	10's	24
84	333	Dexamethasone Tablets IP 0.5 mg	Each uncoated tablet contains: Dexamethasone IP 0.5mg	10's	24
85	334	Dexamethasone Injection 4mg/ml	Each ml contains: Dexamethasone Sodium Phosphate IP equivalent to Dexamethasone Phosphate 4mg	2 ml	24
86	336	Allopurinol Tablets IP 100 mg	Each uncoated tablet contains: Allopurinol IP 100 mg	10's	24
87	352	Bupivacaine Hydrochloride Injection IP 5 mg/ml	Each ml contains: Bupivacaine Hydrochloride 5 mg	20ml	24
88	357	Lignocaine and Adrenaline Injection IP (2%w/v and 1:80000)	Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Adrenaline Bitartrate IP 0.0225 mg equivalent to (Adrenaline 0.0125 mg)	30 ml Vial	24

89	358	Propofol Injection 10 mg/ml	Each ml contains: Propofol 10 mg	10ml Vial	24
90	359	Tetanus Vaccine	Each 0.5 ml contains: Tetanus Toxoid ≥ 5 LF	0.5 ml Amp.	24
91	362	BIPHASIC ISOPHANE INSULIN INJECTION IP (50:50) 4O IU/ML	Each ml contains: Human Insulin IP 40 IU (50% as Soluble Insulin Injection and 50% as Isophane Insulin Injection) (Human Insulin od recombinant DNA origin)	10 ML VIAL	24
92	373	ARTESUNATE INJECTION 60 MG	Each vial contains: Artesunate 60 mg The pack also contains: 1 ml ampoule of Sodium Bicarbonate 5% w/v 5 ml ampoule of Sodium Chloride 0.9% w/v	1 vial with diluent	24
93	377	CLINDAMYCIN CAPSULES 300 MG	Each hard gelatin capsule contains: Clindamycin Hydrochloride equivalent to Clindamycin 300mg	10's	24
94	384	ITRACONAZOLE Capsules 100 mg	Each hard gelatin capsule contains: Itraconazole 100mg	4's	24
95	386	Diethylcarbamazine Tablets IP 50 mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 50mg Excipients q.s.	30's	24
96	392	GRISEOFULVIN TABLETS IP 250 MG	Each uncoated tablet contains: GRISEOFULVIN IP 250 MG	10's	24
97	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	Each dispersible uncoated tablet contains: Aciclovir IP 800mg	5's	24
98	395	CEFUROXIME and POTASSIUM CLAVULANATE Tablets (500MG + 125MG)	Each film-coated tablet contains: Cefuroxime Axetil IP equivalent to Anhydrous Cefuroxime 500mg Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 125mg	6's	24
99	396	AMPHOTERICIN B INJECTION IP 50 mg/vial	Each Vial contains: AMPHOTERICIN B 50 mg	Vial	24
100	401	Amoxycillin and Potassium Clavulanate tablets (250mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 250mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg	6's	24
101	402	Amoxycillin and Potassium Clavulanate tablets (875mg + 125	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin	6's	24

		mg)	875mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg		
102	405	OFLOXACIN INFUSION IP 200 mg /100 ml	Each 100 ml contains: OFLOXACIN IP 200mg	100 ml	24
103	417	TELMISARTAN AND AMLODIPINE Tablets IP (40 mg +5 mg)	Each uncoated tablet contains: Telmisartan IP 40mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	15's	24
104	419	Ointment of Heparin Sodium and Benzyl Nicotinate	Each gram contains: Heparin Sodium 50 IU Benzyl Nicotinate 2mg	20 GM	24
105	423	BISOPROLOL TABLETS 5 MG	Each film-coated tablet contains: Bisoprolol Fumarate 5mg	10's	36
106	425	Diltiazem Sustained Release Tablets 90mg	Each uncoated sustained release tablet contains: Diltiazem Hydrochloride IP 90mg	10's	24
107	427	S(-)AMLODIPINE TABLETS IP 2.5 MG	Each uncoated tablet contains: S(-)AMLODIPINE Besylate IP equivalent to S(-)AMLODIPINE 2.5 MG	10's	36
108	428	DIGOXIN Tablets IP 0.25 mg	Each uncoated tablet contains: DIGOXIN IP 0.25 mg	10's	24
109	429	ATORVASTATIN and FENOFIBRATE Tablets (10mg + 160mg)	Each film-coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Fenofibrate 160mg	15's	24
110	430	AMIODARONE Tablets IP 200 mg	Each uncoated tablet contains: Amiodarone Hydrochloride IP 200mg	10's	36
111	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	Each uncoated tablet contains: Ramipril IP 5mg Hydrochlorothiazide IP 12.5mg	10's	24
112	432	OLMESARTAN MEDOXOMIL Tablets IP 40 mg	Each film-coated tablet contains: OLMESARTAN MEDOXOMIL IP 40 mg	10's	24
113	434	PROPRANOLOL Tablets IP 40 mg	Each uncoated tablet contains: Propranolol Hydrochloride IP 40mg	10's	24
114	437	NIFEDIPINE SUSTAINED RELEASE Tablets IP 20 mg	Each sustained release film coated tablet contains: Nifedipine IP 20mg	10's	30

115	438	INDAPAMIDE TABLETS IP 1.5 MG	Each film-coated tablet contains: Indapamide IP 1.5mg	10's	24
116	439	OLMESARTAN MEDOXOMIL AND HYDROCLORTHIAZIDE Tablets IP (40 mg+12.5 mg)	Each film-coated tablet contains: Olmesartan Medoxomil IP 40mg Hydrochlorothiazide IP 12.5mg	10's	24
117	440	METOPROLOL (ER) AND AMLODIPINE TABLETS (50mg + 5mg)	Each film-coated bilayered tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol Tartrate 50mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	7's	24
118	441	LOSARTAN and AMLODIPINE TABLETS IP (50mg + 5mg)	Each film-coated tablet contains: Losartan Potassium IP 50mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	24
119	442	FENOFIBRATE TABLETS IP 160 MG	Each film-coated tablet contains: FENOFIBRATE IP 160 MG	10's	24
120	444	ENALAPRIL and HYDROCHLOROTHIAZIDE TABLETS IP (10mg + 25mg)	Each uncoated tablet contains: Enalapril Maleate IP 10 mg Hydrochlorothiazide IP 25 mg	30's	24
121	445	OLMESARTAN and AMLODIPINE Tablets (20mg + 5mg)	Each film-coated tablet contains: Olmesartan Medoxomil IP 20mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	24
122	446	AMLODIPINE and HYDROCHLOROTHIAZIDE TABLETS (5mg + 12.5mg)	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Hydrochlorthizide IP 12.5mg	10's	24
123	448	RAMIPRIL AND AMLODIPINE TABLETS (5mg + 5mg)	Each uncoated tablet contains: Ramipril IP 5mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	24
124	449	SPIRONOLACTONE TABLETS IP 25 MG	Each uncoated tablet contains: Spirinolactone IP 25mg	15's	36
125	451	STREPTOKINASE INJECTION IP 15,00,000 IU	Each vial contains: STREPTOKINASE IP 15,00,000 IU	10 ml & wfi	24
126	452	WARFARIN TABLETS IP 5 MG	Each uncoated tablet contains: Warfarin Sodium Clathrate IP equivalent to Warfarin sodium (anhydrous) 5mg	10's	24
127	453	BISOPROLOL and HYDROCHLOROTHIAZIDE TABLETS IP (5mg + 6.25mg)	Each film-coated tablet contains: Bisoprolol Fumarate IP 5mg Hydrochlorthizide IP 6.25mg	10's	24

128	454	VALSARTAN TABLETS IP 80 MG	Each film-coated tablet contains: Valsartan IP 80 mg	10's	24
129	455	VERAPAMIL TABLETS IP 80 MG	Each film-coated tablet contains: Verapamil Hydrochloride IP 80 mg	10's	24
130	457	TORSEMIDE TABLETS IP 20 MG	Each uncoated tablet contains: Torsemide IP 20mg	10's	36
131	458	LABETALOL INJECTION IP 5 mg/ml	Each ml contains: Labetalol 5 mg	4 ml Vial	24
132	461	BETAMETHASONE VALERAT and NEOMYCIN SULFATE CREAM (0.1% w/w and 0.5% w/w)	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	24
133	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12% w/w+ 3% w/w)	BETAMETHASONE VALERATE 0.12% w/w CLIOQUINOL CREAM BP 3%w/w)	30 GM	24
134	468	BACILLUS CLAUSII SPORES SUSPENSION 2 Billion/5ml	Each 5ml oral suspension contains: Spores of polyantibiotic resistant Bacillus Clausii 2 billion (Strains: O/C, N/R, SIN and T)	5 ML	24
135	470	DIASTASE and PEPSIN LIQUID	Each 5ml contains: Diastase IP (1:1200) 50mg Pepsin IP (1:3000) 10mg	200 ML	24
136	471	OXETACAINE, ALUMINIUM HYDROXIDE AND MAGNESIUM HYDROXIDE GEL	Each 5ml contains: Oxetacaine 10 mg Aluminium Hydroxide 0.291 g Magnesium Hydroxide 96 mg	200 ML	24
137	472	Enteric-Coated Esomeprazole and Sustained Release Domperidone Capsules (40mg+30mg)	Each hard gelatin calsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Domperidome (as sustained release) 30mg	10's	24
138	476	LIQUID PARAFFIN, MILK OF MAGNESIA and SODIUM PICOSULPHATE SUSPENSION 170ml	Each 5ml contains: LIQUID PARAFFIN 1.25ml MILK OF MAGNESIA 3.75ml SODIUM PICOSULPHATE 3.33mg	170 ml Bottle	24
139	477	CHLORDIAZEPOXIDE AND CLIDINIUM BROMIDE TABLETS (5mg+2.5mg)	Each sugar-coated tablet contains: Chlordiazepoxide 5mg Clidinium Bromide 2.5mg	10's	24
140	479	Solution of SORBITOL and TRICHOLINE CITRATE	Each 10ml contains: TRICHOLINE CITRATE 0.55g SORBITOL Solution (70%) IP	200 ML	24

			7.15g		
141	480	Enteric-Coated Esomeprazole and Sustained Release Levosulpiride Capsules (40mg+75mg)	Each hard gelatin capsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Levosulpiride (as sustained release) 75mg	10's	24
142	481	RIFAXIMIN TABLETS 400 MG	Each film-coated tablet contains: Rifaximin 400mg	10's	24
143	483	LOPERAMIDE Capsules IP 2 mg	Each hard gelatin calsule contains: LOPERAMIDE HYDROCHLORIDE IP 2 mg	10's	24
144	486	PANCREATIN and Activated DIMETHICONE TABLETS (170mg+80mg)	Each enteric-coated tablet contains: PANCREATIN IP 170mg Activated DIMETHICONE TABLETS IP 80mg	10's	24
145	487	Dicyclomine Hydrochloride and Dimethicone Suspension (10mg+40mg)	Each 5ml contains: Dicyclomine Hydrochloride IP 10mg Simethicone IP 40mg	30 ML	24
146	488	LANSOPRAZOLE CAPSULES IP 15 MG	Each capsule contains: Lansoprazole IP 15 mg (as enteric coated granules)	10's	24
147	489	Sulfasalazine Delayed Release Tablets 1000mg	Each enteric-coated tablet contains: Sulfasalazine 1000mg	10's	24
148	492	Sulfasalazine Delayed Release Tablets 500mg	Each enteric-coated tablet contains: Sulfasalazine 500mg	10's	24
149	496	DYDROGESTERONE TABLETS IP 10 MG	Each film-coated tablet contains: DYDROGESTERONE IP 10 MG	10's	24
150	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	Each film-coated tablet contains: BETAMETHASONE SODIUM PHOSPHATE TABLETS IP equivalent to Betamethasone 0.5 MG	20's	24
151	504	NANDROLONE DECANOATE INJECTION IP 25 MG/ML	Each ml contains: NANDROLONE DECANOATE IP 25 mg	1 ML	24
152	505	CARBIMAZOLE TABLETS 10 MG	Each uncoated tablet contains: CARBIMAZOLE 10 MG	100's	24
153	507	CARBIMAZOLE TABLETS IP 5 MG	Each uncoated tablet contains: CARBIMAZOLE IP 5 MG	10's	24
154	521	Tramadol Sustained release Tablets 100 mg	Each sustained release tablet contains: Tramadol 100mg	10's	30
155	522	ALFACALCIDOL SOFT	Each soft gelatin capsule	10's	24

		GELATIN CAPSULES 0.25 MCG	contains: Alfacalcidol 0.25mcg		
156	523	NAPROXEN TABLETS IP 500 MG	Each uncoated tablet contains: NAPROXEN IP 500 MG	15's	24
157	524	LIGNOCAINE INJECTION IP 2%	Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Sodium chloride IP 6.0 mg Methyl Paraben IP 1.0 mg (as preservative)	30 ML VIAL	24
158	528	PARACETAMOL, PHENYLEPHRINE and CHLORPHENIRAMINE Tablets (325mg+10mg+2mg)	Each uncoated tablet contains: PARACETAMOL IP 325 mg PHENYLEPHRINE HYDROCHLORIDE IP 10 mg CHLORPHENIRAMINE MALEATE IP 2 mg	10's	24
159	529	LEVOSALBUTAMOL AND IPRATROPIUM RESPULES (1.25mcg+500mcg)	Each 2.5ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25mcg	2.5 ML	24
160	530	FORMOTERAL and BUDESONIDE ROTACAPS (6mcg+200mcg)	Each capsule contains: Formoterol Fumarate (as Formoterol Fumarate dihydrate IP) 6mcg Budesonide IP 200mcg	30's	24
161	532	SALMETEROL and FLUTICASONE ROTACAPS (50mcg+250mcg)	Each capsule contains: Salmeterol Fumarate (as Formoterol Xinafoate IP) 50mcg Fluticasone Propionate IP 250mcg	30's	24
162	537	Ambroxol Hydrochloride and Levosalbutamol Sulphate Syrup	Each 5ml contains: Ambroxol Hydrochloride 15mg Levosalbutamol Sulphate equivalent to Levosalbutamol 0.5mg	100 ML	24
163	540	Levosalbutamol and BUDESONIDE Respules (1.25mg+1mg)	Each 2ml respule contains: Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25 mg Budesonide 1 mg	2 ML	24
164	543	MENTHOL (55 mg ± 5.) CINNAMON (12.5 mg ± 2) and PINE OIL (112.5 mg ± 1) SOFT CAPSULES	MENTHOL (55 mg ± 5.) CINNAMON (12.5 mg ± 2) and PINE OIL (112.5 mg ± 1) SOFT CAPSULES	10's	24
165	559	SALBUTAMOL AND THEOPHYLLINE TABLETS (2mg+100mg)	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg Theophylline (anhyd.) IP 100mg	30's	24

166	560	FLUTICASONE PROPIONATE NASAL SPRAY 50 mcg	Each spray delivers: Fluticasone Propionate IP 50 mcg	120 MD	24
167	561	LEVOSALBUTAMOL SYRUP (1mg/5ml)	Each 5ml contains: Levosalbutamol Sulphate IP equivalent to Salbutamol 1mg Flavoured syrup base q.s.	100 ML	24
168	564	Tiotropium Bromide and Formoterol Fumarate Dihydrate Rotacaps (18mcg+12mcg)	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg	15's	24
169	565	Tiotropium Bromide, Formoterol Fumarate Dihydrate and Ciclesonide Rotacaps (18mcg+12mcg+400mcg)	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg Ciclesonide IP 400mcg	15's	24
170	566	Ipratropium Bromide Respirator Solution 250mcg	Each ml contains: Ipratropium bromide IP 250mcg	15 ML	24
171	567	SALBUTAMOL AND IPRATROPIUM INHALER (100mcg+20mcg)	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg Ipratropium bromide IP 20mcg	200 MDI	24
172	568	Salmeterol and Fluticasone Propionate Inhaler IP (25mcg+250mcg)	Each activation delivers: Salmeterol (as Salmeterol Xinofoate) 25mcg Fluticasone Propionate 250mcg	100 MD	24
173	571	Tamsulosin Hydrochloride and Dutasteride Tablets (0.4mg+0.5mg)	Each film-coated tablet contains: Tamsulosin Hydrochloride IP 0.4mg (as modified release tablets) Dutasteride IP 0.5mg	15's	24
174	574	Rabies Vaccine, Human IP	Purified lyophilized Rabies antigen derived from Rabies virus (L.Pasteur 2061/ Vero strain propogated in Vero cells), Inactivated. Potency: ≥ 2.5 IU per Vial Stabilizers: Maltose and Human Albumin q.s. Preservatives: Thiomersal ≤ 0.015% w/v	1 ml with Diluent (0.9% w/v Sodium Chloride inj. IP)	18
175	582	VITAMINS A,C,D,E,AND B COMPLEX AND MINERALS SYRUP	Each 15ml contains: Vitamin A 2500 IU Thiamine Hydrochloride 1.5 mg Riboflavin Sodium Phosphate 1.7 mg Pyridoxine Hydrochloride 1.5 mg Cyanocobalamine 1 mcg Vitamin C 25 mg	200 ML	24

			Vitamin D3 200 IU Vitamin E 10 IU Nicotinamide 20 mg D-Panthenol 5 mg Biotin 10 mcg Zinc 3 mg Iodine 50 mcg Iron 5 mg Manganese 0.8 mg Chromium 8 mcg Molybdenum 8 mcg in a flavoured base q.s.		
176	583	CYPROHEPTADINE Tablets IP 4 mg	Each uncoated tablet contains: Cyproheptadine Hydrochloride IP 4mg	10's	36
177	586	METHYLCOBALAMIN, L- CARTININE L-TARTRATE and FOLIC ACID TABLETS (1500mcg+500mg+1.5mg)	Each film-coated tablet contains: L- CARTININE L- TARTRATE equivalent to L-carnitine 500 mg Methylcobalamine 1500 mcg Folic acid 1.5 mg	10's	24
178	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	Each 5ml contains: Thiamine Hydrochloride 2.25 mg Riboflavin Sodium Phosphate 2.5 mg Nicotinamide 22.5 mg D-panthenol 3.0 mg Pyridoxine Hydrochloride 0.75 mg Lysine Hydrochloride 375 mg	200 ML	24
179	593	Folic Acid, Cyanocobalamine and Nicotinamide Injection (15mg+500mcg+200mg)	Each ml contains: Folic Acid 15 mg Cyanocobalamine 500 mcg Nicotinamide 200 mg Benzyl Alcohol 2.5% v/v Phenol 0.5% w/v (As preservative)	10 ML	24
180	595	THIAMINE, PYRIDOXINE HCl and CYANOCOBALAMIN INJECTION (100mg+50mg+1000mcg)	Each 2 ml ampoule contains: Mecobalamin IP 1000 mcg Pyridoxine HCl IP 50 mg Thiamine 100 mg	2 ML	24
181	597	PYRIDOXINE TABLETS 50 MG	Each uncoated tablet contains: Pyridoxine Hydrochloride 50mg	10's	24
182	601	Disulfiram Tablets 500 mg	Each uncoated tablet contains: Disulfiram 500 mg	4's	24
183	603	Cetirizine Dihydrochloride, Phenylephrine HCl and Paracetamol Tablets (5mg+10mg+325mg)	Each uncoated tablet contains: Cetirizine Dihydrochloride 5mg Phenylephrine Hydrochloride 10mg Paracetamol 325mg	10's	24

184	608	Betamethasone Dipropionate and Salicylic acid Ointment	Contains: Betamethasone Dipropionate 0.05% w/w Salicylic acid 3% w/w	20gm	24
185	609	Silver Nitrate and Chlorhexidine Gluconate Cream	Contains: Silver Nitrate 0.20% w/w Chlorhexidine Gluconate Solution 0.20%w/w Preservative: Chlorocresol 0.12%w/w	15g Tube	24
186	610	Paracetamol, Phenylephrine Hydrochloride and Cetirizine Dihydrochloride Suspension (125mg+5mg+2mg)	Each 5ml contains: Paracetamol IP 125mg Phenylephrine Hydrochloride IP 5mg Cetirizine Dihydrochloride 2mg	60 ML	24
187	611	Cyproheptadine Hydrochloride Syrup IP 2mg	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg	200 ml	24
188	612	Povidone-Iodine Powder 5% w/w	Povidone-Iodine Powder 5% w/w	10gm Container	24
189	613	Diclofenac Potassium, Paracetamol and Serratiopeptidase Tablets (50mg+325mg+10mg)	Each film-coated tablet contains: Diclofenac Potassium 50 mg Paracetamol 325 mg Serratiopeptidase 10mg (20,000 serratiopeptidase unit as enteric coated granules)	10's	24
190	621	Carbonyl Iron, Zinc and Folic Acid Capsules	Each capsule contains: Elemental Iron 50 mg (in the form of Carbonyl Iron) Zinc Sulphate Monohydrate 61.8 mg (equivalent to 22.5 elemental Zinc) Folic Acid 0.5 mg	15's	24
191	626	Ketoconazole Shampoo 2% W/V	Ketoconazole Shampoo 2% W/V	100ml Bottle	24
192	627	Etophylline and Theophylline Prolonged Release Tablets IP (115mg+35mg)	Each film-coated prolonged release tablet contains: Etophylline 115mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 35mg	10's	24
193	628	Etophylline and Theophylline Prolonged Release Tablets (231mg+69mg)	Each film-coated prolonged release tablet contains: Etophylline 231mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 69mg	10's	36
194	632	Etamsylate Tablets 250 mg	Each uncoated tablet contains: Etamsylate 250 mg	10's	24

195	635	Clobetasol Propionate, Neomycin Sulphate, Miconazole Nitrate and Chlorhexidine Gluconate Cream	Contains: Clobetasol Propionate 0.05% w/w Neomycin Sulphate 0.50% w/w Miconazole Nitrate 2.00% w/w Chlorhexidine Gluconate Solution 0.20% w/w Chlorocresol (as preservative) 0.10% w/w In a cream base q.s.	10 gms tube	24
196	640	Nimesulide Gel 1% w/w	Nimesulide Gel 1% w/w	20gm Tube	24
197	645	Nimesulid, Paracetamol and Chlorzoxazone Tablets (100mg+325mg+375mg)	Each uncoated tablet contains: Nimesulide 100mg Paracetamol 325mg Chlorzoxazone 375mg	10's	24
198	649	Dicyclomine Hydrochloride and Simethicone Oral Drops (10mg+40mg)	Each ml contains: Dicyclomine Hydrochloride 10mg Simethicone 40mg	10ml Bottle	24
199	650	Mefenamic Acid and Paracetamol Tablets (500mg+325mg)	Each uncoated tablet contains: Mefenamic Acid 500mg Paracetamol 325mg	10's	36
200	656	Diastase and Pepsin Enzyme Drops	Each ml contains: Diastase (1:1200) 33.33 mg Pepsin (1:3000) 5mg Vit B1 1 mg Vit B2 1 mg Vit B6 1 mg Vit B12 1 mcg Niacinamide 10 mg	15 ml	24
201	659	Chlorhexidine Gluconate and Cetrimide Solution (0.3% w/v and 0.6% w/v)	Chlorhexidine Gluconate 0.3% w/v + Cetrimide 0.6%w/v	200 ml	24
202	662	Gamma Benzene Hexachloride and Cetrimide Lotion	contains: Gamma Benzene Hexachloride 1% w/v Cetrimide 0.1% w/v	200ML	24
203	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	Choline Salicylate sodium 9% w/v Benzalkonium Chloride 0.01% w/w	10gm	24
204	665	Vitamin B complex & Ascorbic Acid Capsules	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 50mg Pyridoxine Hydrochloride 3mg Cynocobalamine 50mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid 150mg	10's	24
205	666	Pheniramine Maleate	Each ml contains:	2 ML	24

		Injection IP 22.75 mg	Pheniramine Maleate IP 22.75 mg		
206	668	Multivitamin Drops	Each ml contains: Vitamin A (as Palmitate) 2500 IU Vitamin E acetate 25 IU Vitamin D3 200 IU Ascorbic Acid 40 mg Thiamine Hydrochloride 1 mg Riboflavin Sodium Phosphate 1.5 mg Niacinamide 10 mg D-Panthenol 3 mg D-Biotin 50mcg Lysine Hydrochloride 18 mcg	15ml	24
207	670	Glucosamine, Diacerein and Methylsulfonylmethane Tablets (750mg+50mg+250mg)	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 750 mg Diacerein 50 mg Methylsulfonylmethane 250mg	10's	24
208	671	Glucosamine and Diacerein Tablets (500mg+50mg)	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 500 mg Diacerein 50 mg	10's	24
209	677	Flupentixol Tablets 0.5 mg	Each film-coated tablet contains: Flupentixol Hydrochloride equivalent to Flupentixol 0.5 mg	10's	24
210	679	Nalidixic Acid Tablets IP 500 mg	Each tablet contains: Nalidixic Acid Tablets IP 500 mg	10's	24
211	681	Phenazopyridine Hydrochloride tablet 100mg	Each sugar coated tablet contains: Phenazopyridine Hydrochloride 100mg	10's	24
212	682	Rabeprazole 20mg + Domperidone 10mg Capsule	Each hard gelatin capsule contains: Rabeprazole sodium Ip (as enteric coated pellets) 20mg Domperidone Ip (as immediate release pellets) 10mg	10's	24
213	686	Magaldrate 400mg + Simethicone 20mg/5ml Oral Suspension IP	Each 5 ml contains: Magaldrate 400 mg Simethicone 20 mg	170 ml	24
214	691	Ofloxacin Eye Drops 0.3%w/v	Ofloxacin Eye Drops 0.3%w/v	10ml	24
215	692	Olopatadine Hydrochloride Ophthalmic Solution 0.1% w/v	Contains: Olopatadine Hydrochloride equivalent to Olopatadine 0.1% w/v Benzalkonium Chloride 0.01% w/v (as preservative)	10ml	24

216	693	Tropicamide Eye Drops IP 1% w/v	Contains: Tropicamide IP 1% w/v Chlorbutol IP 0.5% w/v (as preservative)	5ml	24
217	697	Sulphacetamide eye drop 10 % w/v	Contains: Sulphacetamide Sodium 10 % w/v Phenylethyl Alcohol 0.5% v/v (as preservative)	10 ml	24
218	699	Acyclovir Eye Ointment IP 3% w/w	Contains: Aciclovir IP 3% w/w Benzalkonium chloride IP 0.01% w/w	5gm	24
219	701	Pilocarpine Eye Drops IP 2% w/v	Contains: Pilocarpine Nitrate IP 2% w/v Hydroxypropylmethylcellulose IP 0.35% w/v Chlorbutol IP 0.5% w/v (As preservative)	10 ml	24
220	705	Levofloxacin INFUSION IP 500 mg/100 ml	Each ml contains: Levofloxacin 5 mg	100 ML	24
221	707	Piroxicam Dispersible Tablets 10 mg	Each dispersible uncoated tablet contains: Piroxicam 10mg	10's	24
222	708	Piroxicam Dispersible Tablets 20 mg	Each dispersible uncoated tablet contains: Piroxicam 20mg	10's	30
223	709	Piroxicam Injection 20 mg	Each ml contains: Piroxicam 20 mg Benzyl Alcohol 20 mg (as preservative)	1ml	24
224	715	Glycerin IP 98%w/w	Contains: Glycerin IP 98%w/w	50 GM	24
225	717	Etodolac Tablets IP 300mg	Each film-coated tablet contains: Etodolac IP 300mg	10's	24
226	720	Ringer Lactate Infusion	Sodium chloride (600mg), Sodium Lactate (320mg), Potassium Chloride (40mg), Calcium Chloride (27mg)	500ml in FFS bottle	24
227	725	Dextrose IV fluid IP 5% w/v	Dextrose IV fluid IP 5% w/v	500ml	24
228	728	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	500ml	24
229	732	Sodium Chloride Injection IP 0.9%w/v	Sodium Chloride Injection IP 0.9%w/v	100ml IV fluid plastic container	24
230	733	Progesterone Sustained Release Tablets 200 mg	Each film-coated sustained release tablet contains: Progesterone 200mg	10's	24
231	734	Dehydroepiandrosterone (Micronized) 25 mg Capsule	Each hard gelatin capsule contains: Dehydroepiandrosterone (Micronized) 25 mg	10's	24

232	740	Clarithromycin Tablets IP 250 mg	Each film-coated tablet contains: Clarithromycin IP 250mg	10's	24
233	747	Glimepiride Tablets IP 3mg	Each uncoated tablet contains: Glimepiride IP 3 mg	10's	24
234	753	Clotrimazole and Beclometasone Dipropionate lotion (1%w/v + 0.025%w/v)	Contains: Clotrimazole 1% w/v Beclometasone Dipropionate 0.025% w/v	15ml	24
235	769	Acetyl Salicylic Acid (Aspirin)Tablet 325mg	Each gastro-resistant tablet contains: Aspirin 325mg	14's	24
236	785	Amitriptyline hydrochloride Tablets IP 25mg	Each film-coated tablet contains: Amitriptyline hydrochloride IP 25mg	15's	36
237	791	Atenolol and Amlodipine Tablets (25mg+5mg)	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Atenolol IP 25mg	14's	24
238	793	Atenolol Tablets 25 mg	Each uncoated tablet contains: Atenolol 25mg	14's	24
239	796	Atorvastatin 10mg, Aspirin (EC) 75mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 75mg (as gastro-resistant tablet IP 75mg)	10's	24
240	800	Bacitracin-Neomycin Sulphacetamide Dusting Powder	Each gram contains: Neomycin Sulphate 5 mg Bacitracin 250 units Sulphacetamide 60mg	10gm Powder	24
241	804	Betamethasone Injection IP 4 mg/ml	Each ml contains: Betamethasone Sodium Phosphate 4 mg	1 ml	24
242	806	Bicalutamide Tablets IP 50mg	Each film-coated tablet contains: Bicalutamide IP 50mg	10's	24
243	807	Biphasic Isophane Insulin Injection I.P 100 IU/ml (30:70) (30% Soluble Insulin & 70% Isophane Ins)	Each ml contains: Human Insulin IP 100 IU (30% Soluble Insulin Injection and 70% Isophane Insulin Injection) Preservative: m-cresol, phenol	3ml Cartridge/Penfill	24
244	815	Calcitriol Capsules IP 0.25mcg	Each soft gelatin capsule contains: Calcitriol IP 0.25 mcg	10's	24
245	816	Calcium Acetate Tablets 667mg	Each uncoated tablet contains: Calcium Acetate 667mg	10's	24
246	818	Calcium Gluconate Injection IP 10 %	Contains: Calcium Gluconate IP 10 % w/v	10 ml	24
247	829	Chloramphenicol Eye Ointment IP 1%w/w	Contains: Chloramphenicol IP 1%w/w	5 gm	24

248	832	Chlorthalidone Tablets 12.5mg	Each uncoated tablet contains: Chlorthalidone 12.5mg	10's	36
249	835	Glucosamine Sulphate and Chondroitin Tablets (500mg+400mg)	Each film-coated tablet contains: Chondroitin Sulphate 400mg Glucosamine Sulphate 500mg	10's	24
250	838	Cilostazol Tablets IP 50mg	Each uncoated tablet contains: Cilostazol IP 50mg	10's	24
251	844	Clonazepam Tablets IP 1mg	Each uncoated tablet contains: Clonazepam IP 1mg	10's	36
252	860	Dextromethorphan Hydrobromide Syrup IP	Each 5 ml contains: Dextromethorphan Hydrobromide IP 13.5mg Flaoured base syrup q.s.	50ml	24
253	868	Dicyclomine HCl (Dicycloverine) Injection IP 10mg/ml	Each ml contains: Dicyclomine Hydrochloride IP 10mg	2ml	24
254	875	Donepezil Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Donepezil Hydrochloride IP 10mg	10's	24
255	881	Ebastine Tablets IP 10mg	Each film-coated tablet contains: Ebastine IP 10mg	10's	24
256	885	Ethinylestradiol and Levonorgestrel Tablets IP (0.05mg+0.25mg)	Each uncoated tablet contains: Ethinylestradiol IP 0.05mg Levonorgestrel IP 0.25mg	21's	24
257	899	Frusemide and Spironolactone Tablets (20mg+50mg)	Each film-coated tablet contains: Frusemide IP 20mg Spironolactone IP 50mg	10's	24
258	900	Gabapentin and Methylcobalamine Tablets (100mg+500mcg)	Each film-coated tablet contains: Gabapentin 100 mg Methylcobalamine 500 mcg	10's	24
259	904	Glimepiride and Metformin SR Tablets (1mg + 500mg)	Each uncoated bi-layer tablet contains: Glimepiride IP 1 mg Metformin Hydrochloride 500 mg (as extended release)	10's	24
260	906	Glyceryl Trinitrate Controlled Release Tablets 2.6mg (Nitroglycerin CR Tablets)	Each uncoated tablet contains: Diluted Nitroglycerin equivalent to Nitroglycerin 2.6 mg (in a controlled release system)	30's	30
261	912	Hydroclorthiazide Tablets 12.5mg	Each uncoated tablet contains: Hydroclorthiazide 12.5mg	10's	36
262	915	Hydroxyzine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Hydroxyzine Hydrochloride IP 10mg	10's	36

263	917	Imipramine Hydrochloride Tablets IP 25mg	Each film-coated tablet contains: Imipramine Hydrochloride IP 25mg	10's	36
264	920	Insulin Regular (R-DNA Origin) Injection 100 IU	Insulin Regular (R-DNA Origin) Injection 100 IU	3ml Cartridge/Penfill	24
265	922	Isopropyl Alcohol (70%) (Spirit)	Isopropyl Alcohol (70% Conc.)	100 ML bottle	24
266	931	Lamotrigine Tablets 100mg	Each uncoated tablet contains: Lamotrigine 100 mg	10's	24
267	932	Latanoprost Eye Drops IP 0.005%w/v (50mcg/ml)	Each ml contains: Latanoprost IP 50 mcg	2.5 ML	24
268	933	Leflunomide Tablets IP 20mg	Each film-coated tablet contains: Leflunomide IP 20mg	10's	24
269	939	Levocarnitine Tablets 500mg	Each film-coated tablet contains: Levocarnitine 500mg	10's	24
270	944	Levosalbutamol HCl inhaler 50mcg	Each activation delivers: Levosalbutamol tartrate equivalent to Levosalbutamol 50mcg	200 Mdi	24
271	946	Lignocaine (Lidocaine) Hydrochloride Gel IP 2% w/v	Contains: Lignocaine Hydrochloride IP equivalent to anhydrous Lignocaine Hydrochloride 2% w/v	20g	24
272	947	Lithium Carbonate Prolonged Release Tablets IP 450mg	Each uncoated prolonged release tablet conatins: Lithium Carbonate IP 450 mg	10's	24
273	948	Lorazepam Tablets IP 1mg	Each uncoated tablet conatins: Lorazepam IP 1mg	10's	24
274	951	Lycopene 1000 mcg, Vitamin A 2500 IU, Vitamin E 10 IU, Selenium 35 mcg and Vitamin C 50mg	Each 5 ml contains: Levocarnitine 5% 1000 mcg Vitamin A 2500 IU Vitamin E 10 IU Vitamin C 50 mg Zinc (as Zinc Gluconate) 3 mg Manganese 2 mg Iodine 100 mcg Copper 500 mcg Thiamine HCl 2 mg Riboflavin Sodium Phosphate 3 mg Pyridoxine HCl 1.5 mg	200 ml	24
275	957	Memantine Hydrochloride Tablets IP 10mg	Each film-coated tablet conatins: Memantine Hydrochloride IP 10mg	10's	24
276	965	Miconazole and Fluocinolone Acetonide Ointment (2%w/w+0.01%w/w)	Contains: Miconazole Nitrate 2% w/w Fluocinolone Acetonide 0.01% w/w	15gm Tube	24

277	976	Nebivolol Tablets IP 2.5mg	Each uncoated tablet conatins: Nebivolol Hydrochloride IP 2.5 mg	10's	24
278	978	Nepafenac Eye Drop 0.1% w/v	Each ml contains: Nepafenac 1mg Benzalkonium Chloride IP (as preservative) 0.005% w/v	5ml	24
279	986	Nitrazepam Tablets I.P 10mg	Each uncoated tablet contains: Nitrazepam IP 10 mg	10's	24
280	987	Nitrofurantoin Tablets I.P 100mg	Each uncoated tablet contains: Nitrofurantoin IP 100 mg	10's	24
281	1008	Phytomenadione (Vitamin K1) Injection 1 mg/0.5ml	Each ml contains: Phytonadione 2 mg Polyoxyethylated fatty acid derivative 70 mg, dextrose, hydrous 37.5 mg, benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment.	0.5ml Ampoule	24
282	1009	Pioglitazone Tablets IP 15 mg	Each uncoated tablet contains: Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15 mg	10's	24
283	1024	Promethazine Injection IP 25 mg/ml	Each ml contains: Promethazine Hydrochloride 25 mg	2ml	24
284	1037	Recombinant Human Erythropoietin Injection 4000 IU	Each prefilled syringe contains: Erythropoietin concentrate Solution 4000 IU	Vial	24
285	1038	Recombinant Human Erythropoietin Injection 2000 IU	Each prefilled syringe contains: Erythropoietin concentrate Solution 2000 IU	Vial	24
286	1041	Risperidone and Trihexiphenidyl Tablets (4mg+2mg)	Each uncoated tablet contains: Resperidone 4 mg Trihexyphenidyl hydrochloride IP 2 mg	10's	24
287	1044	Rosuvastatin Tablet I.P 5mg	Each film coated tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 5 mg	10's	24
288	1050	Sertraline Tablets I.P 100mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 100 mg	10's	24
289	1051	Sertraline Tablets I.P 25mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 25 mg	10's	24

290	1060	Sodium Valproate Gastro-resisTablets IP 300mg	Each gastro-resistant tablet contains: Sodium Valproate IP 300mg	10's	24
291	1069	Sulphacetamide Sodium Eye Drop I.P 20% w/v	Each ml contains: Sulfacetamide Sodium IP 20 % w/v Phenylethyl alcohol IP 0.5 % v/v (as preservative)	10ml	24
292	1074	Telmisartan and Hydroclorthiazide Tablets (80mg+12.5mg)	Each uncoated bilayer tablet contains: Telmisartan IP 80 mg Hydrochlorothiazide IP 12.5 mg	10's	24
293	1076	Tenofovir Disoproxil Fumarate Tablets 300 mg	Each film coated tablet contains: Tenofovir Disoproxil fumarate IP 300 mg	10's	24
294	1087	Trihexyphenidyl Hydrochloride Tablets 2mg (benzhexol HCl Tablets IP 2mg)	Each uncoated tablet contains: Trihexyphenidyl Hydrochloride IP 2 mg	10's	24
295	1088	Trimetazidine Hydrochloride Modified Release Tablets 35 mg	Each film-coated modified release tablet contains: Trimetazidine Hydrochloride IP 35 mg	10's	36
296	1097	Vitamin A Capsule 25000 IU	Each soft gelatin capsule contains: Vitamin A IP (as Palmitate) 25000 IU (equivalent to Retinol 7.5 mg) in water soluble form.	30's	24
297	1099	Voglibose and Metformin Tablets (0.3mg+500mg)	Each uncoated tablet contains: Voglibose IP 0.3 mg Metformin Hydrochloride IP 500 mg	10's	24
298	1106	Metoprolol Succinate ER 50 mg & Telmisartan 40mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate IP equivalent to Metoprolol Tartarate 50 mg (as extended release form) Telmisartan IP 40 mg	10's	24
299	1110	Clobazam Tablet IP 5mg	Each uncoated tablet contains: Clobazam IP 5 mg	10's	36
300	1112	Cinnarizine Tablets IP 25mg	Each uncoated tablet contains: Cinnarizine IP 5 mg	10's	24
301	1123	Clomipramine Hydrochloride SR Tablets 75mg	Each film coated sustained release tablet contains: Clomipramine Hydrochloride 75 mg	10's	24
302	1124	Fluvoxamine Maleate Tablets IP 100mg	Each film coated sustained release tablet contains: Fluvoxamine Maleate IP 100 mg	10's	24
303	1125	Aripiprazole Tablets IP 5mg	Each uncoated tablet contains: Aripiprazole IP 5 mg	10's	24

304	1149	Lisinopril Tablets IP 10mg	Each uncoated tablet contains: Lisinopril IP equivalent to anhydrous Lisinopril 2 mg	15's	36
305	1152	Carbamazepine Sustained Release Tablets IP 200mg	Each film coated prolonged release tablet contains: Carbamazepine IP 200 mg	10's	36
306	1154	Diethylcarbamazine Citrate Tablets IP 100mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 100mg Excipients q.s.	30's	24
307	1156	Metoprolol Succinate ER 25 mg & Amlodipine Besylate 5 mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate IP equivalent to Metoprolol Tartarate 25 mg (as extended release form) Amlodipine besylate IP equivalent to Amlodipine 5 mg	7's	24
308	1157	DOXYLAMINE SUCCINATE 20 MG+ PYRIDOXINE HCl 20 MG TABLETS	Each enteric coated tablet contains: Doxylamine Succinate 20 mg Pyridoxine Hydrochloride 20 mg	10's	24
309	1164	NANDROLONE DECANOATE INJECTION IP 50 mg/ml	Each ml contains: Nandrolone decanoate 50mg	2 ml	24
310	1166	MEFENAMIC ACID 250 MG TABLETS	Each uncoated tablet contains: Mefenamic Acid 250 mg	10's	24
311	1168	KETOROLAC Inj. IP 30mg/ml	Each vial contins: Ketorolac tromethamine 30 mg	1 ml	24
312	1170	ACETYLCYSTEINE Injection 200 mg/ml	Each ml contains: Acetylcystein 200 mg	2ml Ampoules	24
313	1187	Cyclosporine Capsules IP 100 mg	Each soft gelatin capsule contains: Cyclosporine IP 100 mg	5's	24
314	1191	Glycopyrrolate Inj IP 0.2mg	Each ml contains: Glycopyrrolate 0.2 mg Benzyl alcohol 0.9 % WFI q.s.	1 ml	24
315	1203	Protamine Inj 10mg/ml	Each ml contains: Protamine Sulphate 10 mg	5ml vial/ampoule	24
316	1219	Amino Acid Solution for IV 200 ml bottle	Nutritive infusion of Pure Crystalline Amino Acids	200 ml Glass Bottle	24
317	1220	Oseltamivir Capsules 75mg	Each hard gelatin capsule contains: Oseltamivir Phosphate IP 98.5 mg equivalent to Oseltamivir 75mg	10's	24
318	1225	Orlistat Capsules 120 mg	Each hard gelatin capsule contains: Orlistat 120 mg (as pellets 50 % w/w)	10's	24
319	1226	Triamcinolone Injection	Each ml contains:	1 ml	24

		40mg/ml	Triamcinolone Acetonide IP 40 mg Benzyl Alcohol IP 0.9%w/v (as preservative)		
320	1231	Vitamin E Acetate & Levocarnitine Tablets (200 mg + 150 mg)	Each film coated tablet contains: Tocopheryl Acetate IP 200 mg (as 50% powder) L-Carnitine-L-Tartarate equivalent to Levocarnitine USP 150 mg	10's	24
321	1237	Methyldopa tablets IP 500 mg	Each film coated tablet contains: Methyldopa IP equivalent to anhydous Methyldopa 500 mg	10's	24
322	1238	Prazosin Hydrochloride Sustained Release Tablets 2.5 mg	Each film coated sustained release tablet contains: Prazosin Hydrochloride IP equivalent to Prazosin 2.5 mg	30's	24
323	1241	Cefaclor Dispersible Tablets 250 mg	Each dispersible tablet contains: Cefaclor IP equivalent to anhydous Cefaclor 250 mg	10's	24
324	1243	Betamethasone Valerate & Salicylic Acid (0.05% w/w + 3.0% w/w) Ointment	Contains: Betamethasone Valerate IP equivalent to betamethasone 0.05% w/w Salicylic Acid IP 3.0%w/w in a greasy base	20gm Tube	24
325	1248	Haematinic syrup of Iron,Folic acid and Vitamin B12(32mg+0.5mg+7.5mcg) 200 ml	Each 15 ml contains: Ferric Ammonium Citrate equivalent to Elemental Iron 32 mg Folic Acid IP 0.5 mg Cyanocobalamin IP 7.5 mg	200ml bottle	24
326	1252	Suspension of Calcium Phosphate with Vitamin D3 & Viatmin B12 (82 mg + 200 IU + 2.5 mcg)	Each 5ml contains: Vitamin D3 (Cholecalciferol IP) 200 IU Vitamin B12 IP 2.5 mcg Calcium Phosphate equivalent to elemental Calcium 82 mg	200 ml	24
327	1255	Montelukast & Acebrophylline Sustained Release (10 mg +200 mg) Tablets	Each film coated bilayered tablet contains: Montelukast Sodium IP equivalent to Montelukast 10 mg (in immediate release form) Acebrophylline 200 mg (in sustained release form)	10's	24
328	1284	Cilnidipine & Telmisartan Tablets (10 mg + 40 mg)	Each film coated tablet contains: Cilnidipine 10 mg	10's	24

			Telmisartan IP 40 mg		
329	1308	Ethinylestradiol IP 0.03mg+ Levonorgestrel IP 0.15mg Tablet	Each uncoated tablet contains: Levonorgestrel IP 0.15 mg Ethinyloestradiol IP 0.03 mg	21's	24
330	1328	Isoxsuprine Injection IP 5 mg	Each ml contains: Isoxsuprine Hydrochloride IP 5 mg WFI IP q.s	2ml Vial	24
331	1342	Mebeverine Hydrochloride Tablets	Each sugar-coated tablet contains: Mebeverine Hydrochloride IP 200 mg	10's	24
332	1368	Olmesartan Medoxomil & Hydrochlorthiazide Tablets (20 mg + 12.5 mg)	Each film coated tablet contains: Olmesartan Medoxomil 20 mg Hydrochlorthiazide IP 12.5 mg	10's	24
333	1409	Teicoplanin Injection 400 mg	Each ml contains (as lyophilisate) Teicoplanin 400 mg Sterile powder for preparation of intramuscular or intravenous injection.	1 ml Vial	24
334	1414	Terlipressin Injection 1000 mcg (1 mg)/10ml	Each 10ml contains: Terlipressin 1 mg	10 ml Vial	24
335	1427	Trypsin, Bromelain & Rutoside Trihydrate Tablets (48 mg + 90 mg + 100 mg)	Each enteric coated tablet contains: Trypsin 48 mg Bromelain 90 mg Rutoside Trihydrate 100 mg	10's	24
336	1431	Valethamate Injection 8 mg/ml (For IM/IV use)	Each ml contains: Valethamate Bromide 8 mg Sodium Chloride IP 8 mg WFI q.s.	1 ml Vial	24
337	1432	Tobramycin Eye Drops 0.3%	Each ml contains: Tobramycin Sulfate equivalent to Tobramycin 3mg Benzalkonium Chloride 0.0001 ml (as preservative)	5ml	24
338	1441	Nirmal (Nicotine Polacrilex chewing gum 2 mg)	Each gum contains: Nicotine Polacrilex equivalent to Nicotine 2 mg	1 x 9's (mono carton pack)	24
339	1449	Enzyme Syrup Mixed Fruit Flavour (Diastase and Pepsin)	Each 5ml contains: Diastase (1:1200) 50mg Pepsin (1:3000) 10mg	200 ml	24
340	1450	PYRANTEL PAMOATE ORAL SUSPENSION IP 250mg/5ml	Each 5ml contains: Pyrantel Pamoate 250 mg	10 ML	24

341	1451	THEOPHYLLINE Controlled release TABLETS 400 MG	Each uncoated tablet contains: Theophylline Anhydrous IP 400mg (in controlled release form)	10's	24
342	1452	Pyridoxine Hydrochloride Sustained Release Tablets 100 mg	Each Sustained release tablet contains: Pyridoxine Hydrochloride IP 100 mg	10's	24
343	1453	Levetiracetam Syrup 100 Mg	Each ml contains: Levetiracetam 100mg	100ml	24
344	1454	Terbutaline Sulphate and Bromhexine Hydrochloride Syrup	Each 5ml contains: Terbutaline Sulphate 2.5mg Bromhexine Hydrochloride 8mg	100 ML	24
345	1455	L-Arginine Granules	Each sachet of 5 g contains: L-Arginine 3 g Excipients q.s	5 gm	24
346	1456	Itraconazole Capsules 200 mg	Each hard gelatin capsule contains: Itraconazole BP 200 mg (As pellets)	4's	24
347	1457	Luliconazole Cream 1% w/w	Contains: Luliconazole 1% w/w Preservatives: Methylparaben 0.14% w/w Benzyl Alcohol 1% w/w in a Cream base q.s.	10 g	24
348	1458	Sodium Chloride Injection IP 0.9%w/v	Sodium Chloride Injection IP 0.9% w/v	500ml IV fluid plastic contai	24

ANNEXURE- XIV
Ref. Clause No. 1(II) C
(Shape, Colour, Packing Type etc. of drugs)

(1)	(2)	(3)	(4)	(5)	(6)	(1)	(2)
S.N.	**Drug Code**	**Generic Name of Drug**	**Composition/Strength**	**Unit Size**	**Shape of Tablets/ Size of Capsule**	**Packing type**	**PVC Colour / bottle shape**
1	1	Aceclofenac 100mg and Paracetamol 325 mg Tablets	Each film-coated tablet contains: Aceclofenac 100mg Paracetamol 325 mg	10's	Oval	Blister	Transparent
2	9	Diclofenac Sodium Sustained Release Tablets IP 100mg	Each sustained release film-coated tablet contains: Diclofenac Sodium IP 100 mg	10's	Round	Strip	Silver
3	10	Diclofenac Sodium Injection IP 25mg/ml	Each ml contains: Diclofenac Sodium IP 25mg	3 ml	Ampoule	Mono carton	Transparent
4	14	Ibuprofen and Paracetamol Tablets IP (400mg + 325mg)	Each uncoated tablet contains: Ibuprofen IP 400mg Paracetamol IP 325 mg	10's	Oval	Blister	Transparent
5	16	Ibuprofen Tablet IP 400 mg	Each film-coated tablet contains: Ibuprofen IP 400mg	15's	Round biconvex	Blister	Transparent
6	17	Indomethacin capsule IP 25 mg	Each capsule contains: Indomethacin IP 25mg	10's	Round biconvex	ALU-ALU	Silver
7	21	Diclofenac Sodium and Paracetamol Tablets IP (50mg + 325mg)	Each uncoated tablet contains: Diclofenac Sodium IP 50mg Paracetamol IP 325 mg	10's	Oval	Blister	Red
8	24	Pentazocine Injection IP 30mg/ml	Each ml contains: Pentazocine 30 mg	1 ml	Ampoule	Mono carton	Transparent
9	26	Tramadol Hcl Injection 100 mg/2 ml	Each ml contains: Tramadol Hcl 50 mg	2ml	Ampoule	Mono carton	Transparent
10	28	Tramadol 50 mg Tablet	Each Film-coated tablet contains: Tramadol Hydrochloride 50mg	10's	Round biconvex	ALU-ALU	Silver
11	29	Acyclovir Tablets IP 400mg	Each uncoated tablet contains: Acyclovir IP 400mg	10's	Oval	Strip	Silver
12	31	Amikacin Injections IP 250mg/2ml	Each ml contains: Amikacin sulphate Ip equivalent to Amikacin 125 mg	2ml Vial	Vial	Mono carton	Transparent
13	32	Amikacin Injections IP 500mg/2ml	Each ml contains: Amikacin sulphate Ip equivalent to Amikacin 250mg	2ml Vial	Vial	Mono carton	Transparent

14	34	Glimepiride and Extended Release Metformin Hydrochloride Tablets (2mg + 500mg)	Each uncoated tablet contains: Glimepiride 2mg Metformin Hydrochloride 500mg (as extended release)	15's	Oval	Blister	Transparent
15	37	Amoxycillin and Potassium Clavulanate Injection 300 mg	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 250 mg Potassium Clavulanate IP equivalent to Clavulanic Acid 50 mg	Vial with WFI	Glass vial	Mono carton	Transparent
16	38	Amoxycillin and Potassium Clavulanate Injection 600 mg	Each vial contains: Amoxycillin Sodium IP equivalent to Amoxycillin 500 mg Potassium Clavulanate IP equivalent to Clavulanic Acid 100 mg	Vial with WFI	Glass vial	Mono carton	Transparent
17	39	Amoxycillin and Potassium Clavulanate tablets IP (500mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 500mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg Colour: Titanium Dioxide IP	6's	Oval	ALU-ALU	Silver
18	40	Amoxycillin and Cloxacillin Capsules (250mg+250mg)	Each hard gelatin capsule contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 250mg Cloxacillin Sodium IP equivalent to Cloxacillin 250mg	10's	Standard size	Blister	Transparent
19	42	Amoxicillin Trihydrate Dispersible Tablets IP 125mg	Each uncoated dispersible tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 125mg	10's	Round biconvex	Strip	Silver
20	48	Azithromycin 100 mg Dispersible Tablets	Each uncoated dispersible tablet contains: Azithromycin 100mg	10's	Round biconvex	Blister	Transparent
21	51	Cefadroxil Dispersible Tablets 250mg	Each uncoted dispersible tablet contains: Cefadroxil equivalent to Cefadroxil Anhydrous 250mg	10's	Round biconvex	Strip	Silver
22	64	Cefotaxime Sodium Injection 500 mg	Each Vial contains: Cefotaxime Sodium 500 mg	Vial & wfi	Standard	Glass vial	Transparent
23	68	Ceftazidime Injection IP 250mg	Each Vial contains: Ceftazidime 250 mg	Vial & wfi	Glass vial	Mono carton	Transparent
24	83	Ciprofloxacin and	Each film-coated tablet contains:	10's	Oval	Blister	Transpar

		Tinidazole Tablets (250mg+300mg)	Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Tinidazole IP 300mg				ent
25	85	Ciprofloxacin Hydrochloride Tablets IP 250 mg	Each film-coated tablet contains: Ciprofloxacin Hydrochloride IP equivalent to Ciprofloxacin 250mg Colour: Titanium Dioxide IP	10's	Oval	Blister	Transparent
26	92	Doxycycline Capsules IP 100mg	Each hard gelatin capsule contains: Doxycycline Hydrochloride IP equivalent to Doxycycline 100mg	10's	Standard size	Blister	Transparent
27	104	Roxithromycin Oral Suspension (50 mg/ 5ml)	Each 5ml contains: Roxithromycin 50mg Flavoured Syrupy Base q.s.	30ml	Plastic bottle	Round	Amber
28	106	Roxithromycin Tablets IP 300 mg	Each film-coated tablet contains: Roxythromycin IP 300mg Colours: Lake of Ponceau 4R & Titanium Dioxide IP	10's	Round biconvex	Blister	Transparent
29	113	Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream	Beclomethasone 0.025%+ Neomycin 0.5% w/w Cream	15g tube	Lami tubes	Standard	milky White
30	124	Povidone Iodine 5% w/w Ointment USP	Povidone Iodine 5% w/w Ointment USP	250 gm tubes/ Jar	Standard	Standard	milky White
31	126	Povidone-Iodine Solution IP 10 % w/v	Povidone-Iodine Solution IP 10 % w/v	500 ml	Standard	Plastic bottle	Amber
32	127	Povidone-Iodine Solution IP 5 % w/v	Povidone-Iodine Solution IP 5 % w/v	100 ml	Standard	Plastic bottle	Amber
33	130	Chlorhexidine Gluconate and Cetrimide Solution (1.5% w/v and 3% w/v)	Chlorhexidine Gluconate 1.5% w/v, Cetrimide 3% w/v Solution	100ml Bottle	Standard	Plastic bottle	Transparent
34	133	Glibenclamide Tablet IP 2.5 mg	Each uncoated tablet contains: Glibenclamide IP 2.5 mg	10's	Scored Oval	PVC Blister	Transparent
35	142	Insulin Injection IP Soluble Insulin, Neutral (Regular)	Each ml contains: Human Insulin IP 40 IU (Human Insulin of recombinant DNA origin) m-cresol 0.25% w/v	10 ml Vial	Standard	Glass vial	Transparent
36	144	Metformin Hydrochloride Sustained Release Tablets IP 1000 mg	Each film-coated sustained release tablet contains: Metformin Hydrochloride IP 1000mg	10's	Oval	PVC Blister	Transparent
37	153	Cisplatin Injection IP 10 mg/10ml	Each ml contains: Cisplatin 1 mg	Vial	Standard	Glass vial	Amber

38	158	Etoposide Injection IP 100 mg/5 ml	Each ml contains: Etoposide IP 20 mg	Vial	Glass vial	Mono carton	Transparent
39	165	Ciprofloxacin infusion IP 200mg (2mg/ml)	Each ml contains: Ciprofloxacin 2 mg	100 ml	Plastic bottle	Round	Transparent
40	170	MANNITOL Injection IP 20% w/v	Each 100 ml contains: Mannitol 20 g	100 ml	Plastic bottle	Round	Transparent
41	172	Metronidazole Infusion IP 500 mg	Each ml contains: Metronidazole 5 mg	100 ml	Plastic bottle	Round	Transparent
42	186	Domperidone Tablets IP 10 mg	Each film-coated tablet contains: Domperidone Maleate IP equivalent to Domperidone 10mg	10's	Round	PVC Blister	Transparent
43	194	Hyoscine Butylbromide Tablets IP 10 mg	Each sugar coated tablet contains: Hyoscine Butylbromide IP 10 mg	10's	Round biconvex	Blister	Transparent
44	196	Lactic Acid Bacillus Tablets (60 M)	Each uncoated tablet contains: Lactic Acid Bacillus not less than 60 million spores.	10's	Round biconvex	Strip	Silver
45	197	Lactulose Solution	Each 15ml contains: Lactulose solution equivalent to Lactulose 10g	100 ml	Standard	Plastic bottle	Amber
46	198	Dried Aluminium Hydroxide 250mg, Magnesium Hydroxide 250mg, Activated Methyl Polysiloxane Suspension 50mg/ 5ml	Each 5ml contains: Dried Aluminium Hydroxide 250mg Magnesium Hydroxide 250mg Activated Methyl Polysiloxane 50mg	170 ml	Plastic bottle	Round	milky White
47	200	Metoclopramide Injection IP 5mg/ml	Each ml contains: Metoclopramide 5 mg	2ml	Glass vial	Mono carton	Transparent
48	201	Metronidazole Tablets IP 200mg	Each film-coated tablet contains: Metronidazole Tablets IP 200mg Excipients q.s.	10's	Round	PVC Blister	Red
49	202	Metronidazole Tablets IP 400mg	Each film-coated tablet contains: Metronidazole Tablets IP 400mg Excipients q.s.	10's	Round	PVC Blister	Red
50	208	Ondansetron injection IP 2mg/ml	Each ml contains: Ondansetron 2 mg	2 ml	Ampoule	Mono carton	Transparent
51	209	Ondansetron Tablets IP 4mg	Each film-coated tablet contains: Ondansetron Hydrochloride IP equivalent to Ondansetron 4mg	10's	Round	Alu-Alu	Aluminium
52	215	Rabeprazole Gastro-resistant Tablets IP 20mg	Each gastro-resistant tablet contains: Rabeprazole Sodium IP 20mg	10's	Round	Strip	Silver
53	217	Ranitidine Tablets IP 150 mg	Each film-coated tablet contains: Ranitidine Hydrochloride IP 167.4mg	10's	Round	Strip	Silver

			equivalent to Ranitidine 150mg Excipients q.s.				
54	220	Calcium with Vitamin D3 Tablets IP (500mg+250IU)	Each film-coated tablet contains: 1250mg Calcium Carbonate equivalent to Elemental Calcium IP 500mg Vitamin D3 IP 250IU	10's	Oval	PVC Blister	Skyblue
55	227	Polyvitamin Tablets NFI (Prophylactic)	Each film-coated tablet contains: Vitamin A 2500 IU Vitamin D3 200IU Vitamin B1 2mg Vitamin B6 0.5mg Vitamin B12 2mg Niacinamide 25mg Calcium Pantothenate 1mg Vitamin C 50mg Folic Acid 0.2mg	10's	Round biconvex	PVC Blister	Transparent
56	230	Vitamin B-Complex fort Zinc Capsule"	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 45mg Pyridoxine Hydrochloride 3mg Cynocobalamine 15mcg Folic acid 1.5mg Ascorbic acid 150mg Zinc Sulfate Monohydrate 61.8mg (Eq. to 22.5 mg of Elemental Zinc)	10's	Standard	Standard	Standard
57	232	Vitamin B-Complex Syrup	Each 5ml contains: Pyridoxine Hydrochloride IP 0.75 mg Thiamine Hydrochloride IP 2.5 mg Riboflavin Sodium Phosphate IP 2.5 mg Cynocobalamine IP 2.5 mcg Nicotinamide IP 22.5 mg D-Panthenol IP 3.0 mg	200 ml	Plastic bottle	Round neck	Amber
58	233	Vitamin-C Chewable 100mg Tablet	Vitamin-C Chewable 100mg Tablet	10's	Round biconvex	Strip	Silver
59	236	Budesonide Inhaler 100mcg	Each activation delivers Budesonide IP 100mcg	200 MDI	Standard size	Standard	Standard Market
60	238	Budesonide Inhaler 200mcg	Each activation delivers Budesonide IP 200mcg	200 md	Standard size	Standard	Standard Market
61	239	Cetirizine Syrup IP (5 mg/ 5 ml)	Each 5ml contains: Cetrizine Hydrochloride IP 5mg	60 ml	Plastic bottle	Round	Amber
62	240	Cetrizine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Cetrizine Hydrochloride IP 10mg	10's	Oval	PVC Blister	Transparent
63	244	Etophyllin and Theophylline Injection	Each ml contains: Etofylline 84.7 mg Theophylline anhydrous	2 ml	Glass vial	Mono carton	Transparent

		(84.7mg+25.3 mg)	equivalent to Theophylline hydrate 25.3 mg				
64	245	Etophylline and Theophylline Tablets 100 mg	Each uncoated tablet contains: Etophylline 77 mg Theophylline (Hydrated) 23 mg	10's	Oval	PVC Blister	Transparent
65	255	Salbutamol Inhalation IP 100 mcg/puff	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg	200 md	Standard size	Standard	Standard Market
66	256	Salbutamol Tablets IP 2mg	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg	10's	Round biconvex	Blister	Transparent
67	265	Atenolol Tablets IP 50 mg	Each uncoated tablet contains: Atenolol IP 50mg	14's	Round	PVC Blister	Transparent
68	268	Clonidine Tablets IP 0.1 mg	Each uncoated tablet contains: Clonidine Hydrochloride IP 100mcg	10's	Round biconvex	Blister	Transparent
69	270	CLOPIDOGREL AND ASPIRIN Tablets (75mg + 75mg)	Each film-coated tablet contains: Clopidogrel Bisulphate IP equivalent to Clopidogrel 75mg Aspirin 75mg	10's	Round biconvex	Strip	Silver
70	273	Dobutamine Injection 250mg/20ml	Each vial (20ml) contains: Dobutamine 250 mg	Vial	Glass vial	Mono carton	Amber
71	274	Dopamine HCl Injection 200 mg/5ml	Each ml contains: Dopamine Hydrochloride 40mg	5 ml	Ampoule	Mono carton	Amber
72	275	Enalapril Tablets IP 5 mg	Each uncoated tablet contains: Enalapril Maleate IP 5 mg	10's	Round	Strip	Silver
73	277	Enoxaparin Injection IP 60 mg/0.6 ml	Each pre-filled syringe contains: Enoxaparin sodium IP 60 mg equivalent to 6,000 IU anti-Xa activity.	0.6 ml	Standard	Pre-filled syringe	Transparent
74	281	Heparin Sodium Injection IP 5000 IU/ml	Each ml contains: Heparin Sodium 5000 IU	5 ml	Glass vial	Mono carton	Amber
75	295	Simvastatin Tablets IP 10mg	Each film-coated tablet contains: Simvastatin IP 10mg	10's	Round biconvex	Blister	Transparent
76	296	Simvastatin Tablets IP 20mg	Each film-coated tablet contains: Simvastatin IP 20mg	10's	Round	PVC Blister	Transparent
77	298	Telmisartan and Hydrochlorothiazide Tablets IP (40mg+12.5 mg)	Each uncoated bilayer tablet contains: Telmisartan IP 40mg Hydrochlorthiazide IP 12.5mg	10's	Round biconvex	Strip	Silver
78	300	Telmisartan Tablets IP 40mg	Each uncoated tablet contains: Telmisartan IP 40 mg	10's	Round biconvex	Strip	Silver
79	304	α-β Arteether Injection 150 mg	Each 2 ml contains: α-β Arteether 150 mg	2ml Vial	Ampoule	Mono carton	Amber
80	305	Chloroquine Phosphate Tablets IP 250 mg	Each film-coated tablet contains: Chloroquine Phosphate IP 250mg	10's	Oval /Round	Blister	Dark amber
81	312	Oral Rehydration Salts 20.5 GM Sachet (WHO	Each pack contains: Sodium Chloride IP 2.6 mg Potassium Chloride IP 1.5 mg	1's	Standard	Sachet	BPPI artwork

		Formula)	Sodium Citrate IP 2.9 mg Dextrose IP (anhydrous) 13.5 mg Excipients q.s.				
82	326	Methyl Ergometrine Tablets IP 0.125mg	Each sugar coated tablet contains: Methylergometrine Maleate IP 0.125mg	10's	Round biconvex	Blister	Transparent
83	330	Prednisolone Tablets IP 10 MG	Each uncoated tablet contains: Prednisolone IP 10 mg	10's	Oval /Round	Blister	Amber
84	333	Dexamethasone Tablets IP 0.5 mg	Each uncoated tablet contains: Dexamethasone IP 0.5mg	10's	Round biconvex	Strip	Silver
85	334	Dexamethasone Injection 4mg/ml	Each ml contains: Dexamethasone Sodium Phosphate IP equivalent to Dexamethasone Phosphate 4mg	2 ml	Ampoule	Mono carton	Amber
86	336	Allopurinol Tablets IP 100 mg	Each uncoated tablet contains: Allopurinol IP 100 mg	10's	Round	Strip	Silver
88	352	Bupivacaine Hydrochloride Injection IP 5 mg/ml	Each ml contains: Bupivacaine Hydrochloride 5 mg	20ml	Standard	Glass vial	Transparent
89	357	Lignocaine and Adrenaline Injection IP (2%w/v and 1:80000)	Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Adrenaline Bitartrate IP 0.0225 mg equivalent to (Adrenaline 0.0125 mg)	30 ml Vial	Glass vial	Mono carton	Amber
90	358	Propofol Injection 10 mg/ml	Each ml contains: Propofol 10 mg	10ml Vial	Glass vial	Mono carton	Transparent
91	359	Tetanus Vaccine	Each 0.5 ml contains: Tetanus Toxoid ≥ 5 LF	0.5 ml Amp.	Ampoule	Mono carton	Transparent
92	362	BIPHASIC ISOPHANE INSULIN INJECTION IP (50:50) 4O IU/ML	Each ml contains: Human Insulin IP 40 IU (50% as Soluble Insulin Injection and 50% as Isophane Insulin Injection) (Human Insulin od recombinant DNA origin)	10 ML VIAL	Standard	Glass vial	Transparent
93	373	ARTESUNATE INJECTION 60 MG	Each vial contains: Artesunate 60 mg The pack also contains: 1 ml ampoule of Sodium Bicarbonate 5% w/v 5 ml ampoule of Sodium Chloride 0.9% w/v	1 vial with diluent	Glass vial	Mono carton	Transparent
94	377	CLINDAMYCIN CAPSULES 300 MG	Each hard gelatin capsule contains: Clindamycin Hydrochloride equivalent to Clindamycin 300mg	10's	Standard	PVC Blister	Transparent
95	384	ITRACONAZOLE Capsules 100 mg	Each hard gelatin capsule contains: Itraconazole 100mg	4's	Standard	Alu-Alu Strip	Aluminium

96	386	Diethylcarbamazine Tablets IP 50 mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 50mg Excipients q.s.	30's	Round	Alu-Alu Strip	Aluminium
97	392	GRISEOFULVIN TABLETS IP 250 MG	Each uncoated tablet contains: GRISEOFULVIN IP 250 MG	10's	Oval /Round	Blister	Transparent
98	393	ACICLOVIR DISPERSIBLE TABLETS IP 800 MG	Each dispersible uncoated tablet contains: Aciclovir IP 800mg	5's	Modified rectangle	Blister	Transparent
99	395	CEFUROXIME and POTASSIUM CLAVULANATE Tablets (500MG + 125MG)	Each film-coated tablet contains: Cefuroxime Axetil IP equivalent to Anhydrous Cefuroxime 500mg Potassium Clavulanate Diluted IP equivalent to Clavulanic Acid 125mg	6's	Oval	ALU-ALU	Silver
100	396	AMPHOTERICIN B INJECTION IP 50 mg/vial	Each Vial contains: AMPHOTERICIN B 50 mg	Vial	Glass vial	Mono carton	Transparent
101	401	Amoxycillin and Potassium Clavulanate tablets (250mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 250mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg	6's	Oval	ALU-ALU	Silver
102	402	Amoxycillin and Potassium Clavulanate tablets (875mg + 125 mg)	Each film-coated tablet contains: Amoxycillin Trihydrate IP equivalent to Amoxycillin 875mg Pottasium Clavulanate IP equivalent to Clavulanic acid 125mg	6's	Oval	ALU-ALU	Silver
103	405	OFLOXACIN INFUSION IP 200 mg /100 ml	Each 100 ml contains: OFLOXACIN IP 200mg	100 ml	Plastic bottle	Round	Transparent
104	417	TELMISARTAN AND AMLODIPINE Tablets IP (40 mg +5 mg)	Each uncoated tablet contains: Telmisartan IP 40mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	15's	Round	Alu-Alu Blister	Silver
105	419	Ointment of Heparin Sodium and Benzyl Nicotinate	Each gram contains: Heparin Sodium 50 IU Benzyl Nicotinate 2mg	20 GM	Lami tubes	Standard	milky White
106	423	BISOPROLOL TABLETS 5 MG	Each film-coated tablet contains: Bisoprolol Fumarate 5mg	10's	Round biconvex	Blister	Transparent
107	425	Diltiazem Sustained Release Tablets 90mg	Each uncoated sustained release tablet contains: Diltiazem Hydrochloride IP 90mg	10's	Round biconvex	Blister	Transparent

108	427	S(-)AMLODIPINE TABLETS IP 2.5 MG	Each uncoated tablet contains: S(-)AMLODIPINE Besylate IP equivalent to S(-)AMLODIPINE 2.5 MG	10's	Round	PVC Blister	Amber
109	428	DIGOXIN Tablets IP 0.25 mg	Each uncoated tablet contains: DIGOXIN IP 0.25 mg	10's	Round biconvex	Strip	Silver
110	429	ATORVASTATIN and FENOFIBRATE Tablets (10mg + 160mg)	Each film-coated tablet contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Fenofibrate 160mg	15's	Oval /Round	ALU-ALU	SILVER
111	430	AMIODARONE Tablets IP 200 mg	Each uncoated tablet contains: Amiodarone Hydrochloride IP 200mg	10's	Round	PVC Blister	Transparent
112	431	RAMIPRIL and HYDROCLORTHIAZIDE TABLETS IP (5MG+12.5 MG)	Each uncoated tablet contains: Ramipril IP 5mg Hydrochlorothiazide IP 12.5mg	10's	Round biconvex	Strip	Silver
113	432	OLMESARTAN MEDOXOMIL Tablets IP 40 mg	Each film-coated tablet contains: OLMESARTAN MEDOXOMIL IP 40 mg	10's	Round biconvex	Strip	Silver
114	434	PROPRANOLOL Tablets IP 40 mg	Each uncoated tablet contains: Propranolol Hydrochloride IP 40mg	10's	Round	PVC Blister	Transparent
115	437	NIFEDIPINE SUSTAINED RELEASE Tablets IP 20 mg	Each sustained release film coated tablet contains: Nifedipine IP 20mg	10's	Round	PVC Blister	Amber
116	438	INDAPAMIDE TABLETS IP 1.5 MG	Each film-coated tablet contains: Indapamide IP 1.5mg	10's	Round biconvex	Blister	Transparent
117	439	OLMESARTAN MEDOXOMIL AND HYDROCLORTHIAZIDE Tablets IP (40 mg+12.5 mg)	Each film-coated tablet contains: Olmesartan Medoxomil IP 40mg Hydrochlorothiazide IP 12.5mg	10's	Round biconvex	Strip	Silver
118	440	METOPROLOL (ER) AND AMLODIPINE TABLETS (50mg + 5mg)	Each film-coated bilayered tablet contains: Metoprolol Succinate IP 47.5mg equivalent to Metoprolol Tartrate 50mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	7's	Round biconvex	Strip	Silver
119	441	LOSARTAN and AMLODIPINE TABLETS IP (50mg + 5mg)	Each film-coated tablet contains: Losartan Potassium IP 50mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	Round biconvex	ALU-ALU	SILVER
120	442	FENOFIBRATE TABLETS IP 160 MG	Each film-coated tablet contains: FENOFIBRATE IP 160 MG	10's	Round biconvex	Blister	Transparent

121	444	ENALAPRIL and HYDROCHLOROTHIAZIDE TABLETS IP (10mg + 25mg)	Each uncoated tablet contains: Enalapril Maleate IP 10 mg Hydrochlorothiazide IP 25 mg	30's	Round biconvex	Strip	Silver
122	445	OLMESARTAN and AMLODIPINE Tablets (20mg + 5mg)	Each film-coated tablet contains: Olmesartan Medoxomil IP 20mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	Round	Alu-Alu Blister	Aluminium
123	446	AMLODIPINE and HYDROCHLOROTHIAZIDE TABLETS (5mg + 12.5mg)	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Hydrochlorthizide IP 12.5mg	10's	Round biconvex	ALU-ALU	SILVER
124	448	RAMIPRIL AND AMLODIPINE TABLETS (5mg + 5mg)	Each uncoated tablet contains: Ramipril IP 5mg Amlodipine Besilate IP equivalent to Amlodipine 5mg	10's	Round biconvex	Strip	Silver
125	449	SPIRONOLACTONE TABLETS IP 25 MG	Each uncoated tablet contains: Spirinolactone IP 25mg	15's	Round	PVC Blister	Red
126	451	STREPTOKINASE INJECTION IP 15,00,000 IU	Each vial contains: STREPTOKINASE IP 15,00,000 IU	10 ml & wfi	Glass vial	Mono carton	Transparent
127	452	WARFARIN TABLETS IP 5 MG	Each uncoated tablet contains: Warfarin Sodium Clathrate IP equivalent to Warfarin sodium (anhydrous) 5mg	10's	Round biconvex	Blister	Amber
128	453	BISOPROLOL and HYDROCHLOROTHIAZIDE TABLETS IP (5mg + 6.25mg)	Each film-coated tablet contains: Bisoprolol Fumarate IP 5mg Hydrochlorthizide IP 6.25mg	10's	Round biconvex	Blister	Transparent
129	454	VALSARTAN TABLETS IP 80 MG	Each film-coated tablet contains: Valsartan IP 80 mg	10's	Round biconvex	ALU-ALU	Silver
130	455	VERAPAMIL TABLETS IP 80 MG	Each film-coated tablet contains: Verapamil Hydrochloride IP 80 mg	10's	Round biconvex	Blister	Amber
131	457	TORSEMIDE TABLETS IP 20 MG	Each uncoated tablet contains: Torsemide IP 20mg	10's	Round biconvex	Blister	Transparent
132	458	LABETALOL INJECTION IP 5 mg/ml	Each ml contains: Labetalol 5 mg	4 ml Vial	Glass vial	Mono carton	Transparent
133	461	BETAMETHASONE VALERAT and NEOMYCIN SULFATE CREAM (0.1% w/w and 0.5% w/w)	BETAMETHASONE VALERAT 0.1 % w/w + NEOMYCIN SULFATE 0.5 % w/w CREAM	20 GM	Lami tubes	Standard	milky White

134	462	BETAMETHASONE VALERATE and CLIOQUINOL CREAM BP (0.12% w/w+ 3% w/w)	BETAMETHASONE VALERATE 0.12% w/w CLIOQUINOL CREAM BP 3%w/w)	30 GM	Lami tubes	Standard	milky White
135	468	BACILLUS CLAUSII SPORES SUSPENSION 2 Billion/5ml	Each 5ml oral suspension contains: Spores of polyantibiotic resistant Bacillus Clausii 2 billion (Strains: O/C, N/R, SIN and T)	5 ML	Plastic bottle	Round	Transparent
136	470	DIASTASE and PEPSIN LIQUID	Each 5ml contains: Diastase IP (1:1200) 50mg Pepsin IP (1:3000) 10mg	200 ML	Plastic bottle	Round	Amber
137	471	OXETACAINE, ALUMINIUM HYDROXIDE AND MAGNESIUM HYDROXIDE GEL	Each 5ml contains: Oxetacaine 10 mg Aluminium Hydroxide 0.291 g Magnesium Hydroxide 96 mg	200 ML	Plastic bottle	Round	milky White
138	472	Enteric-Coated Esomeprazole and Sustained Release Domperidone Capsules (40mg+30mg)	Each hard gelatin calsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Domperidome (as sustained release) 30mg	10's	Standard size	ALU-ALU	Silver
139	476	LIQUID PARAFFIN, MILK OF MAGNESIA and SODIUM PICOSULPHATE SUSPENSION 170ml	Each 5ml contains: LIQUID PARAFFIN 1.25ml MILK OF MAGNESIA 3.75ml SODIUM PICOSULPHATE 3.33mg	170 ml Bottle	Plastic bottle	Round	Amber
140	477	CHLORDIAZEPOXIDE AND CLIDINIUM BROMIDE TABLETS (5mg+2.5mg)	Each sugar-coated tablet contains: Chlordiazepoxide 5mg Clidinium Bromide 2.5mg	10's	Round	PVC Blister	Transparent
141	479	Solution of SORBITOL and TRICHOLINE CITRATE	Each 10ml contains: TRICHOLINE CITRATE 0.55g SORBITOL Solution (70%) IP 7.15g	200 ML	Plastic bottle	Round neck	Amber
142	480	Enteric-Coated Esomeprazole and Sustained Release Levosulpiride Capsules (40mg+75mg)	Each hard gelatin capsule contains: Esomeprazole Magnesium Trihydrate IP equivalent to Esomeprazole (as enteric coated) 40mg Levosulpiride (as sustained	10's	Standard size	ALU-ALU	Silver

			release) 75mg				
143	481	RIFAXIMIN TABLETS 400 MG	Each film-coated tablet contains: Rifaximin 400mg	10's	Modified rectangle	Strip	Silver
144	483	LOPERAMIDE Capsules IP 2 mg	Each hard gelatin calsule contains: LOPERAMIDE HYDROCHLORIDE IP 2 mg	10's	Standard size	Blister	Transparent
145	486	PANCREATIN and Activated DIMETHICONE TABLETS (170mg+80mg)	Each enteric-coated tablet contains: PANCREATIN IP 170mg Activated DIMETHICONE TABLETS IP 80mg	10's	Oval	Strip	Silver
146	487	Dicyclomine Hydrochloride and Dimethicone Suspension (10mg+40mg)	Each 5ml contains: Dicyclomine Hydrochloride IP 10mg Simethicone IP 40mg	30 ML	Plastic bottle	Round	Amber
147	488	LANSOPRAZOLE CAPSULES IP 15 MG	Each capsule contains: Lansoprazole IP 15 mg (as enteric coated granules)	10's	Standard size	ALU-ALU	Silver
148	489	Sulfasalazine Delayed Release Tablets 1000mg	Each enteric-coated tablet contains: Sulfasalazine 1000mg	10's	Modified rectangle	Blister	Transparent
149	492	Sulfasalazine Delayed Release Tablets 500mg	Each enteric-coated tablet contains: Sulfasalazine 500mg	10's	Oval	Blister	Transparent
150	496	DYDROGESTERONE TABLETS IP 10 MG	Each film-coated tablet contains: DYDROGESTERONE IP 10 MG	10's	Round biconvex	Blister	Transparent
151	501	BETAMETHASONE SODIUM PHOSPHATE TABLETS IP 0.5 MG	Each film-coated tablet contains: BETAMETHASONE SODIUM PHOSPHATE TABLETS IP equivalent to Betamethasone 0.5 MG	20's	Round biconvex	Strip	Silver
152	504	NANDROLONE DECANOATE INJECTION IP 25 MG/ML	Each ml contains: NANDROLONE DECANOATE IP 25 mg	1 ML	Glass vial	Mono carton	Transparent
153	505	CARBIMAZOLE TABLETS 10 MG	Each uncoated tablet contains: CARBIMAZOLE 10 MG	100's	Round biconvex	Glass bottle	Amber
154	507	CARBIMAZOLE TABLETS IP 5 MG	Each uncoated tablet contains: CARBIMAZOLE IP 5 MG	10's	Round biconvex	Blister	Transparent
155	521	Tramadol Sustained release Tablets 100 mg	Each sustained release tablet contains: Tramadol 100mg	10's	Modified rectangle	ALU-ALU	Silver
156	522	ALFACALCIDOL SOFT GELATIN CAPSULES 0.25 MCG	Each soft gelatin capsule contains: Alfacalcidol 0.25mcg	10's	Standard size	Blister	Amber
157	523	NAPROXEN TABLETS IP 500	Each uncoated tablet contains: NAPROXEN IP 500 MG	15's	Oval	Blister	Transparent

		MG					
158	524	LIGNOCAINE INJECTION IP 2%	Each ml contains: Lignocaine Hydrochloride IP 21.33 mg Sodium chloride IP 6.0 mg Methyl Paraben IP 1.0 mg (as preservative)	30 ML VIAL	Glass vial	Mono carton	Transparent
159	528	PARACETAMOL, PHENYLEPHRINE and CHLORPHENIRAMINE Tablets (325mg+10mg+2 mg)	Each uncoated tablet contains: PARACETAMOL IP 325 mg PHENYLEPHRINE HYDROCHLORIDE IP 10 mg CHLORPHENIRAMINE MALEATE IP 2 mg	10's	Round biconvex	Blister	Amber
160	529	LEVOSALBUTAMOL AND IPRATROPIUM RESPULES (1.25mcg+500mcg)	Each 2.5ml respule contains: Ipratropium Bromide IP equivalent to Ipratropium Bromide (anhydrous) 500mcg Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25mcg	2.5 ML	Standard size	Standard type	Standard Market
161	530	FORMOTERAL and BUDESONIDE ROTACAPS (6mcg+200mcg)	Each capsule contains: Formoterol Fumarate (as Formoterol Fumarate dihydrate IP) 6mcg Budesonide IP 200mcg	30's	Standard size	Standard type	Standard Market
162	532	SALMETEROL and FLUTICASONE ROTACAPS (50mcg+250mcg)	Each capsule contains: Salmeterol Fumarate (as Formoterol Xinafoate IP) 50mcg Fluticasone Propionate IP 250mcg	30's	Round Amber	Standard type	Standard Market
163	537	Ambroxol Hydrochloride and Levosalbutamol Sulphate Syrup	Each 5ml contains: Ambroxol Hydrochloride 15mg Levosalbutamol Sulphate equivalent to Levosalbutamol 0.5mg	100 ML	Plastic bottle	Round	Amber
164	540	Levosalbutamol and BUDESONIDE Respules (1.25mg+1mg)	Each 2ml respule contains: Levosalbutamol Tartrate equivalent to Levosalbutamol 1.25 mg Budesonide 1 mg	2 ML	Standard size	Standard type	Standard Market
165	543	MENTHOL (55 mg ± 5.) CINNAMON (12.5 mg ± 2) and PINE OIL (112.5 mg ± 1) SOFT CAPSULES	MENTHOL (55 mg ± 5.) CINNAMON (12.5 mg ± 2) and PINE OIL (112.5 mg ± 1) SOFT CAPSULES	10's	Standard size	Blister	Transparent
166	559	SALBUTAMOL AND THEOPHYLLINE TABLETS (2mg+100mg)	Each uncoated tablet contains: Salbutamol Sulphate IP equivalent to Salbutamol 2mg Theophylline (anhyd.) IP 100mg	30's	Round biconvex	Blister	Transparent
167	560	FLUTICASONE PROPIONATE	Each spray delivers: Fluticasone Propionate IP 50 mcg	120 MD	Standard size	Standard type	Standard Market

		NASAL SPRAY 50 mcg					
168	561	LEVOSALBUTAMOL SYRUP (1mg/5ml)	Each 5ml contains: Levosalbutamol Sulphate IP equivalent to Salbutamol 1mg Flavoured syrup base q.s.	100 ML	Plastic bottle	Round	Amber
169	564	Tiotropium Bromide and Formoterol Fumarate Dihydrate Rotacaps (18mcg+12mcg)	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg	15's	Standard size	Standard type	Standard Market
170	565	Tiotropium Bromide, Formoterol Fumarate Dihydrate and Ciclesonide Rotacaps (18mcg +12mcg+400mcg)	Each capsule contains: Tiotropium bromide monohydrate Ip equivalent to Tiotropium 18mcg Formoterol Fumarate Dihydrate IP 12mcg Ciclesonide IP 400mcg	15's	Standard size	Standard type	Standard Market
171	566	Ipratropium Bromide Respirator Solution 250mcg	Each ml contains: Ipratropium bromide IP 250mcg	15 ML	Standard size	Standard type	Standard Market
172	567	SALBUTAMOL AND IPRATROPIUM INHALER (100mcg+20mcg)	Each activation delivers: Salbutamol sulphate IP equivalent to Salbutamol 100mcg Ipratropium bromide IP 20mcg	200 MDI	Standard size	Standard type	Standard Market
173	568	Salmeterol and Fluticasone Propionate Inhaler IP (25mcg+250mcg)	Each activation delivers: Salmeterol (as Salmeterol Xinafoate) 25mcg Fluticasone Propionate 250mcg	100 MD	Standard size	Standard type	Standard Market
174	571	Tamsulosin Hydrochloride and Dutasteride Tablets (0.4mg+0.5mg)	Each film-coated tablet contains: Tamsulosin Hydrochloride IP 0.4mg (as modified release tablets) Dutasteride IP 0.5mg	15's	Round biconvex	ALU-ALU	Silver
175	574	Rabies Vaccine, Human IP	Purified lyophilized Rabies antigen derived from Rabies virus (L.Pasteur 2061/ Vero strain propogated in Vero cells), Inactivated. Potency: ≥ 2.5 IU per Vial Stabilizers: Maltose and Human Albumin q.s. Preservatives: Thiomersal ≤ 0.015% w/v	1 ml with Diluent (0.9% w/v Sodium Chloride inj. IP)	Glass vial	Mono carton	Transparent

176	582	VITAMINS A, C, D, E AND B COMPLEX AND MINERALS SYRUP	Each 15ml contains: Vitamin A 2500 IU Thiamine Hydrochloride 1.5 mg Riboflavin Sodium Phosphate 1.7 mg Pyridoxine Hydrochloride 1.5 mg Cyanocobalamine 1 mcg Vitamin C 25 mg Vitamin D3 200 IU Vitamin E 10 IU Nicotinamide 20 mg D-Panthenol 5 mg Biotin 10 mcg Zinc 3 mg Iodine 50 mcg Iron 5 mg Manganese 0.8 mg Chromium 8 mcg Molybdenum 8 mcg in a flavoured base q.s.	200 ML	Standard	Plastic bottle	Amber
177	583	CYPROHEPTADINE Tablets IP 4 mg	Each uncoated tablet contains: Cyproheptadine Hydrochloride IP 4mg	10's	Round	PVC Blister	Transparent
178	586	METHYLCOBALAMIN, L-CARTININE L-TARTRATE and FOLIC ACID TABLETS (1500mcg+500mg +1.5mg)	Each film-coated tablet contains: L- CARTININE L- TARTRATE equivalent to L-carnitine 500 mg Methylcobalamine 1500 mcg Folic acid 1.5 mg	10's	Almond shape	ALU-ALU	Silver
179	592	L-LYSINE + MULTIVITAMINS (VIT-B1,B2,B3,B5,B6) SYRUP	Each 5ml contains: Thiamine Hydrochloride 2.25 mg Riboflavin Sodium Phosphate 2.5 mg Nicotinamide 22.5 mg D-panthenol 3.0 mg Pyridoxine Hydrochloride 0.75 mg Lysine Hydrochloride 375 mg	200 ML	Plastic bottle	Round neck	Amber
180	593	Folic Acid, Cyanocobalamine and Nicotinamide Injection (15mg+500mcg+200mg)	Each ml contains: Folic Acid 15 mg Cyanocobalamine 500 mcg Nicotinamide 200 mg Benzyl Alcohol 2.5% v/v Phenol 0.5% w/v (As preservative)	10 ML	Glass vial	Mono carton	Amber
181	595	THIAMINE, PYRIDOXINE HCl and CYANOCOBALAMIN INJECTION (100mg +50mg+1000mcg)	Each 2 ml ampoule contains: Mecobalamin IP 1000 mcg Pyridoxine HCl IP 50 mg Thiamine 100 mg	2 ML	Ampoule	Mono carton	Amber

182	597	PYRIDOXINE TABLETS 50 MG	Each uncoated tablet contains: Pyridoxine Hydrochloride 50mg	10's	Round	Strip	Silver
183	601	Disulfiram Tablets 500 mg	Each uncoated tablet contains: Disulfiram 500 mg	4's	Round	PVC Blister	Transparent
184	603	Cetirizine Dihydrochloride, Phenylephrine HCl and Paracetamol Tablets (5mg +10mg+325mg)	Each uncoated tablet contains: Cetirizine Dihydrochloride 5mg Phenylephrine Hydrochloride 10mg Paracetamol 325mg	10's	Oval	Blister	Transparent
185	608	Betamethasone Dipropionate and Salicylic acid Ointment	Contains: Betamethasone Dipropionate 0.05% w/w Salicylic acid 3% w/w	20gm	Lami tubes	Standard	milky White
186	609	Silver Nitrate and Chlorhexidine Gluconate Cream	Contains: Silver Nitrate 0.20% w/w Chlorhexidine Gluconate Solution 0.20%w/w Preservative: Chlorocresol 0.12%w/w	15g Tube	Lami tubes	Standard	milky White
187	610	Paracetamol, Phenylephrine Hydrochloride and Cetirizine Dihydrochloride Suspension (125mg +5mg+2mg)	Each 5ml contains: Paracetamol IP 125mg Phenylephrine Hydrochloride IP 5mg Cetirizine Dihydrochloride 2mg	60 ML	Plastic bottle	Round neck	Amber
188	611	Cyproheptadine Hydrochloride Syrup IP 2mg	Each 5ml contains: Cyproheptadine Hydrochloride IP 2mg	200 ml	Standard	Plastic bottle	Amber
189	612	Povidone-Iodine Powder 5% w/w	Povidone-Iodine Powder 5% w/w	10gm Container	Standard Size	Standard type	Standard Market
190	613	Diclofenac Potassium, Paracetamol and Serratiopeptidase Tablets (50mg+325mg+10 mg)	Each film-coated tablet contains: Diclofenac Potassium 50 mg Paracetamol 325 mg Serratiopeptidase 10mg (20,000 serratiopeptidase unit as enteric coated granules)	10's	Oval	PVC Blister	Transparent
191	621	Carbonyl Iron, Zinc and Folic Acid Capsules	Each capsule contains: Elemental Iron 50 mg (in the form of Carbonyl Iron) Zinc Sulphate Monohydrate 61.8 mg (equivalent to 22.5 elemental Zinc) Folic Acid 0.5 mg	15's	Standard size	Blister	Transparent
192	626	Ketoconazole Shampoo 2% W/V	Ketoconazole Shampoo 2% W/V	100ml Bottle	Plastic bottle	Standard	Standard Market

193	627	Etophylline and Theophylline Prolonged Release Tablets IP (115mg+35mg)	Each film-coated prolonged release tablet contains: Etophylline 115mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 35mg	10's	Oval	Blister	Transparent
194	628	Etophylline and Theophylline Prolonged Release Tablets (231mg+69mg)	Each film-coated prolonged release tablet contains: Etophylline 231mg Theophylline IP Anhydrous equivalent to Theophylline IP Hydrate 69mg	10's	Oval	Blister	Transparent
195	632	Etamsylate Tablets 250 mg	Each uncoated tablet contains: Etamsylate 250 mg	10's	Oval	Blister	Transparent
196	635	Clobetasol Propionate, Neomycin Sulphate, Miconazole Nitrate and Chlorhexidine Gluconate Cream	Contains: Clobetasol Propionate 0.05% w/w Neomycin Sulphate 0.50% w/w Miconazole Nitrate 2.00% w/w Chlorhexidine Gluconate Solution 0.20% w/w Chlorocresol (as preservative) 0.10% w/w In a cream base q.s.	10 gms tube	Lami tubes	Standard	milky White
197	640	Nimesulide Gel 1% w/w	Nimesulide Gel 1% w/w	20gm Tube	Lami tubes	Standard	milky White
198	645	Nimesulid, Paracetamol and Chlorzoxazone Tablets (100mg +325mg+375mg)	Each uncoated tablet contains: Nimesulide 100mg Paracetamol 325mg Chlorzoxazone 375mg	10's	Oval	Blister	Transparent
199	649	Dicyclomine Hydrochloride and Simethicone Oral Drops (10mg+40mg)	Each ml contains: Dicyclomine Hydrochloride 10mg Simethicone 40mg	10ml Bottle	Plastic bottle	Round	Amber
200	650	Mefenamic Acid and Paracetamol Tablets (500mg+325mg)	Each uncoated tablet contains: Mefenamic Acid 500mg Paracetamol 325mg	10's	Oval	Blister	Transparent
201	656	Diastase and Pepsin Enzyme Drops	Each ml contains: Diastase (1:1200) 33.33 mg Pepsin (1:3000) 5mg Vit B1 1 mg Vit B2 1 mg Vit B6 1 mg Vit B12 1 mcg Niacinamide 10 mg	15 ml	Plastic bottle	Round	Amber
202	659	Chlorhexidine Gluconate and Cetrimide Solution (0.3% w/v and	Chlorhexidine Gluconate 0.3% w/v + Cetrimide 0.6%w/v	200 ml	Standard	Plastic bottle	Transparent

		0.6% w/v)					
203	662	Gamma Benzene Hexachloride and Cetrimide Lotion	contains: Gamma Benzene Hexachloride 1% w/v Cetrimide 0.1% w/v	200ML	Standard	Plastic bottle	Amber
204	664	Mouth Ulcer Gel (Choline Salicylate sodium 9% w/v, Benzalkonium Chloride 0.01% w/w)	Choline Salicylate sodium 9% w/v Benzalkonium Chloride 0.01% w/w	10gm	Lami tubes	Standard	milky White
205	665	Vitamin B complex & Ascorbic Acid Capsules	Each hard gelatin capsule contains: Thiamine 10mg Riboflavin 10mg Niacinamide 50mg Pyridoxine Hydrochloride 3mg Cynocobalamine 50mcg Calcium Pantothenate 12.5mg Folic acid 1mg Ascorbic acid 150mg	10's	Standard size	Blister	Amber
206	666	Pheniramine Maleate Injection IP 22.75 mg	Each ml contains: Pheniramine Maleate IP 22.75 mg	2 ML	Ampoule	Round	Amber
207	668	Multivitamin Drops	Each ml contains: Vitamin A (as Palmitate) 2500 IU Vitamin E acetate 25 IU Vitamin D3 200 IU Ascorbic Acid 40 mg Thiamine Hydrochloride 1 mg Riboflavin Sodium Phosphate 1.5 mg Niacinamide 10 mg D-Panthenol 3 mg D-Biotin 50mcg Lysine Hydrochloride 18 mcg	15ml	Plastic bottle	Round neck	Amber
208	670	Glucosamine, Diacerein and Methylsulfonylmethane Tablets (750mg +50mg+250mg)	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 750 mg Diacerein 50 mg Methyl sulfonylmethane 250mg	10's	Oval	Alu-Alu	Silver
209	671	Glucosamine and Diacerein Tablets (500mg+50mg)	Each film-coated tablet contains: Glucosamine Sulphate Potassium Chloride 500 mg Diacerein 50 mg	10's	Oval	ALU-ALU	Silver
210	677	Flupentixol Tablets 0.5 mg	Each film-coated tablet contains: Flupentixol Hydrochloride equivalent to Flupentixol 0.5 mg	10's	Round biconvex	ALU-ALU	Silver
211	679	Nalidixic Acid Tablets IP 500 mg	Each tablet contains: Nalidixic Acid Tablets IP 500 mg	10's	Oval	Strip	Silver

212	681	Phenazopyridine Hydrochloride tablet 100mg	Each sugar coated tablet contains: Phenazopyridine Hydrochloride 100mg	10's	Round biconvex	ALU-ALU	Silver
213	682	Rabeprazole 20mg + Domperidone 10mg Capsule	Each hard gelatin capsule contains: Rabeprazole sodium Ip (as enteric coated pellets) 20mg Domperidone Ip (as immediate release pellets) 10mg	10's	Standard size	ALU-ALU	Silver
214	686	Magaldrate 400mg + Simethicone 20mg/5ml Oral Suspension IP	Each 5 ml contains: Magaldrate 400 mg Simethicone 20 mg	170 ml	Plastic bottle	Round	Amber
215	691	Ofloxacin Eye Drops 0.3%w/v	Ofloxacin Eye Drops 0.3%w/v	10ml	FFS Plastic bottle	Standard type	milky White
216	692	Olopatadine Hydrochloride Ophthalmic Solution 0.1% w/v	Contains: Olopatadine Hydrochloride equivalent to Olopatadine 0.1% w/v Benzalkonium Chloride 0.01% w/v (as preservative)	10ml	FFS Plastic bottle	Standard type	milky White
217	693	Tropicamide Eye Drops IP 1% w/v	Contains: Tropicamide IP 1% w/v Chlorbutol IP 0.5% w/v (as preservative)	5ml	FFS Plastic bottle	Standard type	milky White
218	697	Sulphacetamide eye drop 10 % w/v	Contains: Sulphacetamide Sodium 10 % w/v Phenylethyl Alcohol 0.5% v/v (as preservative)	10 ml	FFS Plastic bottle	Standard type	milky White
87	699	Acyclovir Eye Ointment IP 3% w/w	Contains: Aciclovir IP 3% w/w Benzalkonium chloride IP 0.01% w/w	5gm	Lami tubes	Standard	milky White
219	701	Pilocarpine Eye Drops IP 2% w/v	Contains: Pilocarpine Nitrate IP 2% w/v Hydroxypropylmethylcellulose IP 0.35% w/v Chlorbutol IP 0.5% w/v (As preservative)	10 ml	FFS Plastic bottle	Standard type	milky White
220	705	Levofloxacin INFUSION IP 500 mg/100 ml	Each ml contains: Levofloxacin 5 mg	100 ML	FFS Plastic bottle	Round	Transparent
221	707	Piroxicam Dispersible Tablets 10 mg	Each dispersible uncoated tablet contains: Piroxicam 10mg	10's	Round biconvex	Blister	Transparent
222	708	Piroxicam Dispersible Tablets 20 mg	Each dispersible uncoated tablet contains: Piroxicam 20mg	10's	Oval /Round	Blister	Transparent
223	709	Piroxicam Injection 20 mg	Each ml contains: Piroxicam 20 mg Benzyl Alcohol 20 mg (as preservative)	1ml	Ampoule	Mono carton	Amber

224	715	Glycerin IP 98%w/w	Contains: Glycerin IP 98%w/w	50 GM	Plastic bottle	Round	Transparent
225	717	Etodolac Tablets IP 300mg	Each film-coated tablet contains: Etodolac IP 300mg	10's	Oval	ALU-ALU	Silver
226	720	Ringer Lactate Infusion	Sodium chloride (600mg), Sodium Lactate (320mg), Potassium Chloride (40mg), Calcium Chloride (27mg)	500ml in FFS bottle	Standard	Plastic bottle	Transparent
227	725	Dextrose IV fluid IP 5% w/v	Dextrose IV fluid IP 5% w/v	500ml	FFS Plastic bottle	Round	Transparent
228	728	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	Dextrose and Sodium Chloride Injection (5% w/v + 0.9% w/v)	500ml	Plastic bottle	Round	Transparent
229	732	Sodium Chloride Injection IP 0.9%w/v	Sodium Chloride Injection IP 0.9%w/v	100ml IV fluid plastic container	FFS Plastic bottle	Round	Transparent
230	733	Progesterone Sustained Release Tablets 200 mg	Each film-coated sustained release tablet contains: Progesterone 200mg	10's	Round biconvex	Blister	Transparent
231	734	Dehydroepiandrosterone (Micronized) 25 mg Capsule	Each hard gelatin capsule contains: Dehydroepiandrosterone (Micronized) 25 mg	10's	Standard size	ALU-ALU	Silver
232	740	Clarithromycin Tablets IP 250 mg	Each film-coated tablet contains: Clarithromycin IP 250mg	10's	Oval	PVC Blister	Transparent
233	747	Glimepiride Tablets IP 3mg	Each uncoated tablet contains: Glimepiride IP 3 mg	10's	Round biconvex	Blister	Transparent
234	753	Clotrimazole and Beclometasone Dipropionate lotion (1%w/v + 0.025%w/v)	Contains: Clotrimazole 1% w/v Beclometasone Dipropionate 0.025% w/v	15ml	Standard	Plastic bottle	Milky white
235	769	Acetyl Salicylic Acid (Aspirin)Tablet 325mg	Each gastro-resistant tablet contains: Aspirin 325mg	14's	Round biconvex	Strip	Silver
236	785	Amitriptyline hydrochloride Tablets IP 25mg	Each film-coated tablet contains: Amitriptyline hydrochloride IP 25mg	15's	Round	PVC Blister	Transparent
237	791	Atenolol and Amlodipine Tablets (25mg+5mg)	Each uncoated tablet contains: Amlodipine Besilate IP equivalent to Amlodipine 5mg Atenolol IP 25mg	14's	Round biconvex	Blister	Transparent
238	793	Atenolol Tablets 25 mg	Each uncoated tablet contains: Atenolol 25mg	14's	Round	PVC Blister	Transparent

239	796	Atorvastatin 10mg, Aspirin (EC) 75mg Capsules	Each hard gelatin capsule contains: Atorvastatin Calcium IP equivalent to Atorvastatin 10mg Aspirin IP 75mg (as gastro-resistant tablet IP 75mg)	10's	Standard size	Strip	Silver
240	800	Bacitracin-Neomycin Sulphacetamide Dusting Powder	Each gram contains: Neomycin Sulphate 5 mg Bacitracin 250 units Sulphacetamide 60mg	10gm Powder	Standard Size	Standard type	Standard Market
241	804	Betamethasone Injection IP 4 mg/ml	Each ml contains: Betamethasone Sodium Phosphate 4 mg	1 ml	Glass vial	Mono carton	Transparent
242	806	Bicalutamide Tablets IP 50mg	Each film-coated tablet contains: Bicalutamide IP 50mg	10's	Round	PVC Blister	Transparent
243	807	Biphasic Isophane Insulin Injection I.P 100 IU/ml (30:70) (30% Soluble Insulin & 70% Isophane Ins)	Each ml contains: Human Insulin IP 100 IU (30% Soluble Insulin Injection and 70% Isophane Insulin Injection) Preservative:m-cresol, phenol	3ml Cartridge/Penfill	Glass Cartridge	Mono carton	Transparent
244	815	Calcitriol Capsules IP 0.25mcg	Each soft gelatin capsule contains: Calcitriol IP 0.25 mcg	10's	Standard size	Blister	Red Transparent
245	816	Calcium Acetate Tablets 667mg	Each uncoated tablet contains: Calcium Acetate 667mg	10's	Oval	Blister	Transparent
246	818	Calcium Gluconate Injection IP 10 %	Contains: Calcium Gluconate IP 10 % w/v	10 ml	Glass vial	Mono carton	Transparent
247	829	Chloramphenicol Eye Ointment IP 1%w/w	Contains: Chloramphenicol IP 1%w/w	5 gm	Lami tubes	Standard	milky White
248	832	Chlorthalidone Tablets 12.5mg	Each uncoated tablet contains: Chlorthalidone 12.5mg	10's	Round biconvex	Blister	Transparent
249	835	Glucosamine Sulphate and Chondroitin Tablets (500mg+400mg)	Each film-coated tablet contains: Chondroitin Sulphate 400mg Glucosamine Sulphate 500mg	10's	Modified rectangle	Blister	Transparent
250	838	Cilostazol Tablets IP 50mg	Each uncoated tablet contains: Cilostazol IP 50mg	10's	Round biconvex	Blister	Transparent
251	844	Clonazepam Tablets IP 1mg	Each uncoated tablet contains: Clonazepam IP 1mg	10's	Round biconvex	Blister	Transparent
252	860	Dextromethorphan Hydrobromide Syrup IP	Each 5 ml contains: Dextromethorphan Hydrobromide IP 13.5mg Flaoured base syrup q.s.	50ml	Plastic bottle	Round	Amber
253	868	Dicyclomine HCl (Dicycloverine) Injection IP 10mg/ml	Each ml contains: Dicyclomine Hydrochloride IP 10mg	2ml	Ampoule	Mono carton	Amber

254	875	Donepezil Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Donepezil Hydrochloride IP 10mg	10's	Round biconvex	Blister	Transparent
255	881	Ebastine Tablets IP 10mg	Each film-coated tablet contains: Ebastine IP 10mg	10's	Round	PVC Blister	Transparent
256	885	Ethinylestradiol and Levonorgestrel Tablets IP (0.05mg+0.25mg)	Each uncoated tablet contains: Ethinylestradiol IP 0.05mg Levonorgestrel IP 0.25mg	21's	Round biconvex	Blister	Dark green
257	899	Frusemide and Spironolactone Tablets (20mg+50mg)	Each film-coated tablet contains: Frusemide IP 20mg Spironolactone IP 50mg	10's	Round	PVC Blister	Blue
258	900	Gabapentin and Methylcobalamine Tablets (100mg+500mcg)	Each film-coated tablet contains: Gabapentin 100 mg Methylcobalamine 500 mcg	10's	Round biconvex	Blister	Dark Amber
259	904	Glimepiride and Metformin SR Tablets (1mg + 500mg)	Each uncoated bi-layer tablet contains: Glimepiride IP 1 mg Metformin Hydrochloride 500 mg (as extended release)	10's	Oval	PVC Blister	Transparent
260	906	Glyceryl Trinitrate Controlled Release Tablets 2.6mg (Nitroglycerin CR Tablets)	Each uncoated tablet contains: Diluted Nitroglycerin equivalent to Nitroglycerin 2.6 mg (in a controlled release system)	30's	Standard Size	Plastic Bottle	White
261	912	Hydroclorthiazide Tablets 12.5mg	Each uncoated tablet contains: Hydroclorthiazide 12.5mg	10's	Round biconvex	Blister	Transparent
262	915	Hydroxyzine Hydrochloride Tablets IP 10mg	Each film-coated tablet contains: Hydroxyzine Hydrochloride IP 10mg	10's	Round biconvex	Blister	Transparent
263	917	Imipramine Hydrochloride Tablets IP 25mg	Each film-coated tablet contains: Imipramine Hydrochloride IP 25mg	10's	Round biconvex	Strip	Silver
264	920	Insulin Regular (R-DNA Origin) Injection 100 IU	Insulin Regular (R-DNA Origin) Injection 100 IU	3ml Cartridge/Penfill	Glass Cartridge	Mono carton	Amber
265	922	Isopropyl Alcohol (70%) (Spirit)	Isopropyl Alcohol (70% Conc.)	100 ML bottle	Plastic bottle	Round	Transparent
266	931	Lamotrigine Tablets 100mg	Each uncoated tablet contains: Lamotrigine 100 mg	10's	Round biconvex	Strip	Silver
267	932	Latanoprost Eye Drops IP 0.005%w/v (50mcg/ml)	Each ml contains: Latanoprost IP 50 mcg	2.5 ML	FFS Plastic bottle	Standard type	milky White
268	933	Leflunomide Tablets IP 20mg	Each film-coated tablet contains: Leflunomide IP 20mg	10's	Round biconvex	Blister	Transparent
269	939	Levocarnitine Tablets 500mg	Each film-coated tablet contains: Levocarnitine 500mg	10's	Oval	Alu-Alu	Silver
270	944	Levosalbutamol HCl inhaler 50mcg	Each activation delivers: Levosalbutamol tartrate equivalent to Levosalbutamol	200 Mdi	Standard Size	Standard type	Standard Market

			50mcg				
271	946	Lignocaine (Lidocaine) Hydrochloride Gel IP 2% w/v	Contains: Lignocaine Hydrochloride IP equivalent to anhydrous Lignocaine Hydrochloride 2% w/v	20g	Lami tubes	Standard	milky White
272	947	Lithium Carbonate Prolonged Release Tablets IP 450mg	Each uncoated prolonged release tablet conatins: Lithium Carbonate IP 450 mg	10's	Oval	Blister	Transparent
273	948	Lorazepam Tablets IP 1mg	Each uncoated tablet conatins: Lorazepam IP 1mg	10's	Round	PVC Blister	Amber
274	951	Lycopene 1000 mcg, Vitamin A 2500 IU, Vitamin E 10 IU, Selenium 35 mcg and Vitamin C 50mg	Each 5 ml contains: Levocarnitine 5% 1000 mcg Vitamin A 2500 IU Vitamin E 10 IU Vitamin C 50 mg Zinc (as Zinc Gluconate) 3 mg Manganese 2 mg Iodine 100 mcg Copper 500 mcg Thiamine HCl 2 mg Riboflavin Sodium Phosphate 3 mg Pyridoxine HCl 1.5 mg	200 ml	Plastic bottle	Round neck	Amber
275	957	Memantine Hydrochloride Tablets IP 10mg	Each film-coated tablet conatins: Memantine Hydrochloride IP 10mg	10's	Round biconvex	Blister	Transparent
276	965	Miconazole and Fluocinolone Acetonide Ointment (2%w/w+0.01%w/w)	Contains: Miconazole Nitrate 2% w/w Fluocinolone Acetonide 0.01% w/w	15gm Tube	Lami tubes	Standard	milky White
277	976	Nebivolol Tablets IP 2.5mg	Each uncoated tablet conatins: Nebivolol Hydrochloride IP 2.5 mg	10's	Round biconvex	Blister	Transparent
278	978	Nepafenac Eye Drop 0.1% w/v	Each ml contains: Nepafenac 1mg Benzalkonium Chloride IP (as preservative) 0.005% w/v	5ml	FFS Plastic bottle	Standard type	milky White
279	986	Nitrazepam Tablets I.P 10mg	Each uncoated tablet contains: Nitrazepam IP 10 mg	10's	Round	PVC Blister	Amber
280	987	Nitrofurantoin Tablets I.P 100mg	Each uncoated tablet contains: Nitrofurantoin IP 100 mg	10's	Round	PVC Blister	Milky white
281	1008	Phytomenadione (Vitamin K1) Injection 1 mg/0.5ml	Each ml contains: Phytonadione 2 mg Polyoxyethylated fatty acid derivative 70 mg, dextrose, hydrous 37.5 mg, benzyl alcohol 9 mg added as preservative. May contain hydrochloric acid for pH adjustment.	0.5ml Ampoule	Glass vial	Mono carton	Amber
282	1009	Pioglitazone Tablets IP 15 mg	Each uncoated tablet contains: Pioglitazone Hydrochloride IP equivalent to Pioglitazone 15 mg	10's	Round biconvex	Blister	Milky white
283	1024	Promethazine	Each ml contains:	2ml	Glass	Mono	Transpar

		Injection IP 25 mg/ml	Promethazine Hydrochloride 25 mg		vial	carton	ent
284	1037	Recombinant Human Erythropoietin Injection 4000 IU	Each prefilled syringe contains: Erythropoietin concentrate Solution 4000 IU	Vial	Standard Size	Standard type	Standard Market
285	1038	Recombinant Human Erythropoietin Injection 2000 IU	Each prefilled syringe contains: Erythropoietin concentrate Solution 2000 IU	Vial	Standard Size	Standard type	Standard Market
286	1041	Risperidone and Trihexiphenidyl Tablets (4mg+2mg)	Each uncoated tablet contains: Resperidone 4 mg Trihexyphenidyl hydrochloride IP 2 mg	10's	Round biconvex	Blister	Transparent
287	1044	Rosuvastatin Tablet I.P 5mg	Each film coated tablet contains: Rosuvastatin Calcium IP equivalent to Rosuvastatin 5 mg	10's	Round biconvex	ALU-ALU	Silver
288	1050	Sertraline Tablets I.P 100mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 100 mg	10's	Oval	PVC Blister	Skyblue
289	1051	Sertraline Tablets I.P 25mg	Each film coated tablet contains: Sertraline Hydrochloride IP equivalent to Sertraline 25 mg	10's	Round	PVC Blister	Skyblue
290	1060	Sodium Valproate Gastro-resisTablets IP 300mg	Each gastro-resistant tablet contains: Sodium Valproate IP 300mg	10's	Round	Strip	Silver
291	1069	Sulphacetamide Sodium Eye Drop I.P 20% w/v	Each ml contains: Sulfacetamide Sodium IP 20 % w/v Phenylethyl alcohol IP 0.5 % v/v (as preservative)	10ml	FFS Plastic bottle	Standard type	milky White
292	1074	Telmisartan and Hydroclorthiazide Tablets (80mg+12.5mg)	Each uncoated bilayer tablet contains: Telmisartan IP 80 mg Hydrochlorthiazide IP 12.5 mg	10's	Round biconvex	Strip	Silver
293	1076	Tenofovir Disoproxil Fumarate Tablets 300 mg	Each film coated tablet contains: Tenofovir Disoproxil fumarate IP 300 mg	10's	Oval	Blister	Transparent
294	1087	Trihexyphenidyl Hydrochloride Tablets 2mg (benzhexol HCl Tablets IP 2mg)	Each uncoated tablet contains: Trihexyphenidyl Hydrochloride IP 2 mg	10's	Round	PVC Blister	Transparent
295	1088	Trimetazidine Hydrochloride Modified Release Tablets 35 mg	Each film-coated modified release tablet contains: Trimetazidine Hydrochloride IP 35mg	10's	Round biconvex	Blister	Transparent

296	1097	Vitamin A Capsule 25000 IU	Each soft gelatin capsule contains: Vitamin A IP (as Palmitate) 25000 IU (equivalent to Retinol 7.5 mg) in water soluble form.	30's	Standard size	Blister	Amber
297	1099	Voglibose and Metformin Tablets (0.3mg+500mg)	Each uncoated tablet contains: Voglibose IP 0.3 mg Metformin Hydrochloride IP 500 mg	10's	Oval	Blister	Light Blue
298	1106	Metoprolol Succinate ER 50 mg & Telmisartan 40mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate IP equivalent to Metoprolol Tartarate 50 mg (as extended release form) Telmisartan IP 40 mg	10's	Round biconvex	Strip	Silver
299	1110	Clobazam Tablet IP 5mg	Each uncoated tablet contains: Clobazam IP 5 mg	10's	Round biconvex	Blister	Transparent
300	1112	Cinnarizine Tablets IP 25mg	Each uncoated tablet contains: Cinnarizine IP 5 mg	10's	Round	PVC Blister	Transparent
301	1123	Clomipramine Hydrochloride SR Tablets 75mg	Each film coated sustained release tablet contains: Clomipramine Hydrochloride 75 mg	10's	Round biconvex	Blister	Transparent
302	1124	Fluvoxamine Maleate Tablets IP 100mg	Each film coated sustained release tablet contains: Fluvoxamine Maleate IP 100 mg	10's	Round biconvex	Strip	Silver
303	1125	Aripiprazole Tablets IP 5mg	Each uncoated tablet contains: Aripiprazole IP 5 mg	10's	Round biconvex	Blister	Transparent
304	1149	Lisinopril Tablets IP 10mg	Each uncoated tablet contains: Lisinopril IP equivalent to anhydrous Lisinopril 2 mg	15's	Round biconvex	Blister	Transparent
305	1152	Carbamazepine Sustained Release Tablets IP 200mg	Each film coated prolonged release tablet contains: Carbamazepine IP 200 mg	10's	Round biconvex	Strip	Silver
306	1154	Diethylcarbamazine Citrate Tablets IP 100mg	Each uncoated tablet contains: Diethylcarbamazine Citrate IP 100mg Excipients q.s.	30's	Round biconvex	Blister	Transparent
307	1156	Metoprolol Succinate ER 25 mg & Amlodipine Besylate 5 mg Tablets	Each film coated bilayered tablet contains: Metoprolol Succinate IP equivalent to Metoprolol Tartarate 25 mg (as extended release form) Amlodipine besylate IP equivalent to Amlodipine 5 mg	7's	Round biconvex	Alu-Alu	Silver

308	1157	DOXYLAMINE SUCCINATE 20 MG+ PYRIDOXINE HCl 20 MG TABLETS	Each enteric coated tablet contains: Doxylamine Succinate 20 mg Pyridoxine Hydrochloride 20 mg	10's	Round biconvex	Blister	Transparent
309	1164	NANDROLONE DECANOATE INJECTION IP 50 mg/ml	Each ml contains: Nandrolone decanoate 50mg	2 ml	Glass vial	Mono carton	Amber
310	1166	MEFENAMIC ACID 250 MG TABLETS	Each uncoated tablet contains: Mefenamic Acid 250 mg	10's	Oval /Round	Blister	Transparent
311	1168	KETOROLAC Inj. IP 30mg/ml	Each vial contins: Ketorolac tromethamine 30 mg	1 ml	Glass vial	Mono carton	Amber
312	1170	ACETYLCYSTEINE Injection 200 mg/ml	Each ml contains: Acetylcystein 200 mg	2ml Ampoules	Ampoule	Mono carton	Amber
313	1187	Cyclosporine Capsules IP 100 mg	Each soft gelatin capsule contains: Cyclosporine IP 100 mg	5's	Standard	Alu-Alu	Aluminium
314	1191	Glycopyrrolate Inj IP 0.2mg	Each ml contains: Glycopyrrolate 0.2 mg Benzyl alcohol 0.9 % WFI q.s.	1 ml	Glass vial	Mono carton	Amber
315	1203	Protamine Inj 10mg/ml	Each ml contains: Protamine Sulphate 10 mg	5ml vial/ampoule	Glass vial	Mono carton	Amber
316	1219	Amino Acid Solution for IV 200 ml bottle	Nutritive infusion of Pure Crystalline Amino Acids	200 ml Glass Bottle	Plastic bottle	Round	Amber
317	1220	Oseltamivir Capsules 75mg	Each hard gelatin capsule contains: Oseltamivir Phosphate IP 98.5 mg equivalent to Oseltamivir 75mg	10's	Round biconvex	Blister	Transparent
318	1225	Orlistat Capsules 120 mg	Each hard gelatin capsule contains: Orlistat 120 mg (as pellets 50 % w/w)	10's	Standard	Strip	Silver
319	1226	Triamcinolone Injection 40mg/ml	Each ml contains: Triamcinolone Acetonide IP 40 mg Benzyl Alcohol IP 0.9%w/v (as preservative)	1 ml	Glass vial	Mono carton	Amber
320	1231	Vitamin E Acetate & Levocarnitine Tablets (200 mg + 150 mg)	Each film coated tablet contains: Tocopheryl Acetate IP 200 mg (as 50% powder) L-Carnitine-L-Tartarate equivalent to Levocarnitine USP 150 mg	10's	Oval	Strip	Silver

321	1237	Methyldopa tablets IP 500 mg	Each film coated tablet contains: Methyldopa IP equivalent to anhydous Methyldopa 500 mg	10's	Oval	Blister	Red
322	1238	Prazosin Hydrochloride Sustained Release Tablets 2.5 mg	Each film coated sustained release tablet contains: Prazosin Hydrochloride IP equivalent to Prazosin 2.5 mg	30's	Round biconvex	Blister	Transparent
323	1241	Cefaclor Dispersible Tablets 250 mg	Each dispersible tablet contains: Cefaclor IP equivalent to anhydous Cefaclor 250 mg	10's	Oval	ALU-ALU	Silver
324	1243	Betamethasone Valerate & Salicylic Acid (0.05% w/w + 3.0% w/w) Ointment	Contains: Betamethasone Valerate IP equivalent to betamethasone 0.05% w/w Salicylic Acid IP 3.0%w/w in a greasy base	20gm Tube	Lami tubes	Standard	milky White
325	1248	Haematinic syrup of Iron,Folic acid and Vitamin B12(32mg+0.5mg +7.5mcg) 200 ml	Each 15 ml contains: Ferric Ammonium Citrate equivalent to Elemental Iron 32 mg Folic Acid IP 0.5 mg Cyanocobalamin IP 7.5 mg	200ml bottle	Plastic bottle	Round neck	Amber
326	1252	Suspension of Calcium Phosphate with Vitamin D3 & Viatmin B12 (82 mg + 200 IU + 2.5 mcg)	Each 5ml contains: Vitamin D3 (Cholecalciferol IP) 200 IU Vitamin B12 IP 2.5 mcg Calcium Phosphate equivalent to elemental Calcium 82 mg	200 ml	Plastic bottle	Round neck	Amber
327	1255	Montelukast & Acebrophylline Sustained Release (10 mg +200 mg) Tablets	Each film coated bilayered tablet contains: Montelukast Sodium IP equivalent to Montelukast 10 mg (in immediate release form) Acebrophylline 200 mg (in sustained release form)	10's	Oval	ALU-ALU	Silver
328	1284	Cilnidipine & Telmisartan Tablets (10 mg + 40 mg)	Each film coated tablet contains: Cilnidipine 10 mg Telmisartan IP 40 mg	10's	Round biconvex	Strip	Silver
329	1308	Ethinylestradiol IP 0.03mg+ Levonorgestrel IP 0.15mg Tablet	Each uncoated tablet contains: Levonorgestrel IP 0.15 mg Ethinyloestradiol IP 0.03 mg	21's	Round biconvex	Blister	Transparent
330	1328	Isoxsuprine Injection IP 5 mg	Each ml contains: Isoxsuprine Hydrochloride IP 5 mg WFI IP q.s	2ml Vial	Glass vial	Mono carton	Transparent
331	1342	Mebeverine Hydrochloride Tablets	Each sugar coated tablet contains: Mebeverine Hydrochloride IP 200 mg	10's	Round biconvex	ALU-ALU	Silver
332	1368	Olmesartan Medoxomil & Hydrochlorthiazid	Each film coated tablet contains: Olmesartan Medoxomil 20 mg Hydrochlorthiazide IP 12.5 mg	10's	Round biconvex	ALU-ALU	Silver

		e Tablets (20 mg + 12.5 mg)					
333	1409	Teicoplanin Injection 400 mg	Each ml contains (as lyophilisate) Teicoplanin 400 mg Sterile powder for preparation of intramuscular or intravenous injection.	1 ml Vial	Glass vial	Mono carton	Transparent
334	1414	Terlipressin Injection 1000 mcg (1 mg)/10ml	Each 10ml contains: Terlipressin 1 mg	10 ml Vial	Glass vial	Mono carton	Transparent
335	1427	Trypsin, Bromelain & Rutoside Trihydrate Tablets (48 mg + 90 mg + 100 mg)	Each enteric coated tablet contains: Trypsin 48 mg Bromelain 90 mg Rutoside Trihydrate 100 mg	10's	Round biconvex	Blister	Transparent
336	1431	Valethamate Injection 8 mg/ml (For IM/IV use)	Each ml contains: Valethamate Bromide 8 mg Sodium Chloride IP 8 mg WFI q.s.	1 ml Vial	Glass vial	Mono carton	Transparent
337	1432	Tobramycin Eye Drops 0.3%	Each ml contains: Tobramycin Sulfate equivalent to Tobramycin 3mg Benzalkonium Chloride 0.0001 ml (as preservative)	5ml	FFS Plastic bottle	Standard type	milky White
338	1441	Nirmal (Nicotine Polacrilex chewing gum 2 mg)	Each gum contains: Nicotine Polacrilex equivalent to Nicotine 2 mg	1 x 9's (mono carton pack)	Sqaure/ rectangle white gum	Blister	Light blue
339	1449	Enzyme Syrup Mixed Fruit Flavour (Diastase and Pepsin)	Each 5ml contains: Diastase (1:1200) 50mg Pepsin (1:3000) 10mg	200 ml	Plastic bottle	Round neck	Amber
340	1450	PYRANTEL PAMOATE ORAL SUSPENSION IP 250mg/5ml	Each 5ml contains: Pyrantel Pamoate 250 mg	10 ML	Plastic bottle	Round	Amber
341	1451	THEOPHYLLINE Controlled release TABLETS 400 MG	Each uncoated tablet contains: Theophylline Anhydrous IP 400mg (in controlled release form)	10's	Oval	Blister	Transparent
342	1452	Pyridoxine Hydrochloride Sustained Release Tablets 100 mg	Each Sustained release tablet contains: Pyridoxine Hydrochloride IP 100 mg	10's	Round biconvex	Blister	Dark Amber
343	1453	Levetiracetam Syrup 100 Mg	Each ml contains: Levetiracetam 100mg	100ml	Plastic bottle	Round	Amber
344	1454	Terbutaline Sulphate and Bromhexine Hydrochloride Syrup	Each 5ml contains: Terbutaline Sulphate 2.5mg Bromhexine Hydrochloride 8mg	100 ML	Plastic bottle	Round	Amber

345	1455	L-Arginine Granules	Each sachet of 5 g contains: L-Arginine 3 g Excipients q.s	5 gm	Standard	Sachet	BPPI artwork
346	1456	Itraconazole Capsules 200 mg	Each hard gelatin capsule contains: Itraconazole BP 200 mg (As pellets)	4's	Round	Alu-Alu	Silver
347	1457	Luliconazole Cream 1% w/w	Contains: Luliconazole 1% w/w Preservatives: Methylparaben 0.14% w/w Benzyl Alcohol 1% w/w in a Cream base q.s.	10 g	Standard	Lami-tube	White
348	1458	Sodium Chloride Injection IP 0.9%w/v	Sodium Chloride Injection IP 0.9%w/v	500ml IV fluid plastic container	FFS Plastic bottle	Round	Transparent

---